CA2402912A1 - Transgenic mice containing targeted gene disruptions - Google Patents
Transgenic mice containing targeted gene disruptions Download PDFInfo
- Publication number
- CA2402912A1 CA2402912A1 CA002402912A CA2402912A CA2402912A1 CA 2402912 A1 CA2402912 A1 CA 2402912A1 CA 002402912 A CA002402912 A CA 002402912A CA 2402912 A CA2402912 A CA 2402912A CA 2402912 A1 CA2402912 A1 CA 2402912A1
- Authority
- CA
- Canada
- Prior art keywords
- gene
- agent
- transgenic mouse
- disruption
- abnormality
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 379
- 238000011830 transgenic mouse model Methods 0.000 title claims abstract description 156
- 241000699660 Mus musculus Species 0.000 title abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 264
- 241001465754 Metazoa Species 0.000 claims abstract description 126
- 230000014509 gene expression Effects 0.000 claims abstract description 95
- 230000009261 transgenic effect Effects 0.000 claims abstract description 51
- 210000004027 cell Anatomy 0.000 claims description 243
- 239000003795 chemical substances by application Substances 0.000 claims description 166
- 239000013598 vector Substances 0.000 claims description 89
- 239000012634 fragment Substances 0.000 claims description 85
- 230000005856 abnormality Effects 0.000 claims description 68
- 108090001033 Sulfotransferases Proteins 0.000 claims description 63
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 61
- 238000012360 testing method Methods 0.000 claims description 60
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 58
- 239000003550 marker Substances 0.000 claims description 56
- 230000001419 dependent effect Effects 0.000 claims description 49
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 48
- 230000000694 effects Effects 0.000 claims description 48
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 46
- 101710164507 Photoreceptor-specific nuclear receptor Proteins 0.000 claims description 46
- 230000006399 behavior Effects 0.000 claims description 46
- 239000011777 magnesium Substances 0.000 claims description 46
- 229910052749 magnesium Inorganic materials 0.000 claims description 46
- 230000008685 targeting Effects 0.000 claims description 37
- 230000001413 cellular effect Effects 0.000 claims description 33
- 108700026220 vif Genes Proteins 0.000 claims description 32
- 210000004185 liver Anatomy 0.000 claims description 30
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 29
- 102000040430 polynucleotide Human genes 0.000 claims description 29
- 108091033319 polynucleotide Proteins 0.000 claims description 29
- 239000002157 polynucleotide Substances 0.000 claims description 29
- 241000282414 Homo sapiens Species 0.000 claims description 28
- 208000002111 Eye Abnormalities Diseases 0.000 claims description 27
- 102000009410 Chemokine receptor Human genes 0.000 claims description 22
- 108050000299 Chemokine receptor Proteins 0.000 claims description 22
- 108010000410 MSH receptor Proteins 0.000 claims description 22
- 238000010363 gene targeting Methods 0.000 claims description 21
- 102000004896 Sulfotransferases Human genes 0.000 claims description 20
- 230000001965 increasing effect Effects 0.000 claims description 20
- 238000012216 screening Methods 0.000 claims description 19
- 102100029533 Photoreceptor-specific nuclear receptor Human genes 0.000 claims description 18
- 210000002459 blastocyst Anatomy 0.000 claims description 17
- 210000000056 organ Anatomy 0.000 claims description 16
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 15
- 238000009395 breeding Methods 0.000 claims description 15
- 230000001488 breeding effect Effects 0.000 claims description 15
- 230000008595 infiltration Effects 0.000 claims description 15
- 238000001764 infiltration Methods 0.000 claims description 15
- 210000004072 lung Anatomy 0.000 claims description 14
- 230000002685 pulmonary effect Effects 0.000 claims description 14
- 230000002207 retinal effect Effects 0.000 claims description 14
- 230000003902 lesion Effects 0.000 claims description 13
- 210000001525 retina Anatomy 0.000 claims description 13
- 210000003079 salivary gland Anatomy 0.000 claims description 13
- 210000002784 stomach Anatomy 0.000 claims description 13
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 12
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 11
- 210000000265 leukocyte Anatomy 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 238000004820 blood count Methods 0.000 claims description 10
- 210000001165 lymph node Anatomy 0.000 claims description 10
- 210000000496 pancreas Anatomy 0.000 claims description 10
- 206010011953 Decreased activity Diseases 0.000 claims description 9
- 201000007737 Retinal degeneration Diseases 0.000 claims description 9
- 210000000709 aorta Anatomy 0.000 claims description 9
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 9
- 210000004698 lymphocyte Anatomy 0.000 claims description 9
- 230000004258 retinal degeneration Effects 0.000 claims description 9
- 241001529936 Murinae Species 0.000 claims description 7
- 206010035664 Pneumonia Diseases 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 102000012539 Melanocyte-stimulating hormone receptors Human genes 0.000 claims description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- 208000004453 Retinal Dysplasia Diseases 0.000 claims description 6
- 239000011574 phosphorus Substances 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 6
- 210000003491 skin Anatomy 0.000 claims description 6
- 210000001550 testis Anatomy 0.000 claims description 6
- 208000015580 Increased body weight Diseases 0.000 claims description 5
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 4
- 208000005400 Synovial Cyst Diseases 0.000 claims description 4
- 230000004761 fibrosis Effects 0.000 claims description 4
- 210000003494 hepatocyte Anatomy 0.000 claims description 4
- 206010003694 Atrophy Diseases 0.000 claims description 3
- 206010018341 Gliosis Diseases 0.000 claims description 3
- 230000037444 atrophy Effects 0.000 claims description 3
- 210000003855 cell nucleus Anatomy 0.000 claims description 3
- 230000007387 gliosis Effects 0.000 claims description 3
- 210000004877 mucosa Anatomy 0.000 claims description 3
- 210000004126 nerve fiber Anatomy 0.000 claims description 3
- 108091008695 photoreceptors Proteins 0.000 claims description 3
- 230000004233 retinal vasculature Effects 0.000 claims description 3
- 210000004876 tela submucosa Anatomy 0.000 claims description 3
- 230000002477 vacuolizing effect Effects 0.000 claims description 3
- 206010002536 Anisocytosis Diseases 0.000 claims description 2
- 201000004569 Blindness Diseases 0.000 claims description 2
- 230000008021 deposition Effects 0.000 claims description 2
- 230000000394 mitotic effect Effects 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims 41
- 208000030533 eye disease Diseases 0.000 claims 23
- 230000005823 lung abnormality Effects 0.000 claims 14
- 208000030560 Abnormality of the skin Diseases 0.000 claims 9
- 230000006400 anxiety behaviour Effects 0.000 claims 6
- 208000010676 Abnormality of the gastrointestinal tract Diseases 0.000 claims 5
- 208000019881 Abnormality of the kidney Diseases 0.000 claims 5
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 claims 5
- 208000019782 Abnormality of the liver Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 58
- 201000010099 disease Diseases 0.000 abstract description 52
- 239000000203 mixture Substances 0.000 abstract description 18
- 238000011282 treatment Methods 0.000 abstract description 11
- 238000012512 characterization method Methods 0.000 abstract description 5
- 108020004414 DNA Proteins 0.000 description 98
- 241000699670 Mus sp. Species 0.000 description 83
- 102000004169 proteins and genes Human genes 0.000 description 73
- 150000007523 nucleic acids Chemical group 0.000 description 51
- 239000000047 product Substances 0.000 description 47
- 150000001875 compounds Chemical class 0.000 description 46
- 102000039446 nucleic acids Human genes 0.000 description 43
- 108020004707 nucleic acids Proteins 0.000 description 43
- 108091034117 Oligonucleotide Proteins 0.000 description 37
- 210000001519 tissue Anatomy 0.000 description 34
- 241000699666 Mus <mouse, genus> Species 0.000 description 32
- 230000006870 function Effects 0.000 description 32
- 125000003729 nucleotide group Chemical group 0.000 description 32
- 239000002773 nucleotide Substances 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 30
- 238000010367 cloning Methods 0.000 description 29
- 108090000765 processed proteins & peptides Proteins 0.000 description 28
- 108091028043 Nucleic acid sequence Proteins 0.000 description 26
- 239000013612 plasmid Substances 0.000 description 26
- 102000004190 Enzymes Human genes 0.000 description 25
- 108090000790 Enzymes Proteins 0.000 description 25
- 238000001514 detection method Methods 0.000 description 25
- 229940088598 enzyme Drugs 0.000 description 25
- 108010091086 Recombinases Proteins 0.000 description 24
- 102000018120 Recombinases Human genes 0.000 description 23
- 238000000137 annealing Methods 0.000 description 23
- 230000006801 homologous recombination Effects 0.000 description 23
- 238000002744 homologous recombination Methods 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- 230000004044 response Effects 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 238000003556 assay Methods 0.000 description 19
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 19
- 230000035772 mutation Effects 0.000 description 19
- 230000000295 complement effect Effects 0.000 description 18
- 239000002299 complementary DNA Substances 0.000 description 18
- 239000013615 primer Substances 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- 108091026890 Coding region Proteins 0.000 description 15
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 15
- 238000003780 insertion Methods 0.000 description 15
- 230000037431 insertion Effects 0.000 description 15
- 230000001105 regulatory effect Effects 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 108090000994 Catalytic RNA Proteins 0.000 description 14
- 102000053642 Catalytic RNA Human genes 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 14
- 108091092562 ribozyme Proteins 0.000 description 14
- 239000013604 expression vector Substances 0.000 description 13
- 230000001939 inductive effect Effects 0.000 description 13
- 108060002716 Exonuclease Proteins 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 102000013165 exonuclease Human genes 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- 238000010171 animal model Methods 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 230000006798 recombination Effects 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- -1 viral Substances 0.000 description 11
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 230000003321 amplification Effects 0.000 description 10
- 230000003542 behavioural effect Effects 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 10
- 238000005215 recombination Methods 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000000528 statistical test Methods 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- 241000701959 Escherichia virus Lambda Species 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 230000001747 exhibiting effect Effects 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000000007 visual effect Effects 0.000 description 8
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 7
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 7
- 239000005090 green fluorescent protein Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 208000019901 Anxiety disease Diseases 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 230000036506 anxiety Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 101150036876 cre gene Proteins 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000011813 knockout mouse model Methods 0.000 description 6
- 230000013016 learning Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- 206010000117 Abnormal behaviour Diseases 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 102100026189 Beta-galactosidase Human genes 0.000 description 5
- 101710149858 C-C chemokine receptor type 7 Proteins 0.000 description 5
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 239000004098 Tetracycline Substances 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 229960001484 edetic acid Drugs 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 229960002180 tetracycline Drugs 0.000 description 5
- 229930101283 tetracycline Natural products 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108020005544 Antisense RNA Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 4
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 4
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 101710182846 Polyhedrin Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 239000003184 complementary RNA Substances 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000037023 motor activity Effects 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 238000012346 open field test Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 210000000608 photoreceptor cell Anatomy 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000011273 social behavior Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108020004491 Antisense DNA Proteins 0.000 description 3
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108010046276 FLP recombinase Proteins 0.000 description 3
- 102000034286 G proteins Human genes 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000016571 aggressive behavior Effects 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 239000003816 antisense DNA Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003212 purines Chemical class 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 235000020945 retinal Nutrition 0.000 description 3
- 239000011604 retinal Substances 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000003997 social interaction Effects 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000024188 startle response Effects 0.000 description 3
- 230000019635 sulfation Effects 0.000 description 3
- 238000005670 sulfation reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 3
- HPZMWTNATZPBIH-UHFFFAOYSA-N 1-methyladenine Chemical compound CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 description 2
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 102000001902 CC Chemokines Human genes 0.000 description 2
- 108010040471 CC Chemokines Proteins 0.000 description 2
- 108050006947 CXC Chemokine Proteins 0.000 description 2
- 102000019388 CXC chemokine Human genes 0.000 description 2
- 101150013700 CXCR1 gene Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108091060290 Chromatid Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 241001045988 Neogene Species 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 108010001441 Phosphopeptides Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102100022343 Protein phosphatase 1A Human genes 0.000 description 2
- 101710105644 Protein phosphatase 1A Proteins 0.000 description 2
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 2
- 102100028001 Retinaldehyde-binding protein 1 Human genes 0.000 description 2
- 101710101931 Retinaldehyde-binding protein 1 Proteins 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 2
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 2
- 210000001132 alveolar macrophage Anatomy 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000002616 endonucleolytic effect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001339 gustatory effect Effects 0.000 description 2
- 210000000259 harderian gland Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004995 male reproductive system Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 101150091879 neo gene Proteins 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000016732 phototransduction Effects 0.000 description 2
- 230000006461 physiological response Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000009822 protein phosphorylation Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 210000002105 tongue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000031836 visual learning Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- SATCOUWSAZBIJO-UHFFFAOYSA-N 1-methyladenine Natural products N=C1N(C)C=NC2=C1NC=N2 SATCOUWSAZBIJO-UHFFFAOYSA-N 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- SVBOROZXXYRWJL-UHFFFAOYSA-N 2-[(4-oxo-2-sulfanylidene-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=S)NC1=O SVBOROZXXYRWJL-UHFFFAOYSA-N 0.000 description 1
- LLWPKTDSDUQBFY-UHFFFAOYSA-N 2-[6-(aminomethyl)-2,4-dioxo-1H-pyrimidin-5-yl]acetic acid Chemical compound C(=O)(O)CC=1C(NC(NC=1CN)=O)=O LLWPKTDSDUQBFY-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101000611262 Caenorhabditis elegans Probable protein phosphatase 2C T23F11.1 Proteins 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 101100464671 Drosophila melanogaster pnr gene Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000702191 Escherichia virus P1 Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010017000 Foreign body aspiration Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010056307 Hin recombinase Proteins 0.000 description 1
- 101000826390 Homo sapiens Sulfotransferase 1A3 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101000688229 Leishmania chagasi Protein phosphatase 2C Proteins 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 101000716064 Mus musculus C-C chemokine receptor type 7 Proteins 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010064986 Perivascular dermatitis Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101710167643 Serine/threonine protein phosphatase PstP Proteins 0.000 description 1
- 108010052160 Site-specific recombinase Proteins 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100023983 Sulfotransferase 1A3 Human genes 0.000 description 1
- 102100029862 Sulfotransferase 1E1 Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108010010574 Tn3 resolvase Proteins 0.000 description 1
- 102000006612 Transducin Human genes 0.000 description 1
- 108010087042 Transducin Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010078072 VDJ Recombinases Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003666 anti-fingerprint Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 108010087471 cin recombinase Proteins 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 230000001094 effect on targets Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000008918 emotional behaviour Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 108010017360 estrone sulfotransferase Proteins 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 102000052624 human CXCL8 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000012296 in situ hybridization assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 230000005830 kidney abnormality Effects 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000005817 liver abnormality Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 201000010315 pericholangitis Diseases 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000036278 prepulse Effects 0.000 description 1
- 230000006977 prepulse inhibition Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 231100000586 procarcinogen Toxicity 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 201000004537 pyelitis Diseases 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000010825 rotarod performance test Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 210000002863 seminiferous tubule Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 230000014639 sexual reproduction Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 230000002199 spermatogenetic effect Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 210000004878 submucosal gland Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- High Energy & Nuclear Physics (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in genes, which are useful as models for disease and for identifying agents tha t modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
Description
TRANSGENIC MICE CONTAINING TARGETED GENE DISRUPTIONS
Related Applications This application claims priority to U.S. Application No. 60/190,348, filed March 16, 2000; U.S. Application No. 60/191,128, filed March 22, 2000; U.S. Application No.
60/191,236, filed March 22, 2000; U.S. Application No. 60/191,235, filed March 22, 2000;
U.S. Application No. 60/191,129, filed March 22, 2000; U.S. Application No.
60/191,142, filed March 22, 2000; U.S. Application No. 60/191,240, filed March 22, 2000;
U.S.
Application No. 60/204,227, filed May 15, 2000; U.S. Application No.
60/204,230, filed May 15, 2000; U.S. Application No. 60/215,214, filed June 29, 2000; U.S.
Application No.
60/216,249, filed July 6, 2000; U.S. Application No. 60/216,264, filed July 6, 2000; U.S.
Application No. 60/216,765, filed July 6, 2000; U.S. Application No.
60/218,075, filed July 12, 2000; U.S. Application No. 60/219,167, filed July 19, 2000; U.S.
Application No.
60/219,182, filed July 19, 2000; U.S. Application No. 60/221,485, filed July 27, 2000; and U.S. Application No. 60/223,173, filed August 7, 2000.
Field of the Invention The present invention relates to transgenic animals, compositions and methods relating to the characterization of gene function.
Background of the Invention Experimental animal models are important tools for understanding the role of genes.
More particularly, the ability to develop animals with specific genes altered or inactivated has been invaluable to the study of gene function, and has lead to unexpected discoveries of a gene and/or mechanisms responsible for disease with similar manifestations in humans.
These genetically engineered animals are also useful for identifying and,testing therapeutic treatments for a variety of diseases and disorders.
The identification of the function of numerous genes have been useful in ascertaining their roles in disease. Because of the high level of homology between humans and mice, it is possible to define the function of individual human genes by making targeted germline mutations in selected genes in the mouse. The phenotype of the resulting mutant mice can be used to help define the phenotype in humans.
Several interesting genes have recently been discovered. Identifying the roles of these genes and their expression products may permit the definition of disease pathways and the identification of diagnostically and therapeutically useful targets.
Many medically significant biological processes are mediated by proteins participating in signal transduction pathways that involve G-proteins and/or second t0 messengers such as cAMP. The membrane protein gene superfamily of G-protein coupled receptors (GPCRs) include a wide range of biologically active receptors, such as hormone, viral, growth factor and neuroreceptors. GPCRs have been characterized as having seven putative transmembrane domains (designated TM1, TM2, TM3, TM4, TMS, TM6, and TM7), which are believed to represent transmembrane a-helices connected by extracellular or 15 cytoplasmic loops. Most G-protein coupled receptors have single conserved cysteine residues in each of the first two extracellular loops which form disulfide bonds that are believed to stabilize functional protein structure. G-protein coupled receptors can be intracellularly coupled by heterotrimeric G-proteins to various intracellular enzymes, ion channels and transporters. Different G-protein a-subunits preferentially stimulate particular 20 effectors to modulate various biological functions in a cell.
Nuclear receptor genes that may be potentially important in retinal diseases, specifically retina-specific nuclear receptor genes have been identified.
(Proc. Natl. Acad.
Sci. USA 96:15149). The retina-specific nuclear receptor may be a potential regulator of cellular retinaldehyde-binding protein expressed in retinal pigment epithelium and glial cells.
25 Such genes have been postulated to regulate the visual cycle through its interaction with cellular retinaldehyde binding protein.
A lymphoid-specific member of the GPCR family has been identified by PCR with degenerate oligonucleotides. (GenonZics 23(3), 643-50 (1994)). This receptor, reported as the Epstein-Barr-induced cDNA EBI1, is expressed in normal lymphoid tissues and in several B-30 and T-lymphocyte cell lines. The gene is encoded on human chromosome 17q12-q21.2.
None of the other G-protein-coupled receptors has been mapped to this region, but the C-C
chemokine family has been mapped to 17q11-q21. The mouse EBI1 cDNA has also been isolated and encodes a protein with 86% identity to the human homolog. The murine EBI1 is a C-C chemokine type 7 receptor (variously referred to as CCR-7, C-C CKR-7 or CC-CKR-35 7). Although its gene structure may be known, the function and ligand EBI1 are unknown.
Melanocyte stimulating hormones (MSH) regulates pigmentation function. This peptide also has a variety of biological activities in other areas, including the brain, the pituitary, and the immune system. The murine melanocyte stimulating hormone receptor (MSH-R) mRNA has been cloned (1260 bp) and found to define a subfamily of receptors coupled to guanine nucleotide-binding proteins that may include the cannabinoid receptor (Science 257(5074), 1248-1251 (1992)).
Phosphatases represent unique and attractive targets for small-molecule inhibition and pharmacological intervention. The protein phosphorylation/dephosphorylation cycle is one l0 of the major regulatory mechanisms employed by eukaryotic cells to control cellular activities including growth and differentiation, cell-to-cell contacts, the cell cycle, and oncogenesis. It is estimated that more than 10% of the active proteins in a typical mammalian cell are phosphorylated. During protein phosphorylation/dephosphorylation, phosphate groups are transferred from adenosine triphosphate (ATP) molecules to a protein l5 by protein kinases and are removed from the protein by protein phosphatases.
Since nearly all forms of human neoplasias have altered cell cycle control, the role of phosphatases in cell cycle control makes these molecules attractive targets for pharmaceutical intervention. The ability of phosphatase inhibitors to interfere with aberrant cell activity has been demonstrated. For example, the naturally occurring serine/threonine phosphatase 20 inhibitor okadaic acid has been shown to induce apoptosis in myeloid leukemia cells (J. Cell.
Phy.siol. 150, 484 (1992)) and in rat hepatocytes, rat pituitary adenoma cell, human mammary carcinoma cells and human neuroblastoma cells (Exp. Cell Res. 195, 237 (1991)).
Magnesium dependent protein phosphatases appears to participate in a wide variety of functions including regulating cAMP-activated protein-kinase activity, Ca2+-dependent signal 25 transduction, tRNA splicing, and signal transmission related to heat shock responses.
Recently, it was reported that the complete cDNA sequence encoding PP2C, alpha isoform (or PP2C-alpha) was cloned from mouse brain. PP2C-alpha (GI or NID Number:
532678;
Accession Number: D28117) is a 1387 by sequence which encodes a protein of 382 amino acids with a calculated molecular mass of 42,432 Da (Gene 145(2), 311-312 (1994)).
30 Another important GPCR subfamily is the chemokine receptor family which are known as chemotactic cytokines. The mechanism of chemokine action involves initial specific binding to seven transmembrane spanning GPCRs on target cells. The central role of chemokines in inflammatory reactions has been demonstrated by numerous studies. Local administration of alpha chemokines, e.g., IL,-8, by subcutaneous injection results in acute 35 inflammatory reactions that are dominated by neutrophil infiltration.
Recently, the cloning of a rat CXC chemokine receptorl (CXCR1) gene has been reported (J. Biol. Chem.
271(51), 32770-6 (1996)). This CXCR1 gene (GI or NID number: 1589930; Accession number:
U71089) is homologous to the human interleukin-8 (IL-8) receptors, having an amino acid sequence approximately 70-85% identical to the human IL-8 A and B receptor subtypes, and homologous also to the murine CXCR1 gene.
Phosphodiesterases (PDEs) are a class of enzymes responsible for the degradation of phosphodiester bonds. In particular, cyclic nucleotide phosphodiesterases (CN-PDEs) show specificity for purine cyclic nucleotide substrates and hydrolyze cyclic adenosine l0 monophosphate (CAMP) and cyclic guanosine monophosphate (cGMP) (Pharmac.
Ther. 51, 13-33 (1991)). CN-PDEs regulate the steady-state levels of cAMP and cGMP and modulate both the amplitude and duration of cyclic nucleotide signals. In turn, cAMP
and cGMP are important "second messenger" molecules in signal transduction, the general process by which cells respond to extracellular signals (hormones, drugs, neurotransmitters, growth and differentiation factors, and other agents). Signal transduction regulates all types of cell functions including cell proliferation, differentiation, and gene transcription. At least eight different but homologous gene subfamilies of CN-PDEs are currently known to exist in mammalian tissues.
Members of the type 6 subfamily of PDE (PDE6) are associated with retinal phototransduction (J. Baol. Chem. 266, 10711-14 (1991)). In phototransduction, light impinging on a photoreceptor cell triggers a nerve signal by activating a cascade of biochemical events leading to the hydrolysis of cGMP by PDE6. PDE6 is a tetrameric protein composed of catalytic alpha and beta (a and (3) subunits, and two inhibitory gamma ('y) subunits. Dissociation of the inhibitory gamma subunits from the enzyme complex is induced by a membrane-associated protein called transducin and activates the enzyme. PDE6 defects have been associated with hereditary retinal degenerative diseases, characterized by retinal degeneration. Given the importance of phosphodiesterases, particularly PDEs associated with retinal function (e.g., PDE6), a clear need exists for identification and characterization of phosphodiesterases which can play a role in preventing, ameliorating or courecting dysfunctions or diseases, and, especially, vision-related dysfunctions and diseases, such as retinal degeneration (RD) and, specifically, retinitis pigmentosa (RP).
The metabolism of many drugs, xenobiotics, neurotransmitters and hormones includes a step involving the enzymatic addition of a sulfate (S04) group. The addition of a sulfate group is commonly referred to as sulfate conjugation, or simply sulfation. The enzymes responsible for sulfate conjugation are known as sulfotransferases (or ST's), as they act by transferring a sulfate group from one biological molecule (the sulfate donor) to another (the sulfate acceptor) in a sulfotransferase reaction.
Cytosolic sulfotransferase enzymes in human liver have been subjected to intensive research because sulfation increases the water solubility of most compounds and, therefore, their renal excretion. Sulfation also usually results in a decrease in biological activity.
However, in some cases, sulfate conjugation is required to activate drugs such as the antihypertensive medication minoxidil (Biochem. Pharmacol., 31, 2949-2954 (1982)), and it can also play a role in the bioactivation of procarcinogens such as hydroxylarylamines (Science, 215, 403 (1982); ChenZ. Biol. Interact. 109, 221-35 (1998)).
To date, genetic engineering efforts in the field of sulfate metabolism have resulted in the cloning and expression of cDNAs for several sulfotransferase enzymes:
human liver DHEA ST (Mol. Pharmacol. 41, 865-872 (1992)), TS PST (Mol. Pharmacol. 43, 70-(1993)), TL PST (Biocl2ern. Biophys. Res. Commun. 198, 1119-1127 (1994)) and a group of estrogen sulfotransferases isolated from several tissues of nonhuman mammalian species (Aust. J. Biol. Sci. 41, 507-516 (1988); Mol. Endocrinol. 6, 589-597 (1992)).
Also, the cDNA sequence (1269 bp) of the mouse liver phenol/aryl form of sulfotransferase (mSTpl) has been determined (Biochim. Biophys. Acta 1171(3), (1993)). The cloned cDNA was reported to contain an 897 nucleotide open reading frame (ORF) beginning at nucleotide 65, which encodes a 298 amino acid polypeptide of 34.7 kD.
The mSTp I gene has GI or N>D number 201069 and Accession number L02331. The human STpl gene has been extensively characterized (Pharmacogenetics 6, 473-487 (1996);
Biochem. Biophys. Res. Conamun. 228, 134-140 (1996)). The STpI gene is also referred to as the SLTLT 1 A 1 gene.
Experimental animal models would provide an important tool in understanding the roles of retina-specific nuclear receptor genes, lymphoid-specific GPCR genes, melanocyte stimulating hormone receptor genes, magnesium-dependent protein phosphatase genes, chemokine receptor 1-like protein genes, cGMP phosphodiesterase genes and sulfotransferase genes. Such understanding of their roles may permit the definition of disease pathways, the identification of diagnostically and therapeutically useful targets, and the testing and investigating of potential therapeutic treatments.
Summary of the Invention The present invention generally relates to transgenic animals, as well as to compositions and methods relating to the characterization of gene function.
More specifically, the present invention relates to various genes and their in vivo characterization and function.
The present invention provides transgenic cells comprising a disruption in a target gene. The transgenic cells of the present invention are comprised of any cells capable of undergoing homologous recombination. Preferably the cells of the present invention are stem cells and more preferably, embryonic stem (ES) cells, and most preferably, murine ES cells.
According to one embodiment, the transgenic cells are produced by introducing a targeting l0 construct into a stem cell to produce a homologous recombinant, resulting in a mutation of the target gene. In another embodiment, the transgenic cells are derived from the transgenic animals described below. The cell derived from the transgenic animals includes cells that are isolated or present in a tissue or organ, and any cell lines or any progeny thereof.
The present invention also provides a targeting construct and methods of producing the targeting construct that when introduced into stem cells produces a homologous recombinant. In one embodiment, the targeting construct of the present invention comprises first and second polynucleotide sequences that are homologous to the target gene. The targeting construct also comprises a polynucleotide sequence that encodes a selectable marker that is preferably positioned between the two different homologous polynucleotide sequences in the construct. The targeting construct may also comprise other regulatory elements that may enhance homologous recombination.
The present invention further provides non-human transgenic animals and methods of producing such non-human transgenic animals comprising a disruption in a target gene. The transgenic animals of the present invention include transgenic animals that are heterozygous and homozygous for a mutation in the target gene. In one aspect, the transgenic animals of the present invention are defective in the function of the target gene. In another aspect, the transgenic animals of the present invention comprise a phenotype associated with having a mutation in a target gene.
The present invention also provides methods of identifying agents capable of affecting a phenotype of a transgenic animal. For example, a putative agent is administered to the transgenic animal and a response of the transgenic animal to the putative agent is measured and compared to the response of a "normal" or wild type mouse, or alternatively compared to a transgenic animal control (without agent administration). The invention further provides agents identified according to such methods. The present invention also provides methods of identifying agents useful as therapeutic agents for treating conditions associated with a disruption of the target gene.
The present invention further provides a method of identifying agents having an effect on target gene expression or function. The method includes administering an effective amount of the agent to a transgenic animal, preferably a mouse, having a disruption in a target gene. The method includes measuring a response of the transgenic animal, for example, to the agent, and comparing the response of the transgenic animal to a control animal, which may be, for example, a wild-type animal or alternatively, a transgenic animal control. Compounds that may have an effect on gene expression or function may also be t0 screened against cells in cell-based assays, for example, to identify such compounds.
The invention also provides cell lines comprising nucleic acid sequences of a target gene. Such cell lines may be capable of expressing such sequences by virtue of operable linkage to a promoter functional in the cell line. Preferably, expression of the target gene sequence is under the control of an inducible promoter. Also provided are methods of identifying agents that interact with the target gene, comprising the steps of contacting the target gene with an agent and detecting an agendtarget gene complex. Such complexes can be detected by, for example, measuring expression of an operably linked detectable marker.
The invention further provides methods of treating diseases or conditions associated with a disruption in a target gene, and more particularly, to a disruption in the expression or function of the target gene. In a preferred embodiment, methods of the present invention involve treating diseases or conditions associated with a disruption in the target gene's expression or function, including administering to a subject in need, a therapeutic agent which effects target gene expression or function. In accordance with this embodiment, the method comprises administration of a therapeutically effective amount of a natural, synthetic, semi-synthetic, or recombinant target gene, target gene products or fragments thereof as well as natural, synthetic, semi-synthetic or recombinant analogs.
The present invention further provides methods of treating diseases or conditions associated with disrupted targeted gene expression or function, wherein the methods comprise detecting and replacing through gene therapy mutated target genes.
Definitions As used herein, "gene" refers to (a) a gene containing at least one of the DNA
sequences disclosed herein; (b) any DNA sequence that encodes the amino acid sequence encoded by the DNA sequences disclosed herein and/or; (c) any DNA sequence that hybridizes to the complement of the coding sequences disclosed herein.
Preferably, the term includes coding as well as noncoding regions, and preferably includes all sequences necessary for normal gene expression including promoters, enhancers and other regulatory sequences.
The terms "polynucleotide" and "nucleic acid molecule" are used interchangeably to refer to polymeric forms of nucleotides of any length. The polynucleotides may contain deoxyribonucleotides, ribonucleotides and/or their analogs. Nucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The term "polynucleotide" includes single-, double-stranded and triple helical molecules.
"Oligonucleotide" refers to polynucleotides of between 5 and about 100 nucleotides of single- or double-stranded DNA. Oligonucleotides are also known as oligomers or oligos and may be isolated from genes, or chemically synthesized by methods known in the art. A
"primer" refers to an oligonucleotide, usually single-stranded, that provides a 3'-hydroxyl end for the initiation of enzyme-mediated nucleic acid synthesis.
The following are non-limiting embodiments of polynucleotides: a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. A nucleic acid molecule may also comprise modified nucleic acid molecules, such as methylated nucleic acid molecules and nucleic acid molecule analogs. Analogs of purines and pyrimidines are known in the art, and include, but are not limited to, aziridinycytosine, 4-acetylcytosine, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethyl-aminomethyluracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, pseudouracil, 5-pentylnyluracil and 2,6-diaminopurine.
The use of uracil as a substitute for thymine in a deoxyribonucleic acid is also considered an analogous form of pyrimidine.
A "fragment" of a polynucleotide is a polynucleotide comprised of at least 9 contiguous nucleotides, preferably at least 15 contiguous nucleotides and more preferably at least 45 nucleotides, of coding or non-coding sequences.
As used herein, "base pair," also designated "bp," refers to the complementary nucleic acid molecules. In DNA there are four "types" of bases: the purine base adenine (A) is hydrogen bonded with the pyrimidine base thymine (T), and the purine base guanine (G) with the pyrimidine base cytosine (C). Each hydrogen bonded base pair set is also known as a Watson-Crick base-pair. A thousand base pairs is often called a kilobase pair, or kb. A "base pair mismatch" refers to a location in a nucleic acid molecule in which the bases are not complementary Watson-Crick pairs. The phrase "does not include at least one type of base at any position" refers to a nucleotide sequence which does not have one of the four bases at any position. For example, a sequence lacking one nucleotide (i.e., lacking one type of base) could be made up of A, G, T base pairs and contain no C residues.
As used herein, "gene targeting" is a type of homologous recombination that occurs , when a fragment of genomic DNA is introduced into a mammalian cell and that fragment locates and recombines with endogenous homologous sequences.
l0 The term "homologous recombination" refers to the exchange of DNA fragments between two DNA molecules or chromatids at the site of homologous nucleotide sequences.
The term "homologous" as used herein denotes a characteristic of a DNA
sequence having at least about 70 percent sequence identity as compared to a reference sequence, typically at least about 85 percent sequence identity, preferably at least about 95 percent sequence identity, and more preferably about 98 percent sequence identity, and most preferably about 100 percent sequence identity as compared to a reference sequence. Homology can be determined using a "BLASTN" algorithm. It is understood that homologous sequences can accommodate insertions, deletions and substitutions in the nucleotide sequence. Thus, linear sequences of nucleotides can be essentially identical even if some of the nucleotide residues do not precisely con-espond or align. The reference sequence may be a subset of a larger sequence, such as a portion of a gene or flanking sequence, or a repetitive portion of a chromosome.
As used herein, the term "target gene" (alternatively referred to as "target gene sequence" or "target DNA sequence" or "target sequence") refers to any nucleic acid molecule or polynucleotide of any gene to be modified by homologous recombination. The target sequence includes an intact gene, an exon or intron, a regulatory sequence or any region between genes. In one aspect, the nucleic acid molecule having a sequence in the general population is not associated with any disease or discernible phenotype. It is noted that in the general population, wild-type genes may include multiple prevalent versions that contain alterations in sequence relative to each other and yet do not cause a discernible pathological effect. These variations are designated "polymorphisms" or "allelic variations."
The target gene comprises a portion of a particular gene or genetic locus in the individual's genomic DNA. As provided herein, the target gene of the present invention consists of a retina-specific nuclear receptor gene, a lymphoid-specific GPCR gene, a melanocyte stimulating hormone receptor gene, a magnesium-dependent protein phosphatase gene, a chemokine receptor 1-like protein gene, an cGMP phosphodiesterase gene and a sulfotransferase gene, or a naturally occurring allelic variation or homologue thereof.
As used herein, the term "retina-specific nuclear receptor gene" refers to a sequence comprising SEQ >D N0:19 or the retina-specific nuclear receptor gene identified in Genebank as Accession No.: AF148129; GI NO: 6651226. In one aspect, the coding sequence of the retina-specific nuclear receptor gene comprises SEQ ID N0:19 or the sequence identified in Genebank as Accession No.: AF148129; GI NO: 6651226.
l0 As used herein, the term "lymphoid-specific GPCR gene" refers to a sequence comprising SEQ ID N0:22 or the lymphoid-specific GPCR gene in Genebank as Accession No.: L31580; GI NO: 468340. In one aspect, the coding sequence of the lymphoid-specific GPCR gene comprises SEQ >D N0:22 or the sequence identified in Genebank as Accession No.: L31580; GI NO: 468340.
As used herein, the term "melanocyte stimulating hormone receptor gene" refers to a sequence comprising SEQ 1D N0:25 or the melanocyte stimulating hormone receptor gene identified in Genebank as Accession No.: X65635; GI NO: 53244. In one aspect, the coding sequence of the melanocyte stimulating hormone receptor gene comprises SEQ ID
N0:25 or the sequence identified in Genebank as Accession No.: X65635; GI NO: 53244.
As used herein, the term "magnesium-dependent protein phosphatase gene" refers to a sequence comprising SEQ ID N0:28 or the magnesium-dependent protein phosphatase gene identified in Genebank as Accession No.: D28117; GI NO: 532678. In one aspect, the coding sequence of the magnesium-dependent protein phosphatase gene comprises N0:28 or the sequence identified in Genebank as Accession No.: D28117; GI NO:
532678.
As used herein, the term "chemokine receptor 1-like protein gene" refers to a sequence comprising SEQ ID N0:31 or the chemokine receptor 1-like protein gene identified in Genebank as Accession No.: U71089; GI NO: 1589930. In one aspect, the coding sequence of the chemokine receptor 1-like protein gene comprises SEQ m N0:31 or the sequence identified in Genebank as Accession No.: U71089; GI NO: 1589930.
As used herein, the term an "cGMP phosphodiesterase gene" refers to a sequence comprising SEQ ID N0:34 or the cGMP phosphodiesterase gene identified in Genebank as Accession No.: X60664; GI NO: 53587. In one aspect, the coding sequence of the cGMP
phosphodiesterase gene comprises SEQ ID N0:34 or the sequence identified in Genebank as Accession No.: X60664; GI NO: 53587.
As used herein, the term a "sulfotransferase gene" refers to a sequence comprising SEQ ID N0:37 or the sulfotransferase gene identified in Genebank as Accession No.:
L02331; Gl NO: 201069. In one aspect, the coding sequence of the sulfotransferase gene l0 comprises SEQ m N0:37 or the sequence identified in Genebank as Accession No.:
L02331; GI NO: 201069.
"Disruption" of a target gene occurs when a fragment of genomic DNA locates and recombines with an endogenous homologous sequence. These sequence disruptions or modifications may include insertions, missense, frameshift, deletion, or substitutions, or l0 replacements of DNA sequence, or any combination thereof. Insertions include the insertion of entire genes which may be of animal, plant, prokaryotic, or viral origin.
Disruption, for example, can alter or replace a promoter, enhancer, or splice site of a target gene, and can alter the normal gene product by inhibiting its production partially or completely or by enhancing the normal gene product's activity.
The teen, "transgenic cell", refers to a cell containing within its genome a target gene that has been disrupted, modified, altered, or replaced completely or partially by the method of gene targeting.
As used herein, a "n-ansgenic animal" is an animal that contains within its genome a specific gene that has been disrupted or inactivated completely or partially by the method of gene targeting. The transgenic animal includes both the heterozygote animal (i.e., one defective allele and one wild-type allele) and the homozygous animal (i.e., two defective alleles).
As used herein, the term "construct" refers to an artificially assembled DNA
segment to be transferred into a target tissue, cell line or animal, including human.
Typically, the construct will include the gene or a sequence of particular interest, a marker gene and appropriate control sequences. The term "plasmid" refers to an autonomous, self-replicating extrachromosomal DNA molecule. In a preferred embodiment, the plasmid construct of the present invention contains a positive selection marker positioned between two flanking regions of the gene of interest. Optionally, the construct can also contain a screening marker, for example, green fluorescent protein (GFP). If present, the screening marker is positioned outside of and some distance away from the flanking regions.
As used herein, the terms "selectable marker" or "positive selection marker"
refers to a gene encoding a product that enables only the cells that carry the gene to survive and/or grow under certain conditions. For example, plant and animal cells that express the introduced neomycin resistance (Neon) gene are resistant to the compound 6418.
Cells that do not carry the Neo' gene marker are killed by 6418. Other positive selection markers will be known to those of skill in the art.
"Positive-negative selection" refers to the process of selecting cells that carry a DNA
insert integrated at a specific targeted location (positive selection) and also selecting against cells that can-y a DNA insert integrated at a non-targeted chromosomal site (negative selection). Non-limiting examples of negative selection inserts include the gene encoding thymidine kinase (tk). Genes suitable for positive-negative selection are known in the art, see l0 e.g., U.S. Patent 5,464,764.
"Screening marker" or "reporter gene" refers to a gene that encodes a product that can readily be assayed. For example, reporter genes can be used to determine whether a particular DNA construct has been successfully introduced into a cell, organ or tissue. Non-limiting examples of screening markers include genes encoding for green fluorescent protein (GFP) or genes encoding for a modified fluorescent protein. "Negative screening marker" is not to be construed as negative selection marker; a negative selection marker typically kills cells that express it.
The term "vector" refers to a DNA molecule that can carry inserted DNA and be perpetuated in a host cell. Vectors are also known as cloning vectors, cloning vehicles or vehicles. The term includes vectors that function primarily for insertion of a nucleic acid molecule into a cell, replication vectors that function primarily for the replication of nucleic acid, and expression vectors that function for transcription and/or translation of the DNA or RNA. Also included are vectors that provide more than one of the above functions.
A "host cell" includes an individual cell or cell culture which can be or has been a recipient for vector (s) or for incorporation of nucleic acid molecules and/or proteins. Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in total DNA complement) to the original parent due to natural, accidental, or deliberate mutation. A host cell includes cells transfected with the constructs of the present invention.
The term "genomic library" refers to a collection of clones made from a set of randomly generated overlapping DNA fragments representing the genome of an organism. A
"cDNA library" (complementary DNA library) is a collection of mRNA molecules present in a cell, tissue, or organism, turned into cDNA molecules with the enzyme reverse transcriptase, then inserted into vectors (other DNA molecules which can continue to replicate after addition of foreign DNA). Exemplary vectors for libraries include bacteriophage (also known as "phage"), which are viruses that infect bacteria, for example lambda phage. The library can then be probed for the specific cDNA (and thus mRNA) of interest. In one embodiment, library systems which combine the high efficiency of a phage vector system with the convenience of a plasmid system (for example, ZAP
system from Stratagene, La Jolla, CA) are used in the practice of the present invention.
The term "exonuclease" refers to an enzyme that cleaves nucleotides sequentially from the free ends of a linear nucleic acid substrate. Exonucleases can be specific for double or single-stranded nucleotides and/or directionally specific, for instance, 3'-5' and/or 5'-3'.
l0 Some exonucleases exhibit other enzymatic activities, for example, T4 DNA
polymerase is both a polymerase and an active 3'-5' exonuclease. Other exemplary exonucleases include exonuclease III which removes nucleotides one at a time from the 5'-end of duplex DNA
which does not have a phosphorylated 3'-end, exonuclease VI which makes oligonucleotides by cleaving nucleotides off of both ends of single-stranded DNA, and exonuclease lambda which removes nucleotides from the 5' end of duplex DNA which have 5'-phosphate groups attached to them.
The term "recombinase" encompasses enzymes that induce, mediate or facilitate recombination, and other nucleic acid modifying enzymes that cause, mediate or facilitate the rearrangement of a nucleic acid sequence, or the excision or insertion of a first nucleic acid sequence from or into a second nucleic acid sequence. The "target site" of a recombinase is the nucleic acid sequence or region that is recognized (e.g., specifically binds to) and/or acted upon (excised, cut or induced to recombine) by the recombinase. As used herein, the expression "enzyme-directed site-specific recombination" is intended to include the following events: deletion of a pre-selected DNA segment flanked by recombinase target sites;
inversion of the nucleotide sequence of a pre-selected DNA segment flanked by recombinase target sites; and reciprocal exchange of DNA segments proximate to recombinase target sites located on different DNA molecules.
The term "modulates" as used herein refers to the inhibition, reduction or enhancement of a target gene's function, expression, or alternatively a phenotype associated with a disruption in a target gene.
The term "ameliorates" refers to a decreasing, reducing or eliminating a condition, disease, disorder, or phenotype, including an abnormality or symptom associated with a disruption in a target gene.
The term "abnomnality" refers to any disease, disorder, condition, or a phenotype in which a disruption of a target gene is implicated, including pathological conditions.
Brief Description of the Drawings Figure 1 is a schematic depicting one method of constructing a targeting vector of the present invention. The plasmid PCR method is described in Examples 9 and 10.
Figure 2A is a schematic depicting the pDG2 vector. The vector contains an ampicillin resistance gene and a neomycin (Neo') gene. On each side of the Neo' gene are two sites for ligation-independent cloning along with restriction sites. The sequence of pDG2 is shown in Figure 2B and SEQ ID NO:1.
Figure 3A is schematic depicting the pDG4 vector. The vector contains an ampicillin resistance gene, a neomycin (Neo') gene and a green fluorescent protein (GFP) gene. On each side of the Neo' gene are two sites for ligation-independent cloning along with restriction enzyme recognition sites. The sequence of pDG4 is shown in Figure 3B and SEQ
1D N0:2.
Figure 4 (SEQ ID N0:3 through SEQ 1D NO:10) shows the nucleic acid sequence before and after T4 DNA polymerise treatment of annealing sites 1-4 contained on the ends of PCR-amplified genomic DNA.
Figure 5 (SEQ ID NO:11 through SEQ >I7 N0:18) shows the nucleic acid sequence before and after T4 DNA polymerise treatment of annealing site 1-4 contained within the pDG2 vector.
Figure 6 shows the arrangement of 5' and 3' flanking DNA relative to annealing sites 1, 2, 3 and 4 within the pDG2 vector during an annealing reaction.
Figure 7 shows the arrangement of 5' and 3' flanking DNA relative to annealing sites 1, 2, 3 and 4 and the GFP screening marker within the pDG4 vector during an annealing reaction.
Figure 8 shows the polynucleotide sequence identified as SEQ )D N0:19. Figure also shows the sequences identified as SEQ 1D N0:20 and SEQ >D N0:21, which were used in the retina-specific nuclear receptor gene targeting construct.
Figure 9 shows the polynucleotide sequence identified as SEQ )D N0:22. Figure also shows the sequences identified as SEQ 1D N0:23 and SEQ >D N0:24, which were used in the lymphoid-specific GPCR gene targeting construct.
Figure 10 shows the polynucleotide sequence identified as SEQ 1D N0:25. Figure 10 also shows the sequences identified as SEQ >D N0:26 and SEQ >D N0:27 which were used in the melanocyte stimulating hormone receptor gene targeting construct.
Figure 11 shows the polynucleotide sequence identified as SEQ )D N0:28. Figure 11 also shows the sequences identified as SEQ )D N0:29 and SEQ >D N0:30 which were used in the magnesium-dependent protein phosphatase gene targeting construct.
Figure 12 shows the polynucleotide sequence identified as SEQ >D N0:31. Figure 12 also shows the sequences identified as SEQ ll~ N0:32 and SEQ >D N0:33 which were used in the chemokine receptor 1-like protein gene targeting construct.
Figure 13 shows the polynucleotide sequence identified as SEQ ID N0:34. Figure 13B shows the sequences identified as SEQ ID N0:35 and SEQ ID N0:36 which were used in the cGMP phosphodiesterase gene targeting construct.
Figure 14 shows the polynucleotide sequence identified as SEQ ID N0:37. Figure 14 also shows the sequences identified as SEQ >D N0:36 and SEQ >D N0:37 which were used in the sulfotransferase gene targeting construct.
Detailed Description of the Invention The invention is based, in part, on the evaluation of the expression and role of genes and gene expression products. Among others, the invention permits the definition of disease pathways and the identification of diagnostically and therapeutically useful targets. For example, genes which are mutated or down-regulated under disease conditions may be involved in causing or exacerbating the disease condition. Treatments directed at up-regulating the activity of such genes or treatments which involve alternate pathways, may ameliorate the disease condition.
Any technique known in the art may be used to introduce a target gene transgene into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to pronuclear microinjection (U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten, et al., Proc. Natl. Acad. Sci., USA, 82:6148-6152 (1985)); gene targeting in embryonic stem cells (Thompson, et al., Cell, 56:313-321 (1989));
electroporation of embryos (Lo, Mol Cell. Biol., 3:1803-1814 (1983)); and sperm-mediated gene transfer (Lavitrano, et al., Cell, 57:717-723 (1989)); etc. For a review of such techniques, see Gordon, Transgenic Animals, Intl. Rev. Cytol., 115:171-229 (1989), which is incorporated by reference herein in its entirety.
In a preferred embodiment, homologous recombination is used to generate the knockout mice of the present invention. Preferably, the construct is generated in two steps by (1) amplifying (for example, using long-range PCR) sequences homologous to the target sequence, and (2) inserting another polynucleotide (for example a selectable marker) into the PCR product so that it is flanked by the homologous sequences. Typically, the vector is a plasmid from a plasmid genomic library. The completed construct is also typically a circular plasmid. Thus, as shown in Figure 1, using long-range PCR with "outwardly pointing"
oligonucleotides results in a vector into which a selectable marker can easily be inserted, preferably by ligation-independent cloning. The construct can then be introduced into ES
cells, where it can disrupt the function of the homologous target sequence.
Homologous recombination may also be used to knockout genes in stem cells, and other cell types, which are not totipotent embryonic stem cells. By way of example, stem cells may be myeloid, lymphoid, or neural progenitor and precursor cells. Such transgenic cells may be particularly useful in the study of target gene function in individual developmental pathways. Stem cells may be derived from any vertebrate species, such as mouse, rat, dog, cat, pig, rabbit, human, non-human primates and the like.
In cells which are not totipotent it may be desirable to knock out both copies of the target using methods which are known in the art. For example, cells comprising homologous recombination at a target locus which have been selected for expression of a positive selection marker (e.g., Neor) and screened for non-random integration, can be further selected for multiple copies of the selectable marker gene by exposure to elevated levels of the selective agent (e.g., G418). The cells are then analyzed for homozygosity at the target locus.
Alternatively, a second construct can be generated with a different positive selection marker inserted between the two homologous sequences. The two constructs can be introduced into the cell either sequentially or simultaneously, followed by appropriate selection for each of the positive marker genes. The final cell is screened for homologous recombination of both alleles of the target.
In another aspect, two separate fragments of a clone of interest are amplified and inserted into a vector containing a positive selection marker using ligation-independent cloning technidues. In this embodiment, the clone of interest is generally from a phage library and is identified and isolated using PCR techniques. The ligation-independent cloning can be performed in two steps or in a single step.
According to a preferred method, constructs are used having multiple sites where 5'-3' single-stranded regions can be created. These constructs, preferably plasmids, include a vector capable of directional, four-way ligation-independent cloning.
The constructs typically include a sequence encoding a positive selection marker such as a gene encoding neomycin resistance; a restriction enzyme site on either side of the positive selection marker and a sequence flanking the restriction enzyme sites which does not contain one of the four base pairs. This configuration allows single-stranded ends to be created in the sequence by digesting the construct with the appropriate restriction enzyme and treating the fragments with a compound having exonuclease activity, for example T4 DNA
polymerise.
In one preferred embodiment, a construct suitable for introducing targeted mutations l0 into ES cells is prepared directly from a plasmid genomic library. Using long-range PCR
with specific primers, a sequence of interest is identified and isolated from the plasmid library in a single step. Following isolation of this sequence, a second polynucleotide that will disrupt the target sequence can be readily inserted between two regions encoding the sequence of interest. Using this direct method a targeted construct can be created in as little as 72 hours. In another embodiment, a targeted construct is prepared after identification of a clone of interest in a phage genomic library as described in detail below.
The methods described herein obviate the need for hybridization isolation, restriction mapping and multiple cloning steps. Moreover, the function of any gene can be determined using these methods. For example, a short sequence (e.g., EST) can be used to design oligonucleotide probes. These probes can be used in the direct amplification procedure to create constructs or can be used to screen genomic or cDNA libraries for longer full-length genes. Thus, it is contemplated that any gene can be quickly and efficiently prepared for use in ES cells.
In a preferred embodiment, constructs are prepared directly from a plasmid genomic library. The library can be produced by any method known in the art.
Preferably, DNA from mouse ES cells is isolated and treated with a restriction endonuclease which cleaves the DNA
into fragments. The DNA fragments are then inserted into a vector, for example a bacteriophage or phagemid (e.bf., Lamda ZAPTM, Stratagene, La Jolla, CA) systems. When the library is created in the ZAPTM system, the DNA fragments are preferably between about 5 and about 20 kilobases.
Preferably, the organisms) from which the libraries are made will have no discernible disease or phenotypic effects. Preferably, the library is a mouse library.
This DNA may be obtained from any cell source or body fluid. Non-limiting examples of cell sources available in clinical practice include ES cells, liver, kidney, blood cells, buccal cells, cerviovaginal cells, epithelial cells from urine, fetal cells, or any cells present in tissue obtained by biopsy.
Body fluids include urine, blood cerebrospinal fluid (CSF), and tissue exudates at the site of infection or inflammation. DNA extracted from the cells or body fluid using any method known in the art. Preferably, the DNA is extracted by adding 5 ml of lysis buffer (10 mM
Tris-HC1 pH 7.5), 10 mM EDTA (pH 8.0), 10 mM NaCI, 0.5% SDS and 1 mg/ml Proteinase K) to a confluent 100 mm plate of embryonic stem cells. The cells are then incubated at about 60°C for several hours or until fully lysed. Genomic DNA is purified from the lysed cells by several rounds of gentle phenol:chloroform extraction followed by an ethanol precipitation. For convenience, the genomic library can be arrayed into pools.
In a preferred embodiment, a sequence of interest is identified from the plasmid library using oligonucleotide primers and long-range PCR. Typically, the primers are outwardly-pointing primers which are designed based on sequence information obtained from a partial gene sequence, e.g., a cDNA or an EST sequence. As depicted for example in Figure 1, the product will be a linear fragment that excludes the region which is located between each primer.
PCR conditions found to be suitable are described below in the Examples. It will be understood that optimal PCR conditions can be readily determined by those skilled in the art.
(See, e.g., PCR 2: A Practical Approach (1995) eds. M.J. McPherson, B.D. Hames and G.R.
Taylor, IRL Press, Oxford; Yu, et al., Metlaods Mol. Bio., 58:335-9 (1996);
Munroe, et al., Proc. NatZ Accrd. Sci., USA, 92:2209-13 (1995)). PCR screening of libraries eliminates many of the problems and time-delay associated with conventional hybridization screening in which the library must be plated, filters made, radioactive probes prepared and hybridization conditions established. PCR screening requires only oligonucleotide primers to sequences (genes) of interest. PCR products can be purified liy a variety of methods, including but not limited to, microfiltration, dialysis, gel electrophoresis and the like. It may be desirable to remove the polymerase used in PCR so that no new DNA synthesis can occur.
Suitable thermostable DNA polymerases are commercially available, for example, VentTM
DNA
Polymerase (New England Biolabs), Deep VentTM DNA Polymerase (new England Biolabs), HotTubTM DNA Polymerase (Amersham), Thermo SequenaseTM (Amersham), rBstTM DNA
Polymerase (Epicenter), PfuTM DNA Polymerase (Stratagene), Amplitaq GoldT~'' (Perkin Elmer), and ExpandT'~' (Boehringer-Mannheim).
To form the completed construct, a sequence which will disrupt the target sequence is inserted into the PCR-amplified product. For example, as described herein, the direct method involves joining the long-range PCR product (i.e., the vector) and one fragment (i.e., a gene encoding a selectable marker). As discussed above, the vector contains two different sequence regions homologous to the target DNA sequence. Preferably, the vector also contains a sequence encoding a selectable marker, such as ampicillin. The vector and fragment are designed so that, when treated to form single stranded ends, they will anneal such that the fragment is positioned between the two different regions of substantial homology to the target gene.
Although any method of cloning is suitable, it is preferred that ligation-independent cloning strategies be used to assemble the construct comprising two different homologous regions flanking a selectable marker. Ligation-independent cloning (LIC) is a strategy for the l0 directional cloning of polynucleotides without the use of kinases or ligases. (See, e.g., Aslanidis et al., NLCCIeic Acids Res., 18:6069-74 (1990); Rashtchian, Current Opin. Biotech., 6:30-36 (1995)). Single-stranded tails (also referred to as cloning sites or annealing sequences) are created in LIC vectors, usually by treating the vector (at a digested restriction enzyme site) with T4 DNA polymerise in the presence of only one dNTP. The 3' to 5' exonuclease activity of T4 DNA polymerise removes nucleotides until it encounters a residue con-esponding to the single dNTP present in the reaction mix. At this point, the 5' to 3' polymerise activity of the enzyme counteracts the exonuclease activity to prevent further excision. The vector is designed such that the single-stranded tails created are non-complementary. For example, in the pDG2 vector, none of the single-stranded tails of the four annealing sites are complementary to each other. PCR products are created by building appropriate 5' extensions into oligonucleotide primers. The PCR product is purified to remove dNTPs (and original plasmid if it was used as template) and then treated with T4 DNA polymerise in the presence of the appropriate dNTP to generate the specific vector-compatible overhangs. Cloning occurs by annealing of the compatible tails.
Single-stranded tails are created at the ends of the clone fragments, for example using chemical or enzymatic means. Complementary tails are created on the vector; however, to prevent annealing of the vector without insert, the vector tails are not complementary to each other.
The length of the tails is at least about 5 nucleotides, preferably at least about 12 nucleotides, even more preferably at least about 20 nucleotides.
In one embodiment, placing the overlapping vector and fragments) in the same reaction is sufficient to anneal them. Alternatively, the complementary sequences are combined, heated and allowed to slowly cool. Preferably the heating step is between about 60°C and about 100°C, more preferably between about 60°C
and 80°C, and even more preferably between 60°C and 70°C. The heated reactions are then allowed to cool.
Generally, cooling occurs rather slowly, for instance the reactions are generally at about room temperature after about an hour. The cooling must be sufficiently slow as to allow annealing.
The annealed fragment/vector can be used immediately, or stored frozen at -20°C until use.
Further, annealing can be performed by adjusting the salt and temperature to achieve suitable conditions. Hybridization reactions can be performed in solutions ranging from about 10 mM NaCl to about G00 mM NaCl, at temperatures ranging from about 37°C to about G5°C. It will be understood that the stringency of the hybridization reaction is determined by both the salt concentration and the temperature. For instance, a hybridization l0 performed in 10 mM salt at 37°C may be of similar stringency to one performed in 500 mM
salt at 65°C. For the present invention, any hybridization conditions may be used that form hybrids between homologous complementary sequences.
As shown in Figure 1, in one embodiment, a construct is made after using any of these annealing procedure where the vector portion contains the two different regions of substantial homology to the target gene (amplified from the plasmid library using long-range PCR) and the fragment is a gene encoding a selectable marker.
After annealing, the construct is transformed into competent E. coli cells by methods known in the art, to amplify the construct. The isolated construct is then ready for introduction into ES cells.
In another embodiment, a clone of interest is identified in a pooled genomic library using PCR. In one embodiment, the PCR conditions are such that a gene encoding a selectable marker can be inserted directly into the positively identified clone. The marker is positioned between two different sequences having substantial homology to the target DNA.
Genomic phage libraries can be prepared by any method known in the art.
Preferably, a mouse embryonic stem cell library is prepared in lambda phage by cleaving genomic DNA
into fragments of approximately 20 kilobases in length. The fragments are then inserted into any suitable lambda cloning vector, for example lambda Fix II or lambda Dash II (Stratagene, La Jolla, Ca) In order to quickly and efficiently screen a large number of clones from a library, pools may be created of plated libraries. In a preferred embodiment, a genomic lambda phage library is plated at a density of approximately 1,000 clones (plaques) per plate.
Sufficient plates are created to represent the entire genome of the organism several times over. For example, approximately 1 million clones (1000 plates) will yield approximately 8 genome equivalents. The plaques are then collected, for example by overlaying the plate with a buffer solution, incubating the plates and recollecting the buffer. The amount of buffer used will vary according to the plate size, generally one 100 mm diameter plate will be overlayed with approximately 4 ml of buffer and approximately 2 ml will be collected.
It will be understood that the individual plate lysates can be pooled at any time during this procedure and that they can be pooled in any combinations. For ease in later identification of single clones, however, it is preferable to keep each plate lysate separately and then make a pool. For example, each 2 ml lysate can be placed in a 96 well deep well plate. Pools can then be formed by taking an amount, preferably about 100 ~ l, from each t0 well and combining them in the well of a new plate. Preferably, 100 O1 of 12 individual plate lysates are combined in one well, forming a 1.2 ml pool representative of 12,000 clones of the library.
Each pool is then PCR-amplified using a set of PCR primers known to amplify the target gene. The target gene can be a known full-length gene or, more preferably, a partial eDNA sequence obtained from publicly available nucleic acid sequence databases such as GenBank or EMBL. These databases include partial eDNA sequences known as expressed sequence tags (ESTs). The oligonucleotide PCR primers can be isolated from any organism by any method known in the art or, preferably, synthesized by chemical means.
Once a positive clone of the target gene has been identified in a genomic library, two fragments encoding separate portions of the target gene must be generated. In other words, the flanking regions of the small known region of the target (e.g., EST) are generated.
Although the size of each flanking region is not critical and can range from as few as 100 base pairs to as many as 100 kb, preferably each flanking fragment is greater than about 1 kb in length, more preferably between about 1 and about 10 kb, and even more preferably between about 1 and about 5 kb. One of skill in the art will recognize that although larger fragments may increase the number of homologous recombination events in ES
cells, larger fragments will also be more difficult to clone.
In one embodiment, one of the oligonucleotide PCR primers used to amplify a flanking fragment is specific for the library cloning vector, for example lambda phage.
Therefore, if the library is a lambda phage library, primers specific for the lambda phage arms can be used 111 COlllu11Ct1011 Wlth primers specific for the positive clone to generate long flanking fragments. Multiple PCR reactions can be set up to test different combinations of primers. Preferably, the primers used will generate flanking sequences between about 2 and about 6 kb in length.
Preferably, the oligonucleotide primers are designed with 5' sequences complementary to the vector into which the fragments will be cloned. In addition, the primers are also designed so that the flanking fragments will be in the proper 3'-5' orientation with respect to the vector and each other when the construct is assembled.
Thus, using PCR-based methods, for example, positive clones can be identified by visualization of a band on an electrophoretic gel.
In one aspect, the cloning involves a vector and two fragments. The vector contains a positive selection marker, preferably Neo', and cloning sites on each side of the positive selection marker for two different regions of the target gene. Optionally, the vector also l0 contains a sequence coding for a screening marker (reporter gene), preferably, positioned opposite the positive selection marker. The screening marker will be positioned outside the flanking regions of homologous sequences. Figure 3A shows one embodiment of the vector with the screening marker, GFl', positioned on one side of the vector.
However, the screening marker can be positioned anywhere between Not I and Site 4 on the side opposite the positive selection marker, Neo'.
One example of a suitable vector is the plasmid vector shown in Figure 2 having the sequence of SEQ 1D NO:1. The specific nucleic acid ligation-independent cloning sites (also referred to herein as annealing sites) labeled "sites 1, 2, 3 or 4" in Figure 1 are also shown herein. Generally, the cloning sites are lacking at least one type of base, i.e., thymine (T), guanine (G), cytosine (C) or adenine (A). Accordingly, reacting the vector with an enzyme that acts as both a polymerise and exonuclease in presence of only the one missing nucleotide will create an overhang. For example, T4 DNA polymerise acts as both a 3'-5' exonuclease and a polymerise. Thus, when there are insufficient nucleotides available for the polymerise activity, T4 will act as an exonuclease. Specific overhangs can therefore be created by reacting the pDG2 vector with T4 DNA polymerise in the presence of dTTP only.
Other enzymes useful in the practice of this invention will be known to those in the art, for instance uracil DNA glycosylase (UDG) (See, e.g., WO 93/18175). The vector exemplified herein has an overhand of 24 nucleotides. It will be known by those skilled in the art that as few as 5 nucleotides are required for successful ligation independent cloning.
In another embodiment, a construct is assembled in a two-step cloning protocol. In the first step, each cloning region of homology is separately cloned into two of the annealing sites of the vector. For example, an "upstream" region of homology is cloned into annealing sites 1 and 2 while a separate cloning, a "downstream" region of homology is cloned into annealing sites 3 and 4. Once clones containing each single region of homology are identified, a targeting construct containing both regions of homology can be created by digesting each clone with restriction enzymes where one enzyme digests outside of annealing site 1 (e.g., Not I in Figure 2A) and another enzyme digests between the positive selection marker and annealing site 3 (e.g., Sal I in Figure 2A). The fragments containing the flanking homology regions from each construct will be purified (e.g., by gel electrophoresis) and combined using standard ligation techniques known in the art, to produce the resulting targeting construct.
In yet another embodiment, a construct according to one aspect of the present invention can be formed in a single-step, four-way ligation procedure. The vector and fragments are treated as described above. Briefly, the vector is treated to form two pieces, each piece having a single-stranded tail of specific sequence on each end.
Likewise, the PCR-amplified flanking fragments are also treated to form single-stranded tails complementary to those of the vector pieces. The treated vector pieces and fragments are combined and allowed to anneal as described above. Because of the specificity of the single-stranded tails, the final construct will contain the fragments separated by the positive selection marker in the proper orientation.
The final plasmid constructs are amplified in bacteria, purified and can then be introduced into ES cells, or stored frozen at -20°C until use. Where so desired, the vector is introduced into an embryonic stem cell line (e.g=., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected (.see e.g., Li, et al., Cell, 69:91526 (1992)). Successful recombination may be verified using various techniques known in the art, such as PCR and/or Southern analysis.
Typically, several hundred individual colonies are selected following drug selection in 6418 (for Neo cassettes), expanded for DNA preparation and screened for homologous recombination by PCR analysis. The PCR screening procedure uses a target gene specific oligonucleotide that is not present on the targeting vector and an oligonucleotide corresponding to the Neo (or other selectable marker) cassette. The selection of oligonucleotides outside the targeting vector is used to differentiate homologous recombinants from random integrations of the targeting vector. In general, four independent target gene specific oligonucleotides not present on the targeting vector are tested on wild type ES cell DNA in combination with target gene specific oligonucleotides that are adjacent to the insertion site of the Neo (Figure 9). Oligonucleotides producing background bands or failing to give the predicted size product are eliminated. A single target gene specific oligonucleotide is selected and paired with an oligonucleotide corresponding to the Neo cassette. ES cells that are PCR positive in this screen are confirmed by a second PCR experiment that utilizes a different pair of target gene specific and Neo gene (or other selectable marker) specific oligonucleotides that are adjacent to, but distinct from, the original oligonucleotide pair. In addition, this protocol may be repeated using oligonucleotides specific for target gene sequences located on the opposite side of the selectable marker in conjunction with a marker specific oligonucleotide. In this way proper integration of both homologous sequences of the targeting vector is verified.
Southern blot hybridization may also be used to confirm the ES cell targeting event using a probe that is not contained on the targeting vector but is adjacent to the predicted crossover site of homologous recombination. Southern blot experiments testing for homologous recombination should detect two distinct bands representing the wild type chromosome and mutant gene targeted allele. High molecular weight genomic DNA
is prepared from control ES cell parental lines and ES cell lines that are PCR
positive for homologous recombination. The DNA is digested with a restriction enzyme (EcoRl) that has been demonstrated by restriction mapping to not cut the targeting vector within the arm of the target gene DNA homology and to be diagnostic of homologous recombination. As an EcoRl site is present in the Neo gene, a homologous recombination event should result in the insertion of the Neo cassette and the addition of the EcoRl site. The addition of this site is predicted to result in an overall reduction in size of the band hybridizing to the probe. The digested DNA is separated on a 1 °7o TAE Agarose gel, transferred to a nylon membrane, 2o crosslinked with a UV light (StrataLinker) and hybridized with a 32-P
labeled DNA probe.
This probe does not hybridize to DNA sequences that are on the targeting vector but to a position that is adjacent to the site of homologous integration.
Selected cells are then injected into a blastocyst (or other stage of development suitable for the purposes of creating a viable animal, such as, for example, a morula) of an animal (e.g., a mouse) to form chimeras (see e.g., Bradley, A. in Teratocarcinomas and Embryonic Stenz Cells: A Practical Approach, E. J. Robertson, ed., IRL, Oxford, pp. 113-152 (1987)). Alternatively, selected ES cells can be allowed to aggregate with dissociated mouse embryo cells to form the aggregation chimera. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term.
Chimeric progeny harbouring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA. In one embodiment, chimeric progeny mice are used to generate a mouse with a heterozygous disruption in the target gene. Heterozygous knockout mice can then be mated.
It is well know in the art that typically'/a of the offspring of such matings will have a homozygous disruption in the target gene.
The heterozygous and homozygous knockout mice can then be compared to normal, wild type mice to determine whether disruption of the target gene causes phenotypic changes, especially pathological changes. For example, heterozygous and homozygous mice may be evaluated for phenotypic changes by physical examination, necropsy, histology, clinical chemistry, complete blood count, body weight, organ weights, and cytological evaluation of bone marrow.
In one embodiment, the phenotype (or phenotypic change) associated with a disruption in the target gene is placed into or stored in a database.
Preferably, the database ~0 includes: (i) genotypic data (e.g., identification of the disrupted gene) and (ii) phenotypic data (e.g., phenotype(s) resulting from the gene disruption) associated with the genotypic data.
The database is preferably electronic. In addition, the database is preferably combined with a search tool so that the database is searchable.
The present invention further contemplates conditional knockout animals, such as those produced using recombination methods. Bacteriophage P1 Cre recombinase and flp recombinase from yeast plasmids are two non-limiting examples of site-specific DNA
recombinase enzymes which cleave DNA at specific target sites (lox P sites for cre recombinase and frt sites for flp recombinase) and catalyze a ligation of this DNA to a second cleaved site. A large number of suitable alternative site-specific recombinases have been described, and their genes can be used in accordance with the method of the present invention. Such recombinases include the Int recombinase of bacteriophage 7~
(with or without Xis) (Weisberg, R. et. al., in Lambda 1l, (Hendrix, R., et al., Eds.), Cold Spring Harbor Press, Cold Spring Harbor, NY, pp. 211-50 (1983), herein incorporated by reference);
TpnI and the (3-lactamase transposons (Mercier, et al., J. Bacteriol., 172:3745-57 (1990)); the Tn3 resolvase (Flanagan & Fennewald J. Molec. Biol., 206:295-304 (1989);
Stark, et al., Cell, 58:779-90 (1989)); the yeast recombinases (Matsuzaki, et al., J.
Bacteriol., 172:610-18 (1990)); the B. subtili.s SpoIVC recombinase (Sato, et al., J. Bacteriol.
172:1092-98 (1990));
the Flp recombinase (Schwartz & Sadowski, J. Molec.Biol., 205:647-658 ( 1989);
Parsons, et al., J. Biol. Claen2., 265:4527-33 (1990); Golic & Lindquist, Cell, 59:499-509 (1989); Amin, et al., J. Molec. Biol., 214:55-72 (1990)); the Hin recombinase (Glasgow, et al., J. Biol.
Chem., 264:10072-82 (1989)); immunoglobulin recombinases (Malynn, et al., Cell, 54:453-460 (1988)); and the Cin recombinase (Haffter & Bickle, EMBO J., 7:3991-(1988); Hubner, et al., J. Molec. Biol., 205:493-500 (1989)), all herein incorporated by reference. Such systems are discussed by Echols (J. Biol. Chem. 265:14697-14700 (1990));
de Villartay (Nature, 335:170-74 (1988)); Craig, (Ann. Rev. Genet., 22:77-105 (1988));
Poyart-Salmeron, et al., (EMBO J. 8:2425-33 (1989)); Hunger-Bertling, et al.
(Mol Cell.
BiochenZ., 92:107- l 6 ( 1990)); and Cregg & Madden (Mol. Gen. Genet., 219:320-23 ( 1989)), all herein incorporated by reference.
Cre has been purified to homogeneity, and its reaction with the loxP site has been extensively characterized (Abremski & Hess J. Mol. Biol. 259:1509-14 (1984), herein incorporated by reference). Cre protein has a molecular weight of 35,000 and can be obtained commercially from New England Nuclear/Du Pont. The cre gene (which encodes the Cre protein) has been cloned and expressed (Abremski, et al. Cell 32:1301-11 (1983), herein incorporated by reference). The Cre protein mediates recombination between two loxP sequences (Sternberg, et cal. Cold Spring Harbor Symp. Quant. Biol.
45:297-309 (1981)), which may be present on the same or different DNA molecule. Because the internal spacer sequence of the loxP site is asymmetrical, two IoxP sites can exhibit directionality relative to one another (Hoess & Abremski Proc. Natl. Acad. Sci. U.S.A.
81:1026-29 (1984)).
Thus, when two sites on the same DNA molecule are in a directly repeated orientation, Cre will excise the DNA between the sites (Abremski, et al. Cell 32:1301-11 (1983)). However, if the sites are inverted with respect to each other, the DNA between them is not excised after recombination but is simply inverted. Thus, a circular DNA molecule having two loxP sites in direct orientation will recombine to produce two smaller circles, whereas circular molecules having two loxP sites in an inverted orientation simply invert the DNA sequences flanked by the loxP sites. In addition, recombinase action can result in reciprocal exchange of regions distal to the target site when targets are present on separate DNA
molecules.
Recombinases have important application for characterizing gene function in knockout models. When the constructs described herein are used to disrupt target genes, a fusion transcript can be produced when insertion of the positive selection marker occurs downstream (3~ of the translation initiation site of the target gene. The fusion transcript could result in some level of protein expression with unknown consequence. It has been suggested that insertion of a positive selection marker gene can affect the expression of nearby genes. These effects may make it difficult to determine gene function after a knockout event since one could not discern whether a given phenotype is associated with the inactivation of a gene, or the transcription of nearby genes. Both potential problems are solved by exploiting recombinase activity. When the positive selection marker is flanked by recombinase sites in the same orientation, the addition of the corresponding recombinase will result in the removal of the positive selection marker. In this way, effects caused by the positive selection marker or expression of fusion transcripts are avoided.
In one embodiment, purified recombinase enzyme is provided to the cell by direct microinjection. In another embodiment, recombinase is expressed from a co-transfected construct or vector in which the recombinase gene is operably linked to a functional promoter. An additional aspect of this embodiment is the use of tissue-specific or inducible recombinase constructs which allow the choice of when and where recombination occurs.
t0 One method for practicing the inducible forms of recombinase-mediated recombination involves the use of vectors that use inducible or tissue-specific promoters or other gene regulatory elements to express the desired recombinase activity. The inducible expression elements are preferably operatively positioned to allow the inducible control or activation of expression of the desired recombinase activity. Examples of such inducible promoters or other gene regulatory elements include, but are not limited to, tetracycline, metallothionine, ecdysone, and other steroid-responsive promoters, rapamycin responsive promoters, and the like (No, et al. Proc. Ncztl. Acted. Sci. USA, 93:3346-51 (1996); Furth, et al. Proc. Natl. Acczd.
Sci. USA, 91:9302-6 (1994)). Additional control elements that can be used include promoters requiring specific transcription factors such as viral, promoters. Vectors incorporating such promoters would only express recombinase activity in cells that express the necessary transcription factors.
Other methods known in the art may be used to produce the transgenic cells and knockout mice of the present invention. For example, the methods described in U.S. Patent No. 5,464,764; U.S. Patent No. 5,487,992; U.S. Patent No. 5,627,059; and U.S.
Patent No.
5,631,153 may be used to produce a transgenic cell or knockout mice comprising a disruption in a target gene as provided by the present invention.
Models for Disease The cell- and animal-based systems described herein can be utilized as models for diseases. Animals of any species, including, but not limited to, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, goats, and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate disease animal models. In addition, cells from humans may be used. These systems may be used in a variety of applications. For example, the cell-and animal-based model systems may be used to further characterize a target gene. Such assays may be utilized as part of screening strategies designed to identify compounds which are capable of ameliorating disease symptoms. Thus, the animal- and cell-based models may be used to identify drugs, pharmaceuticals, therapies and interventions which may be effective in treating disease.
Cell-based systems may be used to identify compounds which may act to ameliorate disease symptoms. For example, such cell systems may be exposed to a compound suspected of exhibiting an ability to ameliorate disease symptoms, at a sufficient concentration and for a time sufficient to elicit such an amelioration of disease symptoms in the exposed cells. After exposure, the cells are examined to determine whether one or more of the disease cellular l0 phenotypes has been altered to resemble a more normal or more wild type, non-disease phenotype.
In addition, animal-based disease systems, such as those described herein, may be used to identify compounds capable of ameliorating disease symptoms. Such animal models may be used as test substrates for the identification of drugs, pharmaceuticals, therapies, and interventions which may be effective in treating a disease or other phenotypic characteristic of the animal. For example, animal models may be exposed to a compound or agent suspected of exhibiting an ability to ameliorate disease symptoms, at a sufficient concentration and for a time sufficient to elicit such an amelioration of disease symptoms in the exposed animals. The response of the animals to the exposure may be monitored by assessing the reversal of disorders associated with the disease. Exposure may involve treating mother animals during gestation of the model animals described herein, thereby exposing embryos or fetuses to the compound or agent which may prevent or ameliorate the disease or phenotype. Neonatal, juvenile, and adult animals can also be exposed.
More particularly, using the animal models of the invention, methods of identifying agents and/or compounds are provided, preferably, on the basis of the ability of the agents and/or compounds to affect physiological, histological or behavioral phenotypes associated with a disruption in a gene that encodes a target gene.
In one embodiment, the present invention provides a method of identifying agents having the ability to modulate a target gene's expression or function. The method includes administering an effective amount of the agent to the non-human transgenic animal of the present invention, preferably a mouse, having a disruption in a target gene.
The method includes measuring a response of the animal, for example, to the agent, and comparing the response of such animal to a control animal. A "physiological response" is any biological or physical parameter of an animal which can be measured. Molecular assays (e.g., gene transcription, protein production and degradation rates), physical parameters (e.g., exercise physiology tests, measurement of various parameters of respiration, measurement of heart rate or blood pressure, measurement of bleeding time, aPTT.T, or TT), and cellular assays (e.g,. immunohistochemical assays of cell surface markers, or the ability of cells to aggregate or proliferate) can be used to assess a physiological response.
The animals and cells of the present invention may by utilized as models for diseases, disorders, or conditions associated with phenotypes relating to a disruption in a target gene.
The present invention also provides a unique animal model for testing and developing l0 new treatments relating to the behavioral phenotypes. Analysis of the behavioral phenotype allows for the development of an animal model useful for testing, for instance, the efficacy of proposed genetic and pharmacological therapies for human genetic diseases, such as neurological, neuropsychological, or psychotic illnesses.
A statistical analysis of the various behaviors measured can be carried out using any conventional statistical program routinely used by those skilled in the art (such as, for example, "Analysis of Variance" or ANOVA). A "p" value of about 0.05 or less is generally considered to be statistically significant, although slightly higher p values may still be indicative of statistically significant differences. To statistically analyze abnormal behavior, a comparison is made between the behavior of a transgenic animal (or a group thereof) to the behavior of a wild-type mouse (or a group thereof), typically under certain prescribed conditions. "Abnormal behavior" as used herein refers to behavior exhibited by an animal having a disruption in the target gene, e.g. transgenic animal, which differs from an animal without a disruption in the target gene, e.g. wild-type mouse. Abnormal behavior consists of any number of standard behaviors that can be objectively measured (or observed) and compared. In the case of comparison, it is preferred that the change be statistically significant to confirm that there is indeed a meaningful behavioral difference between the knockout animal and the wild-type control animal. Examples of behaviors which may be measured or observed include, but are not limited to, ataxia, rapid limb movement, eye movement, breathing, motor activity, cognition, emotional behaviors, social behaviors, hyperactivity, hypersensitivity, anxiety, impaired learning, abnormal reward behavior, and abnormal social interaction, such as aggression A series of tests may be used to measure the behavioral phenotype of the animal models of the present invention, including neurological and neuropsychological tests to identify abnormal behavior. These tests may be used to measure abnormal behavior relating to, for example, learning and memory, eating, pain, aggression, sexual reproduction, anxiety, depression, schizophrenia, and drug abuse. (See, e.g., Crawley and Paylor, Hormones and Behavior 3'1:197-211 (1997)).
The social interaction test involves exposing a mouse to other animals in a variety of settings. The social behaviors of the animals (e.g., touching, climbing, sniffing, and mating) are subsequently evaluated. Differences in behaviors can then be statistically analyzed and compared (See, e.g., S. E. File, et al., Pharmacol. Bioch. Behav. 22:941-944 (1985); R. R.
Holson, Phys. Belaav. 37:239-247 (1986)). Examplary behavioral tests include the following.
The mouse startle response test typically involves exposing the animal to a sensory (typically auditory) stimulus and measuring the startle response of the animal (see, e.g., M. A.
Geyer, et al., Braui Res. Bull. 25:485-498 (1990); Paylor and Crawley, Psychopharmacology 132:169-180 (1997)). A pre-pulse inhibition test can also be used, in which the percent inhibition (from a normal startle response) is measured by "cueing" the animal first with a brief low-intensity pre-pulse prior to the startle pulse.
The electric shock test generally involves exposure to an electrified surface and measurement of subsequent behaviors such as, for example, motor activity, learning, social behaviors. The behaviors are measured and statistically analyzed using standard statistical tests. (See, e.g., G. J. Kant, et cal., Pharm. Bioch. Behav. 20:793-797 (1984); N. J.
Leidenheimer, et al., Pharnaacol. Bioch. Behav. 30:351-355 (1988)).
The tail-pinch or immobilization test involves applying pressure to the tail of the animal and/or restraining the animal's movements. Motor activity, social behavior, and cognitive behavior are examples of the areas that are measured. (See, e.g., M.
Bertolucci D'Angic, et al., Nercrnchena. 55:1208-1214 (1990)).
The novelty test generally comprises exposure to a novel environment and/or novel objects. The animal's motor behavior in the novel environment and/or around the novel object are measured and statistically analyzed. (See, e.g., D. K. Reinstein, et al., Pharm.
Bioclz. Behav. 17:193-202 (1982); B. Poucet, Behav. Neurosci. 103:1009-10016 (1989); R. R.
Holson, et al., Pl2y.s. Bel2av. 37:231-238 (1986)). This test may be used to detect visual processing deficiencies or defects.
The learned helplessness test involves exposure to stresses, for example, noxious stimuli, which cannot be affected by the animal's behavior. The animal's behavior can be statistically analyzed using various standard statistical tests. (See, e.g., A. Leshner, et al., Behav. Neural Biol. 26:497-501 ( 1979)).
Alternatively, a tail suspension test may be used, in which the "immobile"
time of the mouse is measured when suspended "upside-down" by its tail. This is a measure of whether the animal struggles, an indicator of depression. In humans, depression is believed to result from feelings of a lack of control over one's life or situation. It is believed that a depressive state can be elicited in animals by repeatedly subjecting them to aversive situations over which they have no control. A condition of "learned helplessness" is eventually reached, in which the animal will stop trying to change its circumstances and simply accept its fate.
Animals that stop struggling sooner are believed to be more prone to depression. Studies have shown that the administration of certain antidepressant drugs prior to testing increases l0 the amount of time that animals struggle before giving up.
The Mon-is water-maze test comprises learning spatial orientations in water and subsequently measuring the animal's behaviors, such as, for example, by counting the number of incorrect choices. The behaviors measured are statistically analyzed using standard statistical tests. (See, e.g., E. M. Spruijt, et al., Brain Res. 527:192-197 (1990)).
Alternatively, a Y-shaped maze may be used (see, e.g., McFarland, D.J., Pharmacology, Baoclzenzistry a~ml Behavior 32:723-726 (1989); Dellu, F., et al., Neurobiology of Learning and Memory 73:31-48 (2000)). The Y-maze is generally believed to be a test of cognitive ability. The dimensions of each arm of the Y-maze can be, for example, approximately 40 cm x 8 cm x 20 cm, although other dimensions may be used.
Each arm can also have, for example, sixteen equally spaced photobeams to automatically detect movement within the arms. At least two different tests can be performed using such a Y-maze. In a continuous Y-maze paradigm, mice are allowed to explore all three arms of a Y-maze for, e.g., approximately 10 minutes. The animals are continuously tracked using photobeam detection grids, and the data can be used to measure spontaneous alteration and positive bias behavior. Spontaneous alteration refers to the natural tendency of a "normal"
animal to visit the least familiar arm of a maze. An alternation is scored when the animal makes two consecutive turns in the same direction, thus representing a sequence of visits to the least recently entered arm of the maze. Position bias determines egocentrically defined responses by measuring the animal's tendency to favor turning in one direction over another.
3o Therefore, the test can detect differences in an animal's ability to navigate on the basis of allocentric or egocentric mechanisms. The two-trial Y-maze memory test measures response to novelty and spatial memory based on a free-choice exploration paradigm.
During the first trial (acquisition), the animals are allowed to freely visit two arms of the Y-maze for, e.g., approximately 15 minutes. The third arm is blocked off during this trial. The second trial (retrieval) is performed after an intertrial interval of, e.g., approximately
Related Applications This application claims priority to U.S. Application No. 60/190,348, filed March 16, 2000; U.S. Application No. 60/191,128, filed March 22, 2000; U.S. Application No.
60/191,236, filed March 22, 2000; U.S. Application No. 60/191,235, filed March 22, 2000;
U.S. Application No. 60/191,129, filed March 22, 2000; U.S. Application No.
60/191,142, filed March 22, 2000; U.S. Application No. 60/191,240, filed March 22, 2000;
U.S.
Application No. 60/204,227, filed May 15, 2000; U.S. Application No.
60/204,230, filed May 15, 2000; U.S. Application No. 60/215,214, filed June 29, 2000; U.S.
Application No.
60/216,249, filed July 6, 2000; U.S. Application No. 60/216,264, filed July 6, 2000; U.S.
Application No. 60/216,765, filed July 6, 2000; U.S. Application No.
60/218,075, filed July 12, 2000; U.S. Application No. 60/219,167, filed July 19, 2000; U.S.
Application No.
60/219,182, filed July 19, 2000; U.S. Application No. 60/221,485, filed July 27, 2000; and U.S. Application No. 60/223,173, filed August 7, 2000.
Field of the Invention The present invention relates to transgenic animals, compositions and methods relating to the characterization of gene function.
Background of the Invention Experimental animal models are important tools for understanding the role of genes.
More particularly, the ability to develop animals with specific genes altered or inactivated has been invaluable to the study of gene function, and has lead to unexpected discoveries of a gene and/or mechanisms responsible for disease with similar manifestations in humans.
These genetically engineered animals are also useful for identifying and,testing therapeutic treatments for a variety of diseases and disorders.
The identification of the function of numerous genes have been useful in ascertaining their roles in disease. Because of the high level of homology between humans and mice, it is possible to define the function of individual human genes by making targeted germline mutations in selected genes in the mouse. The phenotype of the resulting mutant mice can be used to help define the phenotype in humans.
Several interesting genes have recently been discovered. Identifying the roles of these genes and their expression products may permit the definition of disease pathways and the identification of diagnostically and therapeutically useful targets.
Many medically significant biological processes are mediated by proteins participating in signal transduction pathways that involve G-proteins and/or second t0 messengers such as cAMP. The membrane protein gene superfamily of G-protein coupled receptors (GPCRs) include a wide range of biologically active receptors, such as hormone, viral, growth factor and neuroreceptors. GPCRs have been characterized as having seven putative transmembrane domains (designated TM1, TM2, TM3, TM4, TMS, TM6, and TM7), which are believed to represent transmembrane a-helices connected by extracellular or 15 cytoplasmic loops. Most G-protein coupled receptors have single conserved cysteine residues in each of the first two extracellular loops which form disulfide bonds that are believed to stabilize functional protein structure. G-protein coupled receptors can be intracellularly coupled by heterotrimeric G-proteins to various intracellular enzymes, ion channels and transporters. Different G-protein a-subunits preferentially stimulate particular 20 effectors to modulate various biological functions in a cell.
Nuclear receptor genes that may be potentially important in retinal diseases, specifically retina-specific nuclear receptor genes have been identified.
(Proc. Natl. Acad.
Sci. USA 96:15149). The retina-specific nuclear receptor may be a potential regulator of cellular retinaldehyde-binding protein expressed in retinal pigment epithelium and glial cells.
25 Such genes have been postulated to regulate the visual cycle through its interaction with cellular retinaldehyde binding protein.
A lymphoid-specific member of the GPCR family has been identified by PCR with degenerate oligonucleotides. (GenonZics 23(3), 643-50 (1994)). This receptor, reported as the Epstein-Barr-induced cDNA EBI1, is expressed in normal lymphoid tissues and in several B-30 and T-lymphocyte cell lines. The gene is encoded on human chromosome 17q12-q21.2.
None of the other G-protein-coupled receptors has been mapped to this region, but the C-C
chemokine family has been mapped to 17q11-q21. The mouse EBI1 cDNA has also been isolated and encodes a protein with 86% identity to the human homolog. The murine EBI1 is a C-C chemokine type 7 receptor (variously referred to as CCR-7, C-C CKR-7 or CC-CKR-35 7). Although its gene structure may be known, the function and ligand EBI1 are unknown.
Melanocyte stimulating hormones (MSH) regulates pigmentation function. This peptide also has a variety of biological activities in other areas, including the brain, the pituitary, and the immune system. The murine melanocyte stimulating hormone receptor (MSH-R) mRNA has been cloned (1260 bp) and found to define a subfamily of receptors coupled to guanine nucleotide-binding proteins that may include the cannabinoid receptor (Science 257(5074), 1248-1251 (1992)).
Phosphatases represent unique and attractive targets for small-molecule inhibition and pharmacological intervention. The protein phosphorylation/dephosphorylation cycle is one l0 of the major regulatory mechanisms employed by eukaryotic cells to control cellular activities including growth and differentiation, cell-to-cell contacts, the cell cycle, and oncogenesis. It is estimated that more than 10% of the active proteins in a typical mammalian cell are phosphorylated. During protein phosphorylation/dephosphorylation, phosphate groups are transferred from adenosine triphosphate (ATP) molecules to a protein l5 by protein kinases and are removed from the protein by protein phosphatases.
Since nearly all forms of human neoplasias have altered cell cycle control, the role of phosphatases in cell cycle control makes these molecules attractive targets for pharmaceutical intervention. The ability of phosphatase inhibitors to interfere with aberrant cell activity has been demonstrated. For example, the naturally occurring serine/threonine phosphatase 20 inhibitor okadaic acid has been shown to induce apoptosis in myeloid leukemia cells (J. Cell.
Phy.siol. 150, 484 (1992)) and in rat hepatocytes, rat pituitary adenoma cell, human mammary carcinoma cells and human neuroblastoma cells (Exp. Cell Res. 195, 237 (1991)).
Magnesium dependent protein phosphatases appears to participate in a wide variety of functions including regulating cAMP-activated protein-kinase activity, Ca2+-dependent signal 25 transduction, tRNA splicing, and signal transmission related to heat shock responses.
Recently, it was reported that the complete cDNA sequence encoding PP2C, alpha isoform (or PP2C-alpha) was cloned from mouse brain. PP2C-alpha (GI or NID Number:
532678;
Accession Number: D28117) is a 1387 by sequence which encodes a protein of 382 amino acids with a calculated molecular mass of 42,432 Da (Gene 145(2), 311-312 (1994)).
30 Another important GPCR subfamily is the chemokine receptor family which are known as chemotactic cytokines. The mechanism of chemokine action involves initial specific binding to seven transmembrane spanning GPCRs on target cells. The central role of chemokines in inflammatory reactions has been demonstrated by numerous studies. Local administration of alpha chemokines, e.g., IL,-8, by subcutaneous injection results in acute 35 inflammatory reactions that are dominated by neutrophil infiltration.
Recently, the cloning of a rat CXC chemokine receptorl (CXCR1) gene has been reported (J. Biol. Chem.
271(51), 32770-6 (1996)). This CXCR1 gene (GI or NID number: 1589930; Accession number:
U71089) is homologous to the human interleukin-8 (IL-8) receptors, having an amino acid sequence approximately 70-85% identical to the human IL-8 A and B receptor subtypes, and homologous also to the murine CXCR1 gene.
Phosphodiesterases (PDEs) are a class of enzymes responsible for the degradation of phosphodiester bonds. In particular, cyclic nucleotide phosphodiesterases (CN-PDEs) show specificity for purine cyclic nucleotide substrates and hydrolyze cyclic adenosine l0 monophosphate (CAMP) and cyclic guanosine monophosphate (cGMP) (Pharmac.
Ther. 51, 13-33 (1991)). CN-PDEs regulate the steady-state levels of cAMP and cGMP and modulate both the amplitude and duration of cyclic nucleotide signals. In turn, cAMP
and cGMP are important "second messenger" molecules in signal transduction, the general process by which cells respond to extracellular signals (hormones, drugs, neurotransmitters, growth and differentiation factors, and other agents). Signal transduction regulates all types of cell functions including cell proliferation, differentiation, and gene transcription. At least eight different but homologous gene subfamilies of CN-PDEs are currently known to exist in mammalian tissues.
Members of the type 6 subfamily of PDE (PDE6) are associated with retinal phototransduction (J. Baol. Chem. 266, 10711-14 (1991)). In phototransduction, light impinging on a photoreceptor cell triggers a nerve signal by activating a cascade of biochemical events leading to the hydrolysis of cGMP by PDE6. PDE6 is a tetrameric protein composed of catalytic alpha and beta (a and (3) subunits, and two inhibitory gamma ('y) subunits. Dissociation of the inhibitory gamma subunits from the enzyme complex is induced by a membrane-associated protein called transducin and activates the enzyme. PDE6 defects have been associated with hereditary retinal degenerative diseases, characterized by retinal degeneration. Given the importance of phosphodiesterases, particularly PDEs associated with retinal function (e.g., PDE6), a clear need exists for identification and characterization of phosphodiesterases which can play a role in preventing, ameliorating or courecting dysfunctions or diseases, and, especially, vision-related dysfunctions and diseases, such as retinal degeneration (RD) and, specifically, retinitis pigmentosa (RP).
The metabolism of many drugs, xenobiotics, neurotransmitters and hormones includes a step involving the enzymatic addition of a sulfate (S04) group. The addition of a sulfate group is commonly referred to as sulfate conjugation, or simply sulfation. The enzymes responsible for sulfate conjugation are known as sulfotransferases (or ST's), as they act by transferring a sulfate group from one biological molecule (the sulfate donor) to another (the sulfate acceptor) in a sulfotransferase reaction.
Cytosolic sulfotransferase enzymes in human liver have been subjected to intensive research because sulfation increases the water solubility of most compounds and, therefore, their renal excretion. Sulfation also usually results in a decrease in biological activity.
However, in some cases, sulfate conjugation is required to activate drugs such as the antihypertensive medication minoxidil (Biochem. Pharmacol., 31, 2949-2954 (1982)), and it can also play a role in the bioactivation of procarcinogens such as hydroxylarylamines (Science, 215, 403 (1982); ChenZ. Biol. Interact. 109, 221-35 (1998)).
To date, genetic engineering efforts in the field of sulfate metabolism have resulted in the cloning and expression of cDNAs for several sulfotransferase enzymes:
human liver DHEA ST (Mol. Pharmacol. 41, 865-872 (1992)), TS PST (Mol. Pharmacol. 43, 70-(1993)), TL PST (Biocl2ern. Biophys. Res. Commun. 198, 1119-1127 (1994)) and a group of estrogen sulfotransferases isolated from several tissues of nonhuman mammalian species (Aust. J. Biol. Sci. 41, 507-516 (1988); Mol. Endocrinol. 6, 589-597 (1992)).
Also, the cDNA sequence (1269 bp) of the mouse liver phenol/aryl form of sulfotransferase (mSTpl) has been determined (Biochim. Biophys. Acta 1171(3), (1993)). The cloned cDNA was reported to contain an 897 nucleotide open reading frame (ORF) beginning at nucleotide 65, which encodes a 298 amino acid polypeptide of 34.7 kD.
The mSTp I gene has GI or N>D number 201069 and Accession number L02331. The human STpl gene has been extensively characterized (Pharmacogenetics 6, 473-487 (1996);
Biochem. Biophys. Res. Conamun. 228, 134-140 (1996)). The STpI gene is also referred to as the SLTLT 1 A 1 gene.
Experimental animal models would provide an important tool in understanding the roles of retina-specific nuclear receptor genes, lymphoid-specific GPCR genes, melanocyte stimulating hormone receptor genes, magnesium-dependent protein phosphatase genes, chemokine receptor 1-like protein genes, cGMP phosphodiesterase genes and sulfotransferase genes. Such understanding of their roles may permit the definition of disease pathways, the identification of diagnostically and therapeutically useful targets, and the testing and investigating of potential therapeutic treatments.
Summary of the Invention The present invention generally relates to transgenic animals, as well as to compositions and methods relating to the characterization of gene function.
More specifically, the present invention relates to various genes and their in vivo characterization and function.
The present invention provides transgenic cells comprising a disruption in a target gene. The transgenic cells of the present invention are comprised of any cells capable of undergoing homologous recombination. Preferably the cells of the present invention are stem cells and more preferably, embryonic stem (ES) cells, and most preferably, murine ES cells.
According to one embodiment, the transgenic cells are produced by introducing a targeting l0 construct into a stem cell to produce a homologous recombinant, resulting in a mutation of the target gene. In another embodiment, the transgenic cells are derived from the transgenic animals described below. The cell derived from the transgenic animals includes cells that are isolated or present in a tissue or organ, and any cell lines or any progeny thereof.
The present invention also provides a targeting construct and methods of producing the targeting construct that when introduced into stem cells produces a homologous recombinant. In one embodiment, the targeting construct of the present invention comprises first and second polynucleotide sequences that are homologous to the target gene. The targeting construct also comprises a polynucleotide sequence that encodes a selectable marker that is preferably positioned between the two different homologous polynucleotide sequences in the construct. The targeting construct may also comprise other regulatory elements that may enhance homologous recombination.
The present invention further provides non-human transgenic animals and methods of producing such non-human transgenic animals comprising a disruption in a target gene. The transgenic animals of the present invention include transgenic animals that are heterozygous and homozygous for a mutation in the target gene. In one aspect, the transgenic animals of the present invention are defective in the function of the target gene. In another aspect, the transgenic animals of the present invention comprise a phenotype associated with having a mutation in a target gene.
The present invention also provides methods of identifying agents capable of affecting a phenotype of a transgenic animal. For example, a putative agent is administered to the transgenic animal and a response of the transgenic animal to the putative agent is measured and compared to the response of a "normal" or wild type mouse, or alternatively compared to a transgenic animal control (without agent administration). The invention further provides agents identified according to such methods. The present invention also provides methods of identifying agents useful as therapeutic agents for treating conditions associated with a disruption of the target gene.
The present invention further provides a method of identifying agents having an effect on target gene expression or function. The method includes administering an effective amount of the agent to a transgenic animal, preferably a mouse, having a disruption in a target gene. The method includes measuring a response of the transgenic animal, for example, to the agent, and comparing the response of the transgenic animal to a control animal, which may be, for example, a wild-type animal or alternatively, a transgenic animal control. Compounds that may have an effect on gene expression or function may also be t0 screened against cells in cell-based assays, for example, to identify such compounds.
The invention also provides cell lines comprising nucleic acid sequences of a target gene. Such cell lines may be capable of expressing such sequences by virtue of operable linkage to a promoter functional in the cell line. Preferably, expression of the target gene sequence is under the control of an inducible promoter. Also provided are methods of identifying agents that interact with the target gene, comprising the steps of contacting the target gene with an agent and detecting an agendtarget gene complex. Such complexes can be detected by, for example, measuring expression of an operably linked detectable marker.
The invention further provides methods of treating diseases or conditions associated with a disruption in a target gene, and more particularly, to a disruption in the expression or function of the target gene. In a preferred embodiment, methods of the present invention involve treating diseases or conditions associated with a disruption in the target gene's expression or function, including administering to a subject in need, a therapeutic agent which effects target gene expression or function. In accordance with this embodiment, the method comprises administration of a therapeutically effective amount of a natural, synthetic, semi-synthetic, or recombinant target gene, target gene products or fragments thereof as well as natural, synthetic, semi-synthetic or recombinant analogs.
The present invention further provides methods of treating diseases or conditions associated with disrupted targeted gene expression or function, wherein the methods comprise detecting and replacing through gene therapy mutated target genes.
Definitions As used herein, "gene" refers to (a) a gene containing at least one of the DNA
sequences disclosed herein; (b) any DNA sequence that encodes the amino acid sequence encoded by the DNA sequences disclosed herein and/or; (c) any DNA sequence that hybridizes to the complement of the coding sequences disclosed herein.
Preferably, the term includes coding as well as noncoding regions, and preferably includes all sequences necessary for normal gene expression including promoters, enhancers and other regulatory sequences.
The terms "polynucleotide" and "nucleic acid molecule" are used interchangeably to refer to polymeric forms of nucleotides of any length. The polynucleotides may contain deoxyribonucleotides, ribonucleotides and/or their analogs. Nucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The term "polynucleotide" includes single-, double-stranded and triple helical molecules.
"Oligonucleotide" refers to polynucleotides of between 5 and about 100 nucleotides of single- or double-stranded DNA. Oligonucleotides are also known as oligomers or oligos and may be isolated from genes, or chemically synthesized by methods known in the art. A
"primer" refers to an oligonucleotide, usually single-stranded, that provides a 3'-hydroxyl end for the initiation of enzyme-mediated nucleic acid synthesis.
The following are non-limiting embodiments of polynucleotides: a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. A nucleic acid molecule may also comprise modified nucleic acid molecules, such as methylated nucleic acid molecules and nucleic acid molecule analogs. Analogs of purines and pyrimidines are known in the art, and include, but are not limited to, aziridinycytosine, 4-acetylcytosine, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethyl-aminomethyluracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, pseudouracil, 5-pentylnyluracil and 2,6-diaminopurine.
The use of uracil as a substitute for thymine in a deoxyribonucleic acid is also considered an analogous form of pyrimidine.
A "fragment" of a polynucleotide is a polynucleotide comprised of at least 9 contiguous nucleotides, preferably at least 15 contiguous nucleotides and more preferably at least 45 nucleotides, of coding or non-coding sequences.
As used herein, "base pair," also designated "bp," refers to the complementary nucleic acid molecules. In DNA there are four "types" of bases: the purine base adenine (A) is hydrogen bonded with the pyrimidine base thymine (T), and the purine base guanine (G) with the pyrimidine base cytosine (C). Each hydrogen bonded base pair set is also known as a Watson-Crick base-pair. A thousand base pairs is often called a kilobase pair, or kb. A "base pair mismatch" refers to a location in a nucleic acid molecule in which the bases are not complementary Watson-Crick pairs. The phrase "does not include at least one type of base at any position" refers to a nucleotide sequence which does not have one of the four bases at any position. For example, a sequence lacking one nucleotide (i.e., lacking one type of base) could be made up of A, G, T base pairs and contain no C residues.
As used herein, "gene targeting" is a type of homologous recombination that occurs , when a fragment of genomic DNA is introduced into a mammalian cell and that fragment locates and recombines with endogenous homologous sequences.
l0 The term "homologous recombination" refers to the exchange of DNA fragments between two DNA molecules or chromatids at the site of homologous nucleotide sequences.
The term "homologous" as used herein denotes a characteristic of a DNA
sequence having at least about 70 percent sequence identity as compared to a reference sequence, typically at least about 85 percent sequence identity, preferably at least about 95 percent sequence identity, and more preferably about 98 percent sequence identity, and most preferably about 100 percent sequence identity as compared to a reference sequence. Homology can be determined using a "BLASTN" algorithm. It is understood that homologous sequences can accommodate insertions, deletions and substitutions in the nucleotide sequence. Thus, linear sequences of nucleotides can be essentially identical even if some of the nucleotide residues do not precisely con-espond or align. The reference sequence may be a subset of a larger sequence, such as a portion of a gene or flanking sequence, or a repetitive portion of a chromosome.
As used herein, the term "target gene" (alternatively referred to as "target gene sequence" or "target DNA sequence" or "target sequence") refers to any nucleic acid molecule or polynucleotide of any gene to be modified by homologous recombination. The target sequence includes an intact gene, an exon or intron, a regulatory sequence or any region between genes. In one aspect, the nucleic acid molecule having a sequence in the general population is not associated with any disease or discernible phenotype. It is noted that in the general population, wild-type genes may include multiple prevalent versions that contain alterations in sequence relative to each other and yet do not cause a discernible pathological effect. These variations are designated "polymorphisms" or "allelic variations."
The target gene comprises a portion of a particular gene or genetic locus in the individual's genomic DNA. As provided herein, the target gene of the present invention consists of a retina-specific nuclear receptor gene, a lymphoid-specific GPCR gene, a melanocyte stimulating hormone receptor gene, a magnesium-dependent protein phosphatase gene, a chemokine receptor 1-like protein gene, an cGMP phosphodiesterase gene and a sulfotransferase gene, or a naturally occurring allelic variation or homologue thereof.
As used herein, the term "retina-specific nuclear receptor gene" refers to a sequence comprising SEQ >D N0:19 or the retina-specific nuclear receptor gene identified in Genebank as Accession No.: AF148129; GI NO: 6651226. In one aspect, the coding sequence of the retina-specific nuclear receptor gene comprises SEQ ID N0:19 or the sequence identified in Genebank as Accession No.: AF148129; GI NO: 6651226.
l0 As used herein, the term "lymphoid-specific GPCR gene" refers to a sequence comprising SEQ ID N0:22 or the lymphoid-specific GPCR gene in Genebank as Accession No.: L31580; GI NO: 468340. In one aspect, the coding sequence of the lymphoid-specific GPCR gene comprises SEQ >D N0:22 or the sequence identified in Genebank as Accession No.: L31580; GI NO: 468340.
As used herein, the term "melanocyte stimulating hormone receptor gene" refers to a sequence comprising SEQ 1D N0:25 or the melanocyte stimulating hormone receptor gene identified in Genebank as Accession No.: X65635; GI NO: 53244. In one aspect, the coding sequence of the melanocyte stimulating hormone receptor gene comprises SEQ ID
N0:25 or the sequence identified in Genebank as Accession No.: X65635; GI NO: 53244.
As used herein, the term "magnesium-dependent protein phosphatase gene" refers to a sequence comprising SEQ ID N0:28 or the magnesium-dependent protein phosphatase gene identified in Genebank as Accession No.: D28117; GI NO: 532678. In one aspect, the coding sequence of the magnesium-dependent protein phosphatase gene comprises N0:28 or the sequence identified in Genebank as Accession No.: D28117; GI NO:
532678.
As used herein, the term "chemokine receptor 1-like protein gene" refers to a sequence comprising SEQ ID N0:31 or the chemokine receptor 1-like protein gene identified in Genebank as Accession No.: U71089; GI NO: 1589930. In one aspect, the coding sequence of the chemokine receptor 1-like protein gene comprises SEQ m N0:31 or the sequence identified in Genebank as Accession No.: U71089; GI NO: 1589930.
As used herein, the term an "cGMP phosphodiesterase gene" refers to a sequence comprising SEQ ID N0:34 or the cGMP phosphodiesterase gene identified in Genebank as Accession No.: X60664; GI NO: 53587. In one aspect, the coding sequence of the cGMP
phosphodiesterase gene comprises SEQ ID N0:34 or the sequence identified in Genebank as Accession No.: X60664; GI NO: 53587.
As used herein, the term a "sulfotransferase gene" refers to a sequence comprising SEQ ID N0:37 or the sulfotransferase gene identified in Genebank as Accession No.:
L02331; Gl NO: 201069. In one aspect, the coding sequence of the sulfotransferase gene l0 comprises SEQ m N0:37 or the sequence identified in Genebank as Accession No.:
L02331; GI NO: 201069.
"Disruption" of a target gene occurs when a fragment of genomic DNA locates and recombines with an endogenous homologous sequence. These sequence disruptions or modifications may include insertions, missense, frameshift, deletion, or substitutions, or l0 replacements of DNA sequence, or any combination thereof. Insertions include the insertion of entire genes which may be of animal, plant, prokaryotic, or viral origin.
Disruption, for example, can alter or replace a promoter, enhancer, or splice site of a target gene, and can alter the normal gene product by inhibiting its production partially or completely or by enhancing the normal gene product's activity.
The teen, "transgenic cell", refers to a cell containing within its genome a target gene that has been disrupted, modified, altered, or replaced completely or partially by the method of gene targeting.
As used herein, a "n-ansgenic animal" is an animal that contains within its genome a specific gene that has been disrupted or inactivated completely or partially by the method of gene targeting. The transgenic animal includes both the heterozygote animal (i.e., one defective allele and one wild-type allele) and the homozygous animal (i.e., two defective alleles).
As used herein, the term "construct" refers to an artificially assembled DNA
segment to be transferred into a target tissue, cell line or animal, including human.
Typically, the construct will include the gene or a sequence of particular interest, a marker gene and appropriate control sequences. The term "plasmid" refers to an autonomous, self-replicating extrachromosomal DNA molecule. In a preferred embodiment, the plasmid construct of the present invention contains a positive selection marker positioned between two flanking regions of the gene of interest. Optionally, the construct can also contain a screening marker, for example, green fluorescent protein (GFP). If present, the screening marker is positioned outside of and some distance away from the flanking regions.
As used herein, the terms "selectable marker" or "positive selection marker"
refers to a gene encoding a product that enables only the cells that carry the gene to survive and/or grow under certain conditions. For example, plant and animal cells that express the introduced neomycin resistance (Neon) gene are resistant to the compound 6418.
Cells that do not carry the Neo' gene marker are killed by 6418. Other positive selection markers will be known to those of skill in the art.
"Positive-negative selection" refers to the process of selecting cells that carry a DNA
insert integrated at a specific targeted location (positive selection) and also selecting against cells that can-y a DNA insert integrated at a non-targeted chromosomal site (negative selection). Non-limiting examples of negative selection inserts include the gene encoding thymidine kinase (tk). Genes suitable for positive-negative selection are known in the art, see l0 e.g., U.S. Patent 5,464,764.
"Screening marker" or "reporter gene" refers to a gene that encodes a product that can readily be assayed. For example, reporter genes can be used to determine whether a particular DNA construct has been successfully introduced into a cell, organ or tissue. Non-limiting examples of screening markers include genes encoding for green fluorescent protein (GFP) or genes encoding for a modified fluorescent protein. "Negative screening marker" is not to be construed as negative selection marker; a negative selection marker typically kills cells that express it.
The term "vector" refers to a DNA molecule that can carry inserted DNA and be perpetuated in a host cell. Vectors are also known as cloning vectors, cloning vehicles or vehicles. The term includes vectors that function primarily for insertion of a nucleic acid molecule into a cell, replication vectors that function primarily for the replication of nucleic acid, and expression vectors that function for transcription and/or translation of the DNA or RNA. Also included are vectors that provide more than one of the above functions.
A "host cell" includes an individual cell or cell culture which can be or has been a recipient for vector (s) or for incorporation of nucleic acid molecules and/or proteins. Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in total DNA complement) to the original parent due to natural, accidental, or deliberate mutation. A host cell includes cells transfected with the constructs of the present invention.
The term "genomic library" refers to a collection of clones made from a set of randomly generated overlapping DNA fragments representing the genome of an organism. A
"cDNA library" (complementary DNA library) is a collection of mRNA molecules present in a cell, tissue, or organism, turned into cDNA molecules with the enzyme reverse transcriptase, then inserted into vectors (other DNA molecules which can continue to replicate after addition of foreign DNA). Exemplary vectors for libraries include bacteriophage (also known as "phage"), which are viruses that infect bacteria, for example lambda phage. The library can then be probed for the specific cDNA (and thus mRNA) of interest. In one embodiment, library systems which combine the high efficiency of a phage vector system with the convenience of a plasmid system (for example, ZAP
system from Stratagene, La Jolla, CA) are used in the practice of the present invention.
The term "exonuclease" refers to an enzyme that cleaves nucleotides sequentially from the free ends of a linear nucleic acid substrate. Exonucleases can be specific for double or single-stranded nucleotides and/or directionally specific, for instance, 3'-5' and/or 5'-3'.
l0 Some exonucleases exhibit other enzymatic activities, for example, T4 DNA
polymerase is both a polymerase and an active 3'-5' exonuclease. Other exemplary exonucleases include exonuclease III which removes nucleotides one at a time from the 5'-end of duplex DNA
which does not have a phosphorylated 3'-end, exonuclease VI which makes oligonucleotides by cleaving nucleotides off of both ends of single-stranded DNA, and exonuclease lambda which removes nucleotides from the 5' end of duplex DNA which have 5'-phosphate groups attached to them.
The term "recombinase" encompasses enzymes that induce, mediate or facilitate recombination, and other nucleic acid modifying enzymes that cause, mediate or facilitate the rearrangement of a nucleic acid sequence, or the excision or insertion of a first nucleic acid sequence from or into a second nucleic acid sequence. The "target site" of a recombinase is the nucleic acid sequence or region that is recognized (e.g., specifically binds to) and/or acted upon (excised, cut or induced to recombine) by the recombinase. As used herein, the expression "enzyme-directed site-specific recombination" is intended to include the following events: deletion of a pre-selected DNA segment flanked by recombinase target sites;
inversion of the nucleotide sequence of a pre-selected DNA segment flanked by recombinase target sites; and reciprocal exchange of DNA segments proximate to recombinase target sites located on different DNA molecules.
The term "modulates" as used herein refers to the inhibition, reduction or enhancement of a target gene's function, expression, or alternatively a phenotype associated with a disruption in a target gene.
The term "ameliorates" refers to a decreasing, reducing or eliminating a condition, disease, disorder, or phenotype, including an abnormality or symptom associated with a disruption in a target gene.
The term "abnomnality" refers to any disease, disorder, condition, or a phenotype in which a disruption of a target gene is implicated, including pathological conditions.
Brief Description of the Drawings Figure 1 is a schematic depicting one method of constructing a targeting vector of the present invention. The plasmid PCR method is described in Examples 9 and 10.
Figure 2A is a schematic depicting the pDG2 vector. The vector contains an ampicillin resistance gene and a neomycin (Neo') gene. On each side of the Neo' gene are two sites for ligation-independent cloning along with restriction sites. The sequence of pDG2 is shown in Figure 2B and SEQ ID NO:1.
Figure 3A is schematic depicting the pDG4 vector. The vector contains an ampicillin resistance gene, a neomycin (Neo') gene and a green fluorescent protein (GFP) gene. On each side of the Neo' gene are two sites for ligation-independent cloning along with restriction enzyme recognition sites. The sequence of pDG4 is shown in Figure 3B and SEQ
1D N0:2.
Figure 4 (SEQ ID N0:3 through SEQ 1D NO:10) shows the nucleic acid sequence before and after T4 DNA polymerise treatment of annealing sites 1-4 contained on the ends of PCR-amplified genomic DNA.
Figure 5 (SEQ ID NO:11 through SEQ >I7 N0:18) shows the nucleic acid sequence before and after T4 DNA polymerise treatment of annealing site 1-4 contained within the pDG2 vector.
Figure 6 shows the arrangement of 5' and 3' flanking DNA relative to annealing sites 1, 2, 3 and 4 within the pDG2 vector during an annealing reaction.
Figure 7 shows the arrangement of 5' and 3' flanking DNA relative to annealing sites 1, 2, 3 and 4 and the GFP screening marker within the pDG4 vector during an annealing reaction.
Figure 8 shows the polynucleotide sequence identified as SEQ )D N0:19. Figure also shows the sequences identified as SEQ 1D N0:20 and SEQ >D N0:21, which were used in the retina-specific nuclear receptor gene targeting construct.
Figure 9 shows the polynucleotide sequence identified as SEQ )D N0:22. Figure also shows the sequences identified as SEQ 1D N0:23 and SEQ >D N0:24, which were used in the lymphoid-specific GPCR gene targeting construct.
Figure 10 shows the polynucleotide sequence identified as SEQ 1D N0:25. Figure 10 also shows the sequences identified as SEQ >D N0:26 and SEQ >D N0:27 which were used in the melanocyte stimulating hormone receptor gene targeting construct.
Figure 11 shows the polynucleotide sequence identified as SEQ )D N0:28. Figure 11 also shows the sequences identified as SEQ )D N0:29 and SEQ >D N0:30 which were used in the magnesium-dependent protein phosphatase gene targeting construct.
Figure 12 shows the polynucleotide sequence identified as SEQ >D N0:31. Figure 12 also shows the sequences identified as SEQ ll~ N0:32 and SEQ >D N0:33 which were used in the chemokine receptor 1-like protein gene targeting construct.
Figure 13 shows the polynucleotide sequence identified as SEQ ID N0:34. Figure 13B shows the sequences identified as SEQ ID N0:35 and SEQ ID N0:36 which were used in the cGMP phosphodiesterase gene targeting construct.
Figure 14 shows the polynucleotide sequence identified as SEQ ID N0:37. Figure 14 also shows the sequences identified as SEQ >D N0:36 and SEQ >D N0:37 which were used in the sulfotransferase gene targeting construct.
Detailed Description of the Invention The invention is based, in part, on the evaluation of the expression and role of genes and gene expression products. Among others, the invention permits the definition of disease pathways and the identification of diagnostically and therapeutically useful targets. For example, genes which are mutated or down-regulated under disease conditions may be involved in causing or exacerbating the disease condition. Treatments directed at up-regulating the activity of such genes or treatments which involve alternate pathways, may ameliorate the disease condition.
Any technique known in the art may be used to introduce a target gene transgene into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to pronuclear microinjection (U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten, et al., Proc. Natl. Acad. Sci., USA, 82:6148-6152 (1985)); gene targeting in embryonic stem cells (Thompson, et al., Cell, 56:313-321 (1989));
electroporation of embryos (Lo, Mol Cell. Biol., 3:1803-1814 (1983)); and sperm-mediated gene transfer (Lavitrano, et al., Cell, 57:717-723 (1989)); etc. For a review of such techniques, see Gordon, Transgenic Animals, Intl. Rev. Cytol., 115:171-229 (1989), which is incorporated by reference herein in its entirety.
In a preferred embodiment, homologous recombination is used to generate the knockout mice of the present invention. Preferably, the construct is generated in two steps by (1) amplifying (for example, using long-range PCR) sequences homologous to the target sequence, and (2) inserting another polynucleotide (for example a selectable marker) into the PCR product so that it is flanked by the homologous sequences. Typically, the vector is a plasmid from a plasmid genomic library. The completed construct is also typically a circular plasmid. Thus, as shown in Figure 1, using long-range PCR with "outwardly pointing"
oligonucleotides results in a vector into which a selectable marker can easily be inserted, preferably by ligation-independent cloning. The construct can then be introduced into ES
cells, where it can disrupt the function of the homologous target sequence.
Homologous recombination may also be used to knockout genes in stem cells, and other cell types, which are not totipotent embryonic stem cells. By way of example, stem cells may be myeloid, lymphoid, or neural progenitor and precursor cells. Such transgenic cells may be particularly useful in the study of target gene function in individual developmental pathways. Stem cells may be derived from any vertebrate species, such as mouse, rat, dog, cat, pig, rabbit, human, non-human primates and the like.
In cells which are not totipotent it may be desirable to knock out both copies of the target using methods which are known in the art. For example, cells comprising homologous recombination at a target locus which have been selected for expression of a positive selection marker (e.g., Neor) and screened for non-random integration, can be further selected for multiple copies of the selectable marker gene by exposure to elevated levels of the selective agent (e.g., G418). The cells are then analyzed for homozygosity at the target locus.
Alternatively, a second construct can be generated with a different positive selection marker inserted between the two homologous sequences. The two constructs can be introduced into the cell either sequentially or simultaneously, followed by appropriate selection for each of the positive marker genes. The final cell is screened for homologous recombination of both alleles of the target.
In another aspect, two separate fragments of a clone of interest are amplified and inserted into a vector containing a positive selection marker using ligation-independent cloning technidues. In this embodiment, the clone of interest is generally from a phage library and is identified and isolated using PCR techniques. The ligation-independent cloning can be performed in two steps or in a single step.
According to a preferred method, constructs are used having multiple sites where 5'-3' single-stranded regions can be created. These constructs, preferably plasmids, include a vector capable of directional, four-way ligation-independent cloning.
The constructs typically include a sequence encoding a positive selection marker such as a gene encoding neomycin resistance; a restriction enzyme site on either side of the positive selection marker and a sequence flanking the restriction enzyme sites which does not contain one of the four base pairs. This configuration allows single-stranded ends to be created in the sequence by digesting the construct with the appropriate restriction enzyme and treating the fragments with a compound having exonuclease activity, for example T4 DNA
polymerise.
In one preferred embodiment, a construct suitable for introducing targeted mutations l0 into ES cells is prepared directly from a plasmid genomic library. Using long-range PCR
with specific primers, a sequence of interest is identified and isolated from the plasmid library in a single step. Following isolation of this sequence, a second polynucleotide that will disrupt the target sequence can be readily inserted between two regions encoding the sequence of interest. Using this direct method a targeted construct can be created in as little as 72 hours. In another embodiment, a targeted construct is prepared after identification of a clone of interest in a phage genomic library as described in detail below.
The methods described herein obviate the need for hybridization isolation, restriction mapping and multiple cloning steps. Moreover, the function of any gene can be determined using these methods. For example, a short sequence (e.g., EST) can be used to design oligonucleotide probes. These probes can be used in the direct amplification procedure to create constructs or can be used to screen genomic or cDNA libraries for longer full-length genes. Thus, it is contemplated that any gene can be quickly and efficiently prepared for use in ES cells.
In a preferred embodiment, constructs are prepared directly from a plasmid genomic library. The library can be produced by any method known in the art.
Preferably, DNA from mouse ES cells is isolated and treated with a restriction endonuclease which cleaves the DNA
into fragments. The DNA fragments are then inserted into a vector, for example a bacteriophage or phagemid (e.bf., Lamda ZAPTM, Stratagene, La Jolla, CA) systems. When the library is created in the ZAPTM system, the DNA fragments are preferably between about 5 and about 20 kilobases.
Preferably, the organisms) from which the libraries are made will have no discernible disease or phenotypic effects. Preferably, the library is a mouse library.
This DNA may be obtained from any cell source or body fluid. Non-limiting examples of cell sources available in clinical practice include ES cells, liver, kidney, blood cells, buccal cells, cerviovaginal cells, epithelial cells from urine, fetal cells, or any cells present in tissue obtained by biopsy.
Body fluids include urine, blood cerebrospinal fluid (CSF), and tissue exudates at the site of infection or inflammation. DNA extracted from the cells or body fluid using any method known in the art. Preferably, the DNA is extracted by adding 5 ml of lysis buffer (10 mM
Tris-HC1 pH 7.5), 10 mM EDTA (pH 8.0), 10 mM NaCI, 0.5% SDS and 1 mg/ml Proteinase K) to a confluent 100 mm plate of embryonic stem cells. The cells are then incubated at about 60°C for several hours or until fully lysed. Genomic DNA is purified from the lysed cells by several rounds of gentle phenol:chloroform extraction followed by an ethanol precipitation. For convenience, the genomic library can be arrayed into pools.
In a preferred embodiment, a sequence of interest is identified from the plasmid library using oligonucleotide primers and long-range PCR. Typically, the primers are outwardly-pointing primers which are designed based on sequence information obtained from a partial gene sequence, e.g., a cDNA or an EST sequence. As depicted for example in Figure 1, the product will be a linear fragment that excludes the region which is located between each primer.
PCR conditions found to be suitable are described below in the Examples. It will be understood that optimal PCR conditions can be readily determined by those skilled in the art.
(See, e.g., PCR 2: A Practical Approach (1995) eds. M.J. McPherson, B.D. Hames and G.R.
Taylor, IRL Press, Oxford; Yu, et al., Metlaods Mol. Bio., 58:335-9 (1996);
Munroe, et al., Proc. NatZ Accrd. Sci., USA, 92:2209-13 (1995)). PCR screening of libraries eliminates many of the problems and time-delay associated with conventional hybridization screening in which the library must be plated, filters made, radioactive probes prepared and hybridization conditions established. PCR screening requires only oligonucleotide primers to sequences (genes) of interest. PCR products can be purified liy a variety of methods, including but not limited to, microfiltration, dialysis, gel electrophoresis and the like. It may be desirable to remove the polymerase used in PCR so that no new DNA synthesis can occur.
Suitable thermostable DNA polymerases are commercially available, for example, VentTM
DNA
Polymerase (New England Biolabs), Deep VentTM DNA Polymerase (new England Biolabs), HotTubTM DNA Polymerase (Amersham), Thermo SequenaseTM (Amersham), rBstTM DNA
Polymerase (Epicenter), PfuTM DNA Polymerase (Stratagene), Amplitaq GoldT~'' (Perkin Elmer), and ExpandT'~' (Boehringer-Mannheim).
To form the completed construct, a sequence which will disrupt the target sequence is inserted into the PCR-amplified product. For example, as described herein, the direct method involves joining the long-range PCR product (i.e., the vector) and one fragment (i.e., a gene encoding a selectable marker). As discussed above, the vector contains two different sequence regions homologous to the target DNA sequence. Preferably, the vector also contains a sequence encoding a selectable marker, such as ampicillin. The vector and fragment are designed so that, when treated to form single stranded ends, they will anneal such that the fragment is positioned between the two different regions of substantial homology to the target gene.
Although any method of cloning is suitable, it is preferred that ligation-independent cloning strategies be used to assemble the construct comprising two different homologous regions flanking a selectable marker. Ligation-independent cloning (LIC) is a strategy for the l0 directional cloning of polynucleotides without the use of kinases or ligases. (See, e.g., Aslanidis et al., NLCCIeic Acids Res., 18:6069-74 (1990); Rashtchian, Current Opin. Biotech., 6:30-36 (1995)). Single-stranded tails (also referred to as cloning sites or annealing sequences) are created in LIC vectors, usually by treating the vector (at a digested restriction enzyme site) with T4 DNA polymerise in the presence of only one dNTP. The 3' to 5' exonuclease activity of T4 DNA polymerise removes nucleotides until it encounters a residue con-esponding to the single dNTP present in the reaction mix. At this point, the 5' to 3' polymerise activity of the enzyme counteracts the exonuclease activity to prevent further excision. The vector is designed such that the single-stranded tails created are non-complementary. For example, in the pDG2 vector, none of the single-stranded tails of the four annealing sites are complementary to each other. PCR products are created by building appropriate 5' extensions into oligonucleotide primers. The PCR product is purified to remove dNTPs (and original plasmid if it was used as template) and then treated with T4 DNA polymerise in the presence of the appropriate dNTP to generate the specific vector-compatible overhangs. Cloning occurs by annealing of the compatible tails.
Single-stranded tails are created at the ends of the clone fragments, for example using chemical or enzymatic means. Complementary tails are created on the vector; however, to prevent annealing of the vector without insert, the vector tails are not complementary to each other.
The length of the tails is at least about 5 nucleotides, preferably at least about 12 nucleotides, even more preferably at least about 20 nucleotides.
In one embodiment, placing the overlapping vector and fragments) in the same reaction is sufficient to anneal them. Alternatively, the complementary sequences are combined, heated and allowed to slowly cool. Preferably the heating step is between about 60°C and about 100°C, more preferably between about 60°C
and 80°C, and even more preferably between 60°C and 70°C. The heated reactions are then allowed to cool.
Generally, cooling occurs rather slowly, for instance the reactions are generally at about room temperature after about an hour. The cooling must be sufficiently slow as to allow annealing.
The annealed fragment/vector can be used immediately, or stored frozen at -20°C until use.
Further, annealing can be performed by adjusting the salt and temperature to achieve suitable conditions. Hybridization reactions can be performed in solutions ranging from about 10 mM NaCl to about G00 mM NaCl, at temperatures ranging from about 37°C to about G5°C. It will be understood that the stringency of the hybridization reaction is determined by both the salt concentration and the temperature. For instance, a hybridization l0 performed in 10 mM salt at 37°C may be of similar stringency to one performed in 500 mM
salt at 65°C. For the present invention, any hybridization conditions may be used that form hybrids between homologous complementary sequences.
As shown in Figure 1, in one embodiment, a construct is made after using any of these annealing procedure where the vector portion contains the two different regions of substantial homology to the target gene (amplified from the plasmid library using long-range PCR) and the fragment is a gene encoding a selectable marker.
After annealing, the construct is transformed into competent E. coli cells by methods known in the art, to amplify the construct. The isolated construct is then ready for introduction into ES cells.
In another embodiment, a clone of interest is identified in a pooled genomic library using PCR. In one embodiment, the PCR conditions are such that a gene encoding a selectable marker can be inserted directly into the positively identified clone. The marker is positioned between two different sequences having substantial homology to the target DNA.
Genomic phage libraries can be prepared by any method known in the art.
Preferably, a mouse embryonic stem cell library is prepared in lambda phage by cleaving genomic DNA
into fragments of approximately 20 kilobases in length. The fragments are then inserted into any suitable lambda cloning vector, for example lambda Fix II or lambda Dash II (Stratagene, La Jolla, Ca) In order to quickly and efficiently screen a large number of clones from a library, pools may be created of plated libraries. In a preferred embodiment, a genomic lambda phage library is plated at a density of approximately 1,000 clones (plaques) per plate.
Sufficient plates are created to represent the entire genome of the organism several times over. For example, approximately 1 million clones (1000 plates) will yield approximately 8 genome equivalents. The plaques are then collected, for example by overlaying the plate with a buffer solution, incubating the plates and recollecting the buffer. The amount of buffer used will vary according to the plate size, generally one 100 mm diameter plate will be overlayed with approximately 4 ml of buffer and approximately 2 ml will be collected.
It will be understood that the individual plate lysates can be pooled at any time during this procedure and that they can be pooled in any combinations. For ease in later identification of single clones, however, it is preferable to keep each plate lysate separately and then make a pool. For example, each 2 ml lysate can be placed in a 96 well deep well plate. Pools can then be formed by taking an amount, preferably about 100 ~ l, from each t0 well and combining them in the well of a new plate. Preferably, 100 O1 of 12 individual plate lysates are combined in one well, forming a 1.2 ml pool representative of 12,000 clones of the library.
Each pool is then PCR-amplified using a set of PCR primers known to amplify the target gene. The target gene can be a known full-length gene or, more preferably, a partial eDNA sequence obtained from publicly available nucleic acid sequence databases such as GenBank or EMBL. These databases include partial eDNA sequences known as expressed sequence tags (ESTs). The oligonucleotide PCR primers can be isolated from any organism by any method known in the art or, preferably, synthesized by chemical means.
Once a positive clone of the target gene has been identified in a genomic library, two fragments encoding separate portions of the target gene must be generated. In other words, the flanking regions of the small known region of the target (e.g., EST) are generated.
Although the size of each flanking region is not critical and can range from as few as 100 base pairs to as many as 100 kb, preferably each flanking fragment is greater than about 1 kb in length, more preferably between about 1 and about 10 kb, and even more preferably between about 1 and about 5 kb. One of skill in the art will recognize that although larger fragments may increase the number of homologous recombination events in ES
cells, larger fragments will also be more difficult to clone.
In one embodiment, one of the oligonucleotide PCR primers used to amplify a flanking fragment is specific for the library cloning vector, for example lambda phage.
Therefore, if the library is a lambda phage library, primers specific for the lambda phage arms can be used 111 COlllu11Ct1011 Wlth primers specific for the positive clone to generate long flanking fragments. Multiple PCR reactions can be set up to test different combinations of primers. Preferably, the primers used will generate flanking sequences between about 2 and about 6 kb in length.
Preferably, the oligonucleotide primers are designed with 5' sequences complementary to the vector into which the fragments will be cloned. In addition, the primers are also designed so that the flanking fragments will be in the proper 3'-5' orientation with respect to the vector and each other when the construct is assembled.
Thus, using PCR-based methods, for example, positive clones can be identified by visualization of a band on an electrophoretic gel.
In one aspect, the cloning involves a vector and two fragments. The vector contains a positive selection marker, preferably Neo', and cloning sites on each side of the positive selection marker for two different regions of the target gene. Optionally, the vector also l0 contains a sequence coding for a screening marker (reporter gene), preferably, positioned opposite the positive selection marker. The screening marker will be positioned outside the flanking regions of homologous sequences. Figure 3A shows one embodiment of the vector with the screening marker, GFl', positioned on one side of the vector.
However, the screening marker can be positioned anywhere between Not I and Site 4 on the side opposite the positive selection marker, Neo'.
One example of a suitable vector is the plasmid vector shown in Figure 2 having the sequence of SEQ 1D NO:1. The specific nucleic acid ligation-independent cloning sites (also referred to herein as annealing sites) labeled "sites 1, 2, 3 or 4" in Figure 1 are also shown herein. Generally, the cloning sites are lacking at least one type of base, i.e., thymine (T), guanine (G), cytosine (C) or adenine (A). Accordingly, reacting the vector with an enzyme that acts as both a polymerise and exonuclease in presence of only the one missing nucleotide will create an overhang. For example, T4 DNA polymerise acts as both a 3'-5' exonuclease and a polymerise. Thus, when there are insufficient nucleotides available for the polymerise activity, T4 will act as an exonuclease. Specific overhangs can therefore be created by reacting the pDG2 vector with T4 DNA polymerise in the presence of dTTP only.
Other enzymes useful in the practice of this invention will be known to those in the art, for instance uracil DNA glycosylase (UDG) (See, e.g., WO 93/18175). The vector exemplified herein has an overhand of 24 nucleotides. It will be known by those skilled in the art that as few as 5 nucleotides are required for successful ligation independent cloning.
In another embodiment, a construct is assembled in a two-step cloning protocol. In the first step, each cloning region of homology is separately cloned into two of the annealing sites of the vector. For example, an "upstream" region of homology is cloned into annealing sites 1 and 2 while a separate cloning, a "downstream" region of homology is cloned into annealing sites 3 and 4. Once clones containing each single region of homology are identified, a targeting construct containing both regions of homology can be created by digesting each clone with restriction enzymes where one enzyme digests outside of annealing site 1 (e.g., Not I in Figure 2A) and another enzyme digests between the positive selection marker and annealing site 3 (e.g., Sal I in Figure 2A). The fragments containing the flanking homology regions from each construct will be purified (e.g., by gel electrophoresis) and combined using standard ligation techniques known in the art, to produce the resulting targeting construct.
In yet another embodiment, a construct according to one aspect of the present invention can be formed in a single-step, four-way ligation procedure. The vector and fragments are treated as described above. Briefly, the vector is treated to form two pieces, each piece having a single-stranded tail of specific sequence on each end.
Likewise, the PCR-amplified flanking fragments are also treated to form single-stranded tails complementary to those of the vector pieces. The treated vector pieces and fragments are combined and allowed to anneal as described above. Because of the specificity of the single-stranded tails, the final construct will contain the fragments separated by the positive selection marker in the proper orientation.
The final plasmid constructs are amplified in bacteria, purified and can then be introduced into ES cells, or stored frozen at -20°C until use. Where so desired, the vector is introduced into an embryonic stem cell line (e.g=., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected (.see e.g., Li, et al., Cell, 69:91526 (1992)). Successful recombination may be verified using various techniques known in the art, such as PCR and/or Southern analysis.
Typically, several hundred individual colonies are selected following drug selection in 6418 (for Neo cassettes), expanded for DNA preparation and screened for homologous recombination by PCR analysis. The PCR screening procedure uses a target gene specific oligonucleotide that is not present on the targeting vector and an oligonucleotide corresponding to the Neo (or other selectable marker) cassette. The selection of oligonucleotides outside the targeting vector is used to differentiate homologous recombinants from random integrations of the targeting vector. In general, four independent target gene specific oligonucleotides not present on the targeting vector are tested on wild type ES cell DNA in combination with target gene specific oligonucleotides that are adjacent to the insertion site of the Neo (Figure 9). Oligonucleotides producing background bands or failing to give the predicted size product are eliminated. A single target gene specific oligonucleotide is selected and paired with an oligonucleotide corresponding to the Neo cassette. ES cells that are PCR positive in this screen are confirmed by a second PCR experiment that utilizes a different pair of target gene specific and Neo gene (or other selectable marker) specific oligonucleotides that are adjacent to, but distinct from, the original oligonucleotide pair. In addition, this protocol may be repeated using oligonucleotides specific for target gene sequences located on the opposite side of the selectable marker in conjunction with a marker specific oligonucleotide. In this way proper integration of both homologous sequences of the targeting vector is verified.
Southern blot hybridization may also be used to confirm the ES cell targeting event using a probe that is not contained on the targeting vector but is adjacent to the predicted crossover site of homologous recombination. Southern blot experiments testing for homologous recombination should detect two distinct bands representing the wild type chromosome and mutant gene targeted allele. High molecular weight genomic DNA
is prepared from control ES cell parental lines and ES cell lines that are PCR
positive for homologous recombination. The DNA is digested with a restriction enzyme (EcoRl) that has been demonstrated by restriction mapping to not cut the targeting vector within the arm of the target gene DNA homology and to be diagnostic of homologous recombination. As an EcoRl site is present in the Neo gene, a homologous recombination event should result in the insertion of the Neo cassette and the addition of the EcoRl site. The addition of this site is predicted to result in an overall reduction in size of the band hybridizing to the probe. The digested DNA is separated on a 1 °7o TAE Agarose gel, transferred to a nylon membrane, 2o crosslinked with a UV light (StrataLinker) and hybridized with a 32-P
labeled DNA probe.
This probe does not hybridize to DNA sequences that are on the targeting vector but to a position that is adjacent to the site of homologous integration.
Selected cells are then injected into a blastocyst (or other stage of development suitable for the purposes of creating a viable animal, such as, for example, a morula) of an animal (e.g., a mouse) to form chimeras (see e.g., Bradley, A. in Teratocarcinomas and Embryonic Stenz Cells: A Practical Approach, E. J. Robertson, ed., IRL, Oxford, pp. 113-152 (1987)). Alternatively, selected ES cells can be allowed to aggregate with dissociated mouse embryo cells to form the aggregation chimera. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term.
Chimeric progeny harbouring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA. In one embodiment, chimeric progeny mice are used to generate a mouse with a heterozygous disruption in the target gene. Heterozygous knockout mice can then be mated.
It is well know in the art that typically'/a of the offspring of such matings will have a homozygous disruption in the target gene.
The heterozygous and homozygous knockout mice can then be compared to normal, wild type mice to determine whether disruption of the target gene causes phenotypic changes, especially pathological changes. For example, heterozygous and homozygous mice may be evaluated for phenotypic changes by physical examination, necropsy, histology, clinical chemistry, complete blood count, body weight, organ weights, and cytological evaluation of bone marrow.
In one embodiment, the phenotype (or phenotypic change) associated with a disruption in the target gene is placed into or stored in a database.
Preferably, the database ~0 includes: (i) genotypic data (e.g., identification of the disrupted gene) and (ii) phenotypic data (e.g., phenotype(s) resulting from the gene disruption) associated with the genotypic data.
The database is preferably electronic. In addition, the database is preferably combined with a search tool so that the database is searchable.
The present invention further contemplates conditional knockout animals, such as those produced using recombination methods. Bacteriophage P1 Cre recombinase and flp recombinase from yeast plasmids are two non-limiting examples of site-specific DNA
recombinase enzymes which cleave DNA at specific target sites (lox P sites for cre recombinase and frt sites for flp recombinase) and catalyze a ligation of this DNA to a second cleaved site. A large number of suitable alternative site-specific recombinases have been described, and their genes can be used in accordance with the method of the present invention. Such recombinases include the Int recombinase of bacteriophage 7~
(with or without Xis) (Weisberg, R. et. al., in Lambda 1l, (Hendrix, R., et al., Eds.), Cold Spring Harbor Press, Cold Spring Harbor, NY, pp. 211-50 (1983), herein incorporated by reference);
TpnI and the (3-lactamase transposons (Mercier, et al., J. Bacteriol., 172:3745-57 (1990)); the Tn3 resolvase (Flanagan & Fennewald J. Molec. Biol., 206:295-304 (1989);
Stark, et al., Cell, 58:779-90 (1989)); the yeast recombinases (Matsuzaki, et al., J.
Bacteriol., 172:610-18 (1990)); the B. subtili.s SpoIVC recombinase (Sato, et al., J. Bacteriol.
172:1092-98 (1990));
the Flp recombinase (Schwartz & Sadowski, J. Molec.Biol., 205:647-658 ( 1989);
Parsons, et al., J. Biol. Claen2., 265:4527-33 (1990); Golic & Lindquist, Cell, 59:499-509 (1989); Amin, et al., J. Molec. Biol., 214:55-72 (1990)); the Hin recombinase (Glasgow, et al., J. Biol.
Chem., 264:10072-82 (1989)); immunoglobulin recombinases (Malynn, et al., Cell, 54:453-460 (1988)); and the Cin recombinase (Haffter & Bickle, EMBO J., 7:3991-(1988); Hubner, et al., J. Molec. Biol., 205:493-500 (1989)), all herein incorporated by reference. Such systems are discussed by Echols (J. Biol. Chem. 265:14697-14700 (1990));
de Villartay (Nature, 335:170-74 (1988)); Craig, (Ann. Rev. Genet., 22:77-105 (1988));
Poyart-Salmeron, et al., (EMBO J. 8:2425-33 (1989)); Hunger-Bertling, et al.
(Mol Cell.
BiochenZ., 92:107- l 6 ( 1990)); and Cregg & Madden (Mol. Gen. Genet., 219:320-23 ( 1989)), all herein incorporated by reference.
Cre has been purified to homogeneity, and its reaction with the loxP site has been extensively characterized (Abremski & Hess J. Mol. Biol. 259:1509-14 (1984), herein incorporated by reference). Cre protein has a molecular weight of 35,000 and can be obtained commercially from New England Nuclear/Du Pont. The cre gene (which encodes the Cre protein) has been cloned and expressed (Abremski, et al. Cell 32:1301-11 (1983), herein incorporated by reference). The Cre protein mediates recombination between two loxP sequences (Sternberg, et cal. Cold Spring Harbor Symp. Quant. Biol.
45:297-309 (1981)), which may be present on the same or different DNA molecule. Because the internal spacer sequence of the loxP site is asymmetrical, two IoxP sites can exhibit directionality relative to one another (Hoess & Abremski Proc. Natl. Acad. Sci. U.S.A.
81:1026-29 (1984)).
Thus, when two sites on the same DNA molecule are in a directly repeated orientation, Cre will excise the DNA between the sites (Abremski, et al. Cell 32:1301-11 (1983)). However, if the sites are inverted with respect to each other, the DNA between them is not excised after recombination but is simply inverted. Thus, a circular DNA molecule having two loxP sites in direct orientation will recombine to produce two smaller circles, whereas circular molecules having two loxP sites in an inverted orientation simply invert the DNA sequences flanked by the loxP sites. In addition, recombinase action can result in reciprocal exchange of regions distal to the target site when targets are present on separate DNA
molecules.
Recombinases have important application for characterizing gene function in knockout models. When the constructs described herein are used to disrupt target genes, a fusion transcript can be produced when insertion of the positive selection marker occurs downstream (3~ of the translation initiation site of the target gene. The fusion transcript could result in some level of protein expression with unknown consequence. It has been suggested that insertion of a positive selection marker gene can affect the expression of nearby genes. These effects may make it difficult to determine gene function after a knockout event since one could not discern whether a given phenotype is associated with the inactivation of a gene, or the transcription of nearby genes. Both potential problems are solved by exploiting recombinase activity. When the positive selection marker is flanked by recombinase sites in the same orientation, the addition of the corresponding recombinase will result in the removal of the positive selection marker. In this way, effects caused by the positive selection marker or expression of fusion transcripts are avoided.
In one embodiment, purified recombinase enzyme is provided to the cell by direct microinjection. In another embodiment, recombinase is expressed from a co-transfected construct or vector in which the recombinase gene is operably linked to a functional promoter. An additional aspect of this embodiment is the use of tissue-specific or inducible recombinase constructs which allow the choice of when and where recombination occurs.
t0 One method for practicing the inducible forms of recombinase-mediated recombination involves the use of vectors that use inducible or tissue-specific promoters or other gene regulatory elements to express the desired recombinase activity. The inducible expression elements are preferably operatively positioned to allow the inducible control or activation of expression of the desired recombinase activity. Examples of such inducible promoters or other gene regulatory elements include, but are not limited to, tetracycline, metallothionine, ecdysone, and other steroid-responsive promoters, rapamycin responsive promoters, and the like (No, et al. Proc. Ncztl. Acted. Sci. USA, 93:3346-51 (1996); Furth, et al. Proc. Natl. Acczd.
Sci. USA, 91:9302-6 (1994)). Additional control elements that can be used include promoters requiring specific transcription factors such as viral, promoters. Vectors incorporating such promoters would only express recombinase activity in cells that express the necessary transcription factors.
Other methods known in the art may be used to produce the transgenic cells and knockout mice of the present invention. For example, the methods described in U.S. Patent No. 5,464,764; U.S. Patent No. 5,487,992; U.S. Patent No. 5,627,059; and U.S.
Patent No.
5,631,153 may be used to produce a transgenic cell or knockout mice comprising a disruption in a target gene as provided by the present invention.
Models for Disease The cell- and animal-based systems described herein can be utilized as models for diseases. Animals of any species, including, but not limited to, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, goats, and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate disease animal models. In addition, cells from humans may be used. These systems may be used in a variety of applications. For example, the cell-and animal-based model systems may be used to further characterize a target gene. Such assays may be utilized as part of screening strategies designed to identify compounds which are capable of ameliorating disease symptoms. Thus, the animal- and cell-based models may be used to identify drugs, pharmaceuticals, therapies and interventions which may be effective in treating disease.
Cell-based systems may be used to identify compounds which may act to ameliorate disease symptoms. For example, such cell systems may be exposed to a compound suspected of exhibiting an ability to ameliorate disease symptoms, at a sufficient concentration and for a time sufficient to elicit such an amelioration of disease symptoms in the exposed cells. After exposure, the cells are examined to determine whether one or more of the disease cellular l0 phenotypes has been altered to resemble a more normal or more wild type, non-disease phenotype.
In addition, animal-based disease systems, such as those described herein, may be used to identify compounds capable of ameliorating disease symptoms. Such animal models may be used as test substrates for the identification of drugs, pharmaceuticals, therapies, and interventions which may be effective in treating a disease or other phenotypic characteristic of the animal. For example, animal models may be exposed to a compound or agent suspected of exhibiting an ability to ameliorate disease symptoms, at a sufficient concentration and for a time sufficient to elicit such an amelioration of disease symptoms in the exposed animals. The response of the animals to the exposure may be monitored by assessing the reversal of disorders associated with the disease. Exposure may involve treating mother animals during gestation of the model animals described herein, thereby exposing embryos or fetuses to the compound or agent which may prevent or ameliorate the disease or phenotype. Neonatal, juvenile, and adult animals can also be exposed.
More particularly, using the animal models of the invention, methods of identifying agents and/or compounds are provided, preferably, on the basis of the ability of the agents and/or compounds to affect physiological, histological or behavioral phenotypes associated with a disruption in a gene that encodes a target gene.
In one embodiment, the present invention provides a method of identifying agents having the ability to modulate a target gene's expression or function. The method includes administering an effective amount of the agent to the non-human transgenic animal of the present invention, preferably a mouse, having a disruption in a target gene.
The method includes measuring a response of the animal, for example, to the agent, and comparing the response of such animal to a control animal. A "physiological response" is any biological or physical parameter of an animal which can be measured. Molecular assays (e.g., gene transcription, protein production and degradation rates), physical parameters (e.g., exercise physiology tests, measurement of various parameters of respiration, measurement of heart rate or blood pressure, measurement of bleeding time, aPTT.T, or TT), and cellular assays (e.g,. immunohistochemical assays of cell surface markers, or the ability of cells to aggregate or proliferate) can be used to assess a physiological response.
The animals and cells of the present invention may by utilized as models for diseases, disorders, or conditions associated with phenotypes relating to a disruption in a target gene.
The present invention also provides a unique animal model for testing and developing l0 new treatments relating to the behavioral phenotypes. Analysis of the behavioral phenotype allows for the development of an animal model useful for testing, for instance, the efficacy of proposed genetic and pharmacological therapies for human genetic diseases, such as neurological, neuropsychological, or psychotic illnesses.
A statistical analysis of the various behaviors measured can be carried out using any conventional statistical program routinely used by those skilled in the art (such as, for example, "Analysis of Variance" or ANOVA). A "p" value of about 0.05 or less is generally considered to be statistically significant, although slightly higher p values may still be indicative of statistically significant differences. To statistically analyze abnormal behavior, a comparison is made between the behavior of a transgenic animal (or a group thereof) to the behavior of a wild-type mouse (or a group thereof), typically under certain prescribed conditions. "Abnormal behavior" as used herein refers to behavior exhibited by an animal having a disruption in the target gene, e.g. transgenic animal, which differs from an animal without a disruption in the target gene, e.g. wild-type mouse. Abnormal behavior consists of any number of standard behaviors that can be objectively measured (or observed) and compared. In the case of comparison, it is preferred that the change be statistically significant to confirm that there is indeed a meaningful behavioral difference between the knockout animal and the wild-type control animal. Examples of behaviors which may be measured or observed include, but are not limited to, ataxia, rapid limb movement, eye movement, breathing, motor activity, cognition, emotional behaviors, social behaviors, hyperactivity, hypersensitivity, anxiety, impaired learning, abnormal reward behavior, and abnormal social interaction, such as aggression A series of tests may be used to measure the behavioral phenotype of the animal models of the present invention, including neurological and neuropsychological tests to identify abnormal behavior. These tests may be used to measure abnormal behavior relating to, for example, learning and memory, eating, pain, aggression, sexual reproduction, anxiety, depression, schizophrenia, and drug abuse. (See, e.g., Crawley and Paylor, Hormones and Behavior 3'1:197-211 (1997)).
The social interaction test involves exposing a mouse to other animals in a variety of settings. The social behaviors of the animals (e.g., touching, climbing, sniffing, and mating) are subsequently evaluated. Differences in behaviors can then be statistically analyzed and compared (See, e.g., S. E. File, et al., Pharmacol. Bioch. Behav. 22:941-944 (1985); R. R.
Holson, Phys. Belaav. 37:239-247 (1986)). Examplary behavioral tests include the following.
The mouse startle response test typically involves exposing the animal to a sensory (typically auditory) stimulus and measuring the startle response of the animal (see, e.g., M. A.
Geyer, et al., Braui Res. Bull. 25:485-498 (1990); Paylor and Crawley, Psychopharmacology 132:169-180 (1997)). A pre-pulse inhibition test can also be used, in which the percent inhibition (from a normal startle response) is measured by "cueing" the animal first with a brief low-intensity pre-pulse prior to the startle pulse.
The electric shock test generally involves exposure to an electrified surface and measurement of subsequent behaviors such as, for example, motor activity, learning, social behaviors. The behaviors are measured and statistically analyzed using standard statistical tests. (See, e.g., G. J. Kant, et cal., Pharm. Bioch. Behav. 20:793-797 (1984); N. J.
Leidenheimer, et al., Pharnaacol. Bioch. Behav. 30:351-355 (1988)).
The tail-pinch or immobilization test involves applying pressure to the tail of the animal and/or restraining the animal's movements. Motor activity, social behavior, and cognitive behavior are examples of the areas that are measured. (See, e.g., M.
Bertolucci D'Angic, et al., Nercrnchena. 55:1208-1214 (1990)).
The novelty test generally comprises exposure to a novel environment and/or novel objects. The animal's motor behavior in the novel environment and/or around the novel object are measured and statistically analyzed. (See, e.g., D. K. Reinstein, et al., Pharm.
Bioclz. Behav. 17:193-202 (1982); B. Poucet, Behav. Neurosci. 103:1009-10016 (1989); R. R.
Holson, et al., Pl2y.s. Bel2av. 37:231-238 (1986)). This test may be used to detect visual processing deficiencies or defects.
The learned helplessness test involves exposure to stresses, for example, noxious stimuli, which cannot be affected by the animal's behavior. The animal's behavior can be statistically analyzed using various standard statistical tests. (See, e.g., A. Leshner, et al., Behav. Neural Biol. 26:497-501 ( 1979)).
Alternatively, a tail suspension test may be used, in which the "immobile"
time of the mouse is measured when suspended "upside-down" by its tail. This is a measure of whether the animal struggles, an indicator of depression. In humans, depression is believed to result from feelings of a lack of control over one's life or situation. It is believed that a depressive state can be elicited in animals by repeatedly subjecting them to aversive situations over which they have no control. A condition of "learned helplessness" is eventually reached, in which the animal will stop trying to change its circumstances and simply accept its fate.
Animals that stop struggling sooner are believed to be more prone to depression. Studies have shown that the administration of certain antidepressant drugs prior to testing increases l0 the amount of time that animals struggle before giving up.
The Mon-is water-maze test comprises learning spatial orientations in water and subsequently measuring the animal's behaviors, such as, for example, by counting the number of incorrect choices. The behaviors measured are statistically analyzed using standard statistical tests. (See, e.g., E. M. Spruijt, et al., Brain Res. 527:192-197 (1990)).
Alternatively, a Y-shaped maze may be used (see, e.g., McFarland, D.J., Pharmacology, Baoclzenzistry a~ml Behavior 32:723-726 (1989); Dellu, F., et al., Neurobiology of Learning and Memory 73:31-48 (2000)). The Y-maze is generally believed to be a test of cognitive ability. The dimensions of each arm of the Y-maze can be, for example, approximately 40 cm x 8 cm x 20 cm, although other dimensions may be used.
Each arm can also have, for example, sixteen equally spaced photobeams to automatically detect movement within the arms. At least two different tests can be performed using such a Y-maze. In a continuous Y-maze paradigm, mice are allowed to explore all three arms of a Y-maze for, e.g., approximately 10 minutes. The animals are continuously tracked using photobeam detection grids, and the data can be used to measure spontaneous alteration and positive bias behavior. Spontaneous alteration refers to the natural tendency of a "normal"
animal to visit the least familiar arm of a maze. An alternation is scored when the animal makes two consecutive turns in the same direction, thus representing a sequence of visits to the least recently entered arm of the maze. Position bias determines egocentrically defined responses by measuring the animal's tendency to favor turning in one direction over another.
3o Therefore, the test can detect differences in an animal's ability to navigate on the basis of allocentric or egocentric mechanisms. The two-trial Y-maze memory test measures response to novelty and spatial memory based on a free-choice exploration paradigm.
During the first trial (acquisition), the animals are allowed to freely visit two arms of the Y-maze for, e.g., approximately 15 minutes. The third arm is blocked off during this trial. The second trial (retrieval) is performed after an intertrial interval of, e.g., approximately
2 hours. During the retrieval trial, the blocked arm is opened and the animal is allowed access to all three arms for, e.g., approximately 5 minutes. Data are collected during the retrieval trial and analyzed for the number and duration of visits to each arm. Because the three arms of the maze are virtually identical, discrimination between novelty and familiarity is dependent on "environmental" spatial cues around the room relative to the position of each arm. Changes in arm entry and duration of time spent in the novel arm in a transgenic animal model may be indicative of a role of that gene in mediating novelty and recognition processes.
The passive avoidance or shuttle box test generally involves exposure to two or more environments, one of which is noxious, providing a choice to be learned by the animal.
Behavioral measures include, for example, response latency, number of correct responses, and consistency of response. (See, e.g., R. Ader, et al., Psychon. Sci. 26:125-128 (1972); R.
R. Holson, Phys. Behcav. 37:221-230 (1986)). Alternatively, a zero-maze can be used. In a zero-maze, the animals can, for example, be placed in a closed quadrant of an elevated IS annular platform having, e.g., 2 open and 2 closed quadrants, and are allowed to explore for approximately 5 minutes. This paradigm exploits an approach-avoidance conflict between normal exploratory activity and an aversion to open spaces in rodents. This test measures anxiety levels and can be used to evaluate the effectiveness of anti-anxiolytic drugs. The time spent in open quadrants versus closed quadrants may be recorded automatically, with, for example, the placement of photobeams at each transition site.
The food avoidance test involves exposure to novel food and objectively measuring, for example, food intake and intake latency. The behaviors measured are statistically analyzed using standard statistical tests. (See, e.g., B. A. Campbell, et al., J. Comp. Physiol.
Psychol. 67:15-22 (1969)).
The elevated plus-maze test comprises exposure to a maze, without sides, on a platform, the animal's behavior is objectively measured by counting the number of maze entries and maze learning. The behavior is statistically analyzed using standard statistical tests. (See, e.g., H. A. Baldwin, et al., Brain Res. Bull, 20:603-606 (1988)).
The stimulant-induced hyperactivity test involves injection of stimulant drugs (e.g., amphetamines, cocaine, PCP, and the like), and objectively measuring, for example, motor activity, social interactions, cognitive behavior. The animal's behaviors are statistically analyzed using standard statistical tests. (See, e.g., P. B. S. Clarke, et al., Psychopharrrcacology 96:51 L-520 (1988); P. Kuczenski, et al., J. Neuroscience 11:2703-2712 (1991)).
The self-stimulation test generally comprises providing the mouse with the opportunity to regulate electrical and/or chemical stimuli to its own brain.
Behavior is measured by frequency and pattern of self-stimulation. Such behaviors are statistically analyzed using standard statistical tests. (See, e.g., S. Nassif, et al., Brain Re.s., 332:247-257 (1985); W. L. Isaac, et al., Behav. Neurosci. 103:345-355 (1989)).
The reward test involves shaping a variety of behaviors, e.g., motor, cognitive, and social, measuring, for example, rapidity and reliability of behavioral change, and statistically analyzing the behaviors measured. (See, e.g., L. E. Jarrard, et al., Exp.
Brain Res. 61:519-530 (1986)).
The DRL (differential reinforcement to low rates of responding) performance test involves exposure to intermittent reward paradigms and measuring the number of proper responses, e.g., lever pressing. Such behavior is statistically analyzed using standard statistical tests. (See, e.g., J. D. Sinden, et al., Behav. Neurosci. 100:320-329 (1986); V.
Nalwa, et al., Behav Brain Res. 17:73-76 (1985); and A. J. Nonneman, et al., J. Comp.
Physiol. Psych. 95:588-602 (1981)).
The spatial learning test involves exposure to a complex novel environment, measuring the rapidity and extent of spatial learning, and statistically analyzing the behaviors measured. (See, e.g., N. Pitsikas, et al., Pharm. Bioch. Behav. 38:931-934 (1991); B. poucet, et al., Brain Res. 37:269-280 (1990); D. Christie, et al., Brain Res. 37:263-268 (1990); and F.
Van Haaren, et al., Behav. Neurosci. 102:481-488 (1988)). Alternatively, an open-field (of) test may be used, in which the greater distance traveled for a given amount of time is a measure of the activity level and anxiety of the animal. When the open field is a novel environment, it is believed that an approach-avoidance situation is created, in which the animal is "torn" between the drive to explore and the drive to protect itself.
Because the chamber is lighted and has no places to hide other than the corners, it is expected that a "normal" mouse will spend more time in the corners and around the periphery than it will in the center where there is no place to hide. "Normal" mice will, however, venture into the central regions as they explore more and more of the chamber. It can then be extrapolated that especially anxious mice will spend most of their time in the corners, with relatively little or no exploration of the central region, whereas bold (i.e., less anxious) mice will travel a greater distance, showing little preference for the periphery versus the central region.
The visual, somatosensory and auditory neglect tests generally comprise exposure to a sensory stimulus, objectively measuring, for example, orientating responses, and statistically analyzing the behaviors measured. (See, e.g., J. M. Vargo, et al., Exp.
Neurol. 102:199-209 (1988)).
The consummatory behavior test generally comprises feeding and drinking, and objectively measuring quantity of consumption. The behavior measured is statistically analyzed using standard statistical tests. (See, e.g., P. J. Fletcher, et al., Psychopharmacol.
102:301-308 (1990); M. G. Corda, et al." Proc. Nato Acad. Sci. USA 80:2072-2076 (1983)).
A visual discrimination test can also be used to evaluate the visual processing of an animal. One or two similar objects are placed in an open field and the animal is allowed to explore for about 5-10 minutes. The time spent exploring each object (proximity to, i.e., l0 movement within, e.g., about 3-5 cm of the object is considered exploration of an object) is recorded. The animal is then removed from the open field, and the objects are replaced by a similar object and a novel object. The animal is returned to the open field and the percent time spent exploring the novel object over the old object is measured (again, over about a 5-minute span). "Normal" animals will typically spend a higher percentage of time exploring the novel object rather than the old object. If a delay is imposed between sampling and testing, the memory task becomes more hippocampal-dependent. If no delay is imposed, the task is more based on simple visual discrimination. This test can also be used for olfactory discrimination, in which the objects (preferably, simple blocks) can be sprayed or otherwise treated to hold an odor. This test can also be used to determine if the animal can make gustatory discriminations; animals that return to the previously eaten food instead of novel food exhibit gustatory neophobia.
A hot plate analgesia test can be used to evaluate an animal's sensitivity to heat or painful stimuli. For example, a mouse can be placed on an approximately 55°C hot plate and the mouse's response latency (e.g., time to pick up and lick a hind paw) can be recorded.
These responses are not reflexes, but rather "higher" responses requiring cortical involvement. This test may be used to evaluate a nociceptive disorder.
An accelerating rotarod test may be used to measure coordination and balance in mice. Animals can be, for example, placed on a rod that acts like a rotating treadmill (or rolling log). The rotarod can be made to rotate slowly at first and then progressively faster until it reaches a speed of, e.g., approximately 60 rpm. The mice must continually reposition themselves in order to avoid falling off. The animals are preferably tested in at least three trials, a minimum of 20 minutes apart. Those mice that are able to stay on the rod the longest are believed to have better coordination and balance.
A metrazol administration test can be used to screen animals for varying susceptibilities to seizures or similar events. For example, a 5mg/ml solution of metrazol can be infused through the tail vein of a mouse at a rate of, e.g., approximately 0.375 ml/min.
The infusion will cause all mice to experience seizures, followed by death.
Those mice that enter the seizure stage the soonest are believed to be more prone to seizures.
Four distinct physiological stages can be recorded: soon after the start of infusion, the mice will exhibit a noticeable "twitch", followed by a series of seizures, ending in a final tensing of the body known as "tonic extension", which is followed by death.
Target Gene Products The present invention further contemplates use of the target gene sequence to produce target gene products. Target gene products may include proteins that represent functionally equivalent gene products. Such an equivalent gene product may contain deletions, additions or substitutions of amino acid residues within the amino acid sequence encoded by the gene sequences described herein, but which result in a silent change, thus producing a functionally t5 equivalent target gene product. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.
For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine;
positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
"Functionally equivalent", as utilized herein, refers to a protein capable of exhibiting a substantially similar in vivo activity as the endogenous gene products encoded by the target gene sequences.
Alternatively, when utilized as part of an assay, "functionally equivalent"
may refer to peptides capable of interacting with other cellular or extracellular molecules in a manner substantially similar to the way in which the corresponding portion of the endogenous gene product would.
Other protein products useful according to the methods of the invention are peptides derived from or based on the target gene produced by recombinant or synthetic means (derived peptides).
Target gene products may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing the gene polypeptides and peptides of the invention by expressing nucleic acid encoding gene sequences are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing gene protein coding sequences and appropriate transcriptional/translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination (see, e.g., Sambrook, et al., 1989, supra, and Ausubel, et al., 1989, supra).
Alternatively, RNA capable of encoding gene protein sequences may be chemically synthesized using, for example, automated synthesizers (see, e.g.
Oligonucleotide Synthesis:
A Practical Approach, Gait, M. J. ed., IRL Press, Oxford (1984)).
A variety of host-expression vector systems may be utilized to express the gene t0 coding sequences of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, exhibit the gene protein of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing gene protein coding sequences; yeast (e.g. Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing the gene protein coding sequences;
insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the gene protein coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing gene protein coding sequences; or mammalian cell systems (e.g. COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5 K promoter).
In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the gene protein being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of antibodies or to screen peptide libraries, for example, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the E. coli expression vector pUR278 (Ruther et al., EMBO J., 2:1791-94 (1983)), in which the gene protein coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN
vectors (Inouye & Inouye, Nucleic Acids Res., 13:3101-09 (1985); Van Heeke et al., J. Biol.
Chem., 264:5503-9 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene protein can be released from the GST moiety.
In a prefen-ed embodiment, full length cDNA sequences are appended with in-frame Bam HI sites at the amino terminus and Eco RI sites at the carboxyl terminus using standard PCR methodologies (Innis, et al. (eds) PCR Protocols: A Guide to Methods and Applications, l0 Academic Press, San Diego (1990)) and ligated into the pGEX-2TK vector (Pharmacia, Uppsala, Sweden). The resulting cDNA construct contains a kinase recognition site at the amino terminus for radioactive labeling and glutathione S-transferase sequences at the carboxyl terminus for affinity purification (Nilsson, et al., EMBO J., 4: 1075-80 (1985);
Zabeau et al., EMBO J., 1: 1217-24 (1982)).
IS In an insect system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in Spodoptera frugiperda cells.
The gene coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV
promoter (for example the polyhedrin promoter). Successful insertion of gene coding sequence will 20 result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect Spodoptera frugiperda cells in which the inserted gene is expressed (see, e.g., Smith, et al., J. Virol. 46: 584-93 (1983); U.S.
Pat. No.
4,745,051 ).
25 In mammalian host cells, a number of viral-based expression systems may be utilized.
In cases where an adenovirus is used as an expression vector, the gene coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of 30 the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing gene protein in infected hosts. (e.g., see Logan et al., Proc. Natl. Acad.
Sci. USA, 81:3655-59 (1984)). Specific initiation signals may also be required for efficient translation of inserted gene coding sequences. These signals include the ATG
initiation codon and adjacent sequences. In cases where an entire gene, including its own initiation 35 codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of the gene coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bitter, et al., Methods in Enzymol., 153:516-44 (1987)).
l0 In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification 15 of proteins. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, 20 WI38, etc.
For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the gene protein may be engineered.
Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., 25 promoter, enhances, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells which stably integrate the plasmid into their chromosomes and grow, to form 30 foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the gene protein.
Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the gene protein.
In a preferred embodiment, control of timing and/or quantity of expression of the 35 recombinant protein can be controlled using an inducible expression construct. Inducible constructs and systems for inducible expression of recombinant proteins will be well known to those skilled in the art. Examples of such inducible promoters or other gene regulatory elements include, but are not limited to, tetracycline, metallothionine, ecdysone, and other steroid-responsive promoters, rapamycin responsive promoters, and the like (No, et al., Proc.
Natl. Acad. Sci. USA, 93:3346-51 (1996); Furth, et al., Proc. Natl. Acad. Sci.
USA, 91:9302-6 (1994)). Additional control elements that can be used include promoters requiring specific transcription factors such as viral, particularly HN, promoters. In one in embodiment, a Tet inducible gene expression system is utilized. (Gossen et al., Proc. Natl.
Acad. Sci. USA, l0 89:5547-51 (1992); Gossen, et al., Science, 268:1766-69 (1995)). Tet Expression Systems are based on two regulatory elements derived from the tetracycline-resistance operon of the E. coli TnlO transposon-the tetracycline repressor protein (TetR) and the tetracycline operator sequence (tet0) to which TetR binds. Using such a system, expression of the recombinant protein is placed under the control of the tet0 operator sequence and transfected or transformed into a host cell. In the presence of TetR, which is co-transfected into the host cell, expression of the recombinant protein is repressed due to binding of the TetR protein to the tet0 regulatory element. High-level, regulated gene expression can then be induced in response to varying concentrations of tetracycline (Tc) or Tc derivatives such as doxycycline (Dox), which compete with tet0 elements for binding to TetR. Constructs and materials for tet inducible gene expression are available commercially from CLONTECH
Laboratories, Inc.,~Palo Alto, CA.
When used as a component in an assay system, the gene protein may be labeled, either directly or indirectly, to facilitate detection of a complex formed between the gene protein and a test substance. Any of a variety of suitable labeling systems may be used including but not limited to radioisotopes such as 125I; enzyme labeling systems that generate a detectable calorimetric signal or light when exposed to substrate;
and fluorescent labels. Where recombinant DNA technology is used to produce the gene protein for such assay systems, it may be advantageous to engineer fusion proteins that can facilitate labeling, immobilization and/or detection.
Indirect labeling involves the use of a protein, such as a labeled antibody, which specifically binds to the gene product. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments and fragments produced by a Fab expression library.
Production of Antibodies Described herein are methods for the production of antibodies capable of specifically recognizing one or more epitopes. Such antibodies may include, but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab~2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Such antibodies may be used, for example, in the detection of a target gene in a biological sample, or, alternatively, as a method for the inhibition of abnormal target gene activity. Thus, such antibodies may be utilized as part of disease treatment methods, and/or l0 may be used as part of diagnostic techniques whereby patients may be tested for abnormal levels of target gene proteins, or for the presence of abnormal forms of the such proteins.
For the production of antibodies, various host animals may be immunized by injection with the target gene, its expression product or a portion thereof. Such host animals may include but are not limited to rabbits, mice, and rats, to name but a few.
Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium loarvacm.
Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen, such as target gene product, or an antigenic functional derivative thereof. For the production of polyclonal antibodies, host animals such as those described above, may be-immunized by injection with gene product supplemented with adjuvants as also described above.
Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to the hybridoma technique of Kohler and Milstein, Nature, 256:495-7 (1975); and U.S. Pat.
No. 4,376,110), the human B-cell hybridoma technique (Kosbor, et al., Immunology Today, 4:72 (1983); Cote, et al., Proc. Natl. Acad. Sci. USA, 80:2026-30 (1983)), and the EBV-hybridoma technique (Cole, et al., in Monoclonal Antibodies And Cancer Therapy, Alan R.
Liss, Inc., New York, pp. 77-96 (1985)). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the presently preferred method of production.
In addition, techniques developed for the production of "chimeric antibodies"
(Morrison, et al., Proc. Natl. Acad. Sci., 81:6851-6855 (1984); Takeda, et al., Nature, 314:452-54 (1985)) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.
Alternatively, techniques described for the production of single chain antibodies (U.S.
Pat. No. 4,946,778; Bird, Science 242:423-26 (1988); Huston, et al., Proc.
Natl. Acad. Sci.
USA, 85:5879-83 (1988); and Ward, et al., Nature, 334:544-46 (1989)) can be adapted to produce gene-single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.
Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include but are not limited to: the F(ab~2 fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab~2 fragments.
Alternatively, Fab expression libraries may be constructed (Huse, et al., Science, 246:1275-81 (1989)) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.
Screening for Therapeutic Agents Cells that contain and express target gene sequences may be used to screen for therapeutic agents. Such cells may include non-recombinant monocyte cell lines, such as U937 (ATCC# CRL-1593), THP-1 (ATCC# TIB-202), and P388D1 (ATCC# TIB-63);
endothelial cells such as HUVEC's and bovine aortic endothelial cells (BAEC's); as well as generic mammalian cell lines such as HeLa cells and COS cells, e.g., COS-7 (ATCC# CRL-1651). Further, such cells may include recombinant, transgenic cell lines. For example, the knockout mice of the invention may be used to generate cell lines, containing one or more cell types involved in a disease, that can be used as cell culture models for that disorder.
While cells, tissues, and primary cultures derived from the disease transgenic animals of the invention may be utilized, the generation of continuous cell lines is preferred. For examples of techniques which may be used to derive a continuous cell line from the transgenic animals, see Small, et al., Mol. Cell Biol., 5:642-48 (1985).
Target gene sequences may be introduced into, and overexpressed in, the genome of the cell of interest. In order to overexpress a target gene sequence, the coding portion of the target gene sequence may be ligated to a regulatory sequence which is capable of driving gene expression in the cell type of interest. Such regulatory regions will be well known to those of skill in the art, and may be utilized in the absence of undue experimentation. Target gene sequences may also be disrupted or underexpressed. Cells having target gene disruptions or underexpressed target gene sequences may be used, for example, to screen for agents capable of affecting alternative pathways which compensate for any loss of function attributable to the disruption or underexpression.
In vitro systems may be designed to identify compounds capable of binding the target gene products. Such compounds may include, but are not limited to, peptides made of D-and/or L-configuration amino acids (in, for example, the form of random peptide libraries;
see e.g., Lam, et al., Natc~re, 354:82-4 (1991)), phosphopeptides (in, for example, the form of random or partially degenerate, directed phosphopeptide libraries; see, e.g., Songyang, et al., Cell, 72:767-78 (1993)), antibodies, and small organic or inorganic molecules.
Compounds identified may be useful, for example, in modulating the activity of target gene proteins, preferably mutant target gene proteins; elaborating the biological function of the target gene protein; or screening for compounds that disrupt normal target gene interactions or themselves disrupt such interactions.
The principle of the assays used to identify compounds that bind to the target gene protein involves preparing a reaction mixture of the target gene protein and the test compound under conditions and for a time sufficient to allow the two components to interact and bind, thus forming a complex which can be removed and/or detected in the reaction mixture. These assays can be conducted in a variety of ways. For example, one method to conduct such an assay would involve anchoring the target gene protein or the test substance onto a solid phase and detecting target protein/test substance complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method, the target gene protein may be anchored onto a solid surface, and the test compound, which is not anchored, may be labeled, either directly or indirectly.
In practice, microtitre plates are conveniently utilized. The anchored component may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished simply by coating the solid surface with a solution of the protein and drying.
Alternatively, an immobilized antibody, preferably a monoclonal antibody, specific for the protein may be used to anchor the protein to the solid surface. The surfaces may be prepared in advance and stored.
In order to conduct the assay, the nonimmobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the previously l0 nonimmobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously nonimmobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface;
e.g., using a labeled antibody specific for the previously nonimmobilized component (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody).
Alternatively, a reaction can be conducted in a liquid phase, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for target gene product or the test compound to anchor any complexes formed in solution, and a labeled antibody specific for the other component of the possible complex to detect anchored complexes.
Compounds that are shown to bind to a particular target gene product through one of the methods described above can be further tested for their ability to elicit a biochemical response from the target gene protein. Agonists, antagonists and/or inhibitors of the expression product can be identified utilizing assays well known in the art.
Antisense, Ribozymes, and Antibodies Other agents which may be used as therapeutics include the target gene, its expression products) and functional fragments thereof. Additionally, agents which reduce or inhibit mutant target gene activity may be used to ameliorate disease symptoms. Such agents include antisense, ribozyme, and triple helix molecules. Techniques for the production and use of such molecules are well known to those of skill in the art.
Anti-sense RNA and DNA molecules act to directly block the translation of mRNA
by hybridizing to targeted mRNA and preventing protein translation. With respect to antisense DNA, oligodeoxyribonucleotides derived from the translation initiation site, e.g., between the -10 and +10 regions of the target gene nucleotide sequence of interest, are preferred.
Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage.
The composition of ribozyme molecules must include one or more sequences complementary to the target gene mRNA, and must include the well known catalytic sequence responsible for mRNA cleavage. For this sequence, see U.S. Pat. No. 5,093,246, which is incorporated by reference herein in its entirety. As such within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of RNA sequences encoding target gene proteins.
Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the molecule of interest for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features, such as secondary structure, that may render the oligonucleotide sequence unsuitable. The suitability of candidate sequences may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.
Nucleic acid molecules to be used in triple helix formation for the inhibition of transcription should be single stranded and composed of deoxyribonucleotides.
The base composition of these oligonucleotides must be designed to promote triple helix formation via Hoogsteen base pairing rules, which generally require sizeable stretches of either purines or pyrimidines to be present on one strand of a duplex. Nucleotide sequences may be pyrimidine-based, which will result in TAT and CGC triplets across the three associated strands of the resulting triple helix. The pyrimidine-rich molecules provide base complementarity to a purine-rich region of a single strand of the duplex in a parallel orientation to that strand. In addition, nucleic acid molecules may be chosen that are purine-rich, for example, containing a stretch of G residues. These molecules will form a triple helix with a DNA duplex that is rich in GC pairs, in which the majority of the purine residues are located on a single strand of the targeted duplex, resulting in GGC triplets across the three strands in the triplex.
Alternatively, the potential sequences that can be targeted for triple helix formation may be increased by creating a so called "switchback" nucleic acid molecule.
Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.
It is possible that the antisense, ribozyme, and/or triple helix molecules described herein may reduce or inhibit the transcription (triple helix) andlor translation (antisense, ribozyme) of mRNA produced by both normal and mutant target gene alleles. In order to ensure that substantially normal levels of target gene activity are maintained, nucleic acid molecules that encode and express target gene polypeptides exhibiting normal activity may l0 be introduced into cells that do not contain sequences susceptible to whatever antisense, ribozyme, or triple helix treatments are being utilized. Alternatively, it may be preferable to coadminister normal target gene protein into the cell or tissue in order to maintain the requisite level of cellular or tissue target gene activity.
Anti-sense RNA and DNA, ribozyme, and triple helix molecules of the invention may be prepared by any method known in the art for the synthesis of DNA and RNA
molecules.
These include techniques for chemically synthesizing oligodeoxyribonucleotides and oligoribonucleotides well known in the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molecule. Such DNA
sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerise promoters such as the T7 or SP6 polymerise promoters.
Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.
Various well-known modifications to the DNA molecules may be introduced as a means of increasing intracellular stability and half-life. Possible modifications include but are not limited to the addition of flanking sequences of ribonucleotides or deoxyribonucleotides to the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the oligodeoxyribonucleotide backbone.
Antibodies that are both specific for target gene protein, and in particular, mutant gene protein, and interfere with its activity may be used to inhibit mutant target gene function. Such antibodies may be generated against the proteins themselves or against peptides corresponding to portions of the proteins using standard techniques known in the art and as also described herein. Such antibodies include but are not limited to polyclonal, monoclonal, Fab fragments, single chain antibodies, chimeric antibodies, etc.
In instances where the target gene protein is intracellular and whole antibodies are used, internalizing antibodies may be preferred. However, lipofectin liposomes may be used to deliver the antibody or a fragment of the Fab region which binds to the target gene epitope into cells. Where fragments of the antibody are used, the smallest inhibitory fragment which binds to the target or expanded target protein's binding domain is preferred.
For example, peptides having an amino acid sequence corresponding to the domain of the variable region of the antibody that binds to the target gene protein may be used. Such peptides may be synthesized chemically or produced via recombinant DNA technology using methods well known in the art (see, e.g., Creighton, Proteins: Structures and Molecular Principles (1984) W.1-I. Freeman, New York 1983, sccpra; and Sambrook, et al., 1989, supra).
Alternatively, single chain neutralizing antibodies which bind to intracellular target gene epitopes may also be administered. Such single chain antibodies may be administered, for example, by expressing nucleotide sequences encoding single-chain antibodies within the target cell population by utilizing, for example, techniques such as those described in Marasco, et al., Proc. Natl. Acad. Sci. USA, 90:7889-93 (1993).
RNA sequences encoding target gene protein may be directly administered to a patient exhibiting disease symptoms, at a concentration sufficient to produce a level of target gene protein such that disease symptoms are ameliorated. Patients may be treated by gene replacement therapy. One or more copies of a normal target gene, or a portion of the gene that directs the production of a normal target gene protein with target gene function, may be inserted into cells using vectors which include, but are not limited to adenovirus, adeno-associated virus, and retrovirus vectors, in addition to other particles that introduce DNA into cells, such as liposomes. Additionally, techniques such as those described above may be utilized for the introduction of normal target gene sequences into human cells.
Cells, preferably, autologous cells, containing normal target gene expressing gene sequences may then be introduced or reintroduced into the patient at positions which allow for the amelioration of disease symptoms.
Pharmaceutical Compositions, Effective Dosages, and Routes of Administration The identified compounds that inhibit target mutant gene expression, synthesis and/or activity can be administered to a patient at therapeutically effective doses to treat or ameliorate the disease. A therapeutically effective dose refers to that amount of the compound sufficient to result in amelioration of symptoms of the disease.
Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LDso (the dose lethal to 50°Io of the population) and the EDSO (the dose therapeutically effective in 50°70 of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LDSOBDSO. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the EDSO
with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the 15 invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the ICSO (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
Such information can be used to more accurately determine useful doses in humans.
Levels in 20 plasma may be measured, for example, by high performance liquid chromatography.
Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients. Thus, the compounds and their physiologically acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the 25 nose) or oral, buccal, parenteral, topical, subcutaneous, intraperitoneal, intraveneous, intrapleural, intraoccular, intraarterial, or rectal administration. It is also contemplated that pharmaceutical compositions may be administered with other products that potentiate the activity of the compound and optionally, may include other therapeutic ingredients.
For oral administration, the pharmaceutical compositions may take the form of, for 30 example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyn-olidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or 35 wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats);
emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, l0 flavoring, coloring and sweetening agents as appropriate.
Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.
For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. Oral ingestion is possibly the easiest method of taking any medication.
Such a route of administration, is generally simple and straightforward and is frequently the least inconvenient or unpleasant route of administration from the patient's point of view.
However. this involves passing the material through the stomach, which is a hostile environment for many materials, including proteins and other biologically active compositions. As the acidic, hydrolytic and proteolytic environment of the stomach has evolved efficiently to digest proteinaceous materials into amino acids and oligopeptides for subsequent anabolism, it is hardly surprising that very little or any of a wide variety of biologically active proteinaceous material, if simply taken orally, would survive its passage through the stomach to be taken up by the body in the small intestine. The result, is that many proteinaceous medicaments must be taken in through another method, such as parenterally, often by subcutaneous, intramuscular or intravenous injection.
l0 Pharmaceutical compositions may also include various buffers (e.g., Tris, acetate, phosphate), solubilizers (e.g., Tween, Polysorbate), carriers such as human serum albumin, preservatives (thimerosol, benzyl alcohol) and anti-oxidants such as ascorbic acid in order to stabilize pharmaceutical activity. The stabilizing agent may be a detergent, such as tween-20, tween-80, NP-40 or Triton X-100. EBP may also be incorporated into particulate preparations of polymeric compounds for controlled delivery to a patient over an extended period of time. A more extensive survey of components in pharmaceutical compositions is found in Remington's Pharmaceutical Sciences, 18th ed., A. R. Gennaro, ed., Mack Publishing, Easton, Pa. (1990).
In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil). or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.
Dia ng ostics A variety of methods may be employed to diagnose disease conditions associated with the target gene. Specifically, reagents may be used, for example, for the detection of the .
presence of target gene mutations, or the detection of either over or under expression of target gene mRNA.
According to the diagnostic and prognostic method of the present invention, alteration of the wild-type target gene locus is detected. In addition, the method can be performed by detecting the wild-type target gene locus and confirming the lack of a predisposition or neoplasia. "Alteration of a wild-type gene" encompasses all forms of mutations including deletions, insertions and point mutations in the coding and noncoding regions.
Deletions may be of the entire gene or only a portion of the gene. Point mutations may result in stop codons, frameshift mutations or amino acid substitutions. Somatic mutations are those which occur only in certain tissues, e.g., in the tumor tissue, and are not inherited in the germline.
Germline mutations can be found in any of a body's tissues and are inherited.
If only a single allele is somatically mutated, an early neoplastic state is indicated.
However, if both alleles are mutated, then a late neoplastic state may be indicated. The finding of gene mutations thus provides both diagnostic and prognostic information. A target gene allele which is not deleted (e.g., that found on the sister chromosome to a chromosome carrying a target gene deletion) can be screened for other mutations, such as insertions, small deletions, and point mutations. Mutations found in tumor tissues may be linked to decreased expression of the target gene product. However, mutations leading to non-functional gene products may also be linked to a cancerous state. Point mutational events may occur in regulatory regions, such as in the promoter of the gene, leading to loss or diminution of expression of the mRNA.
Point mutations may also abolish proper RNA processing, leading to loss of expression of the target gene product, or a decrease in mRNA stability or translation efficiency.
One test available for detecting mutations in a candidate locus is to directly compare genomic target sequences from cancer patients with those from a control population.
Alternatively, one could sequence messenger RNA after amplification, e.g., by PCR, thereby eliminating the necessity of determining the exon structure of the candidate gene. Mutations from cancer patients falling outside the coding region of the target gene can be detected by examining the non-coding regions, such as introns and regulatory sequences near or within the target gene. An early indication that mutations in noncoding regions are important may come from Northern blot experiments that reveal messenger RNA molecules of abnormal size or abundance in cancer patients as compared to control individuals.
The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one specific gene nucleic acid or anti-gene antibody reagent described herein, which may be conveniently used, e.g., in clinical settings, to diagnose patients exhibiting disease symptoms or at risk for developing disease.
Any cell type or tissue, preferably monocytes, endothelial cells, or smooth muscle cells, in which the gene is expressed may be utilized in the diagnostics described below.
DNA or RNA from the cell type or tissue to be analyzed may easily be isolated using procedures which are well known to those in the art. Diagnostic procedures may also be performed in situ directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections, such that no nucleic acid purification is necessary. Nucleic acid reagents may be used as probes and/or primers for such in situ procedures (see, for example, Nuovo, PCR In Situ Hybridization: Protocols and Applications, Raven Press, N.Y. (1992)).
Gene nucleotide sequences, either RNA or DNA, may, for example, be used in hybridization or amplification assays of biological samples to detect disease-related gene structures and expression. Such assays may include, but are not limited to, Southern or Northern analyses, restriction fragment length polymorphism assays, single stranded conformational polymorphism analyses, in situ hybridization assays, and polymerase chain reaction analyses. Such analyses may reveal both quantitative aspects of the expression pattern of the gene, and qualitative aspects of the gene expression and/or gene composition.
That is, such aspects may include, for example, point mutations, insertions, deletions, chromosomal rearrangements, and/or activation or inactivation of gene expression.
Preferred diagnostic methods for the detection of gene-specific nucleic acid molecules may involve for example, contacting and incubating nucleic acids, derived from the cell type or tissue being analyzed, with one or more labeled nucleic acid reagents under conditions favorable for the specific annealing of these reagents to their complementary sequences within the nucleic acid molecule of interest. Preferably, the lengths of these nucleic acid reagents are at least 9 to 30 nucleotides. After incubation, all non-annealed nucleic acids are removed from the nucleic acid:fingeiprint molecule hybrid. The presence of nucleic acids from the fingerprint tissue which have hybridized, if any such molecules exist, is then detected. Using such a detection scheme, the nucleic acid from the tissue or cell type of interest may be immobilized, for example, to a solid support such as a membrane, or a plastic surface such as that on a microtitre plate or polystyrene beads. In this case, after incubation, non-annealed, labeled nucleic acid reagents are easily removed. Detection of the remaining, annealed, labeled nucleic acid reagents is accomplished using standard techniques well-known to those in the art.
Alternative diagnostic methods for the detection of gene-specific nucleic acid molecules may involve their amplification, e.g., by PCR (the experimental embodiment set forth in Mullis U.S. Pat. No. 4,683,202 (1987)), ligase chain reaction (Barany, Proc. Natl.
Aced. Sci. USA, 88:189-93 (1991 )), self sustained sequence replication (Guatelli, et al., Proc.
Natl. Acad. Sci. USA, 87:1874-78 (1990)), transcriptional amplification system (Kwoh, etal., Proc. Natl. Accc~l. Sci. USA, 86:1173-77 ( 1989)), Q-Beta Replicase (Lizardi et cal., BiolTechnology, 6:1197 (1988)), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.
In one embodiment of such a detection scheme, a cDNA molecule is obtained from an RNA molecule of interest (e.g., by reverse transcription of the RNA molecule into cDNA).
Cell types or tissues from which such RNA may be isolated include any tissue in which wild type fingerprint gene is known to be expressed, including, but not limited, to monocytes, endothelium, and/or smooth muscle. A sequence within the cDNA is then used as the template for a nucleic acid amplification reaction, such as a PCR
amplification reaction, or the like. The nucleic acid reagents used as synthesis initiation reagents (e.g., primers) in the reverse transcription and nucleic acid amplification steps of this method may be chosen from among the gene nucleic acid reagents described herein. The preferred lengths of such nucleic acid reagents are at least 15-30 nucleotides. For detection of the amplified product, the nucleic acid amplification may be performed using radioactively or non-radioactively labeled nucleotides. Alternatively, enough amplified product may be made such that the product may be visualized by standard ethidium bromide staining or by utilizing any other suitable nucleic acid staining method.
Antibodies directed against wild type or mutant gene peptides may also be used as disease diagnostics and prognostics. Such diagnostic methods, may be used to detect abnormalities in the level of gene protein expression, or abnormalities in the structure and/or tissue, cellular, or subcellular location of fingerprint gene protein.
Structural differences may include, for example, differences in the size, electronegativity, or antigenicity of the mutant fingerprint gene protein relative to the normal fingerprint gene protein.
Protein from the tissue or cell type to be analyzed may easily be detected or isolated using techniques which are well known to those of skill in the art, including but not limited to western blot analysis. For a detailed explanation of methods for carrying out western blot analysis, see Sambrook, et al. (1989) supra, at Chapter 18. The protein detection and isolation methods employed herein may also be such as those described in Harlow and Lane, for example, (Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1988)).
Preferred diagnostic methods for the detection of wild type or mutant gene peptide molecules may involve, for example, immunoassays wherein fingerprint gene peptides are detected by their interaction with an anti-fingerprint gene-specific peptide antibody.
For example, antibodies, or fragments of antibodies useful in the present invention may be used to quantitatively or qualitatively detect the presence of wild type or mutant gene peptides. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody (see below) coupled with light microscopic, flow cytometric, or fluorimetric detection. Such techniques are especially preferred if the fingerprint gene peptides are expressed on the cell surface.
The antibodies (or fragments thereof) useful in the present invention may, l0 additionally, be employed histologically, as in immunofluorescence or immunoelectron microscopy, for i~z situ detection of fingerprint gene peptides. In situ detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labeled antibody of the present invention. The antibody (or fragment) is preferably applied by overlaying the labeled antibody (or fragment) onto a biological sample.
Through the use of such a procedure, it is possible to determine not only the presence of the fingerprint gene peptides, but also their distribution in the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of a wide variety of histological methods (such as staining procedures) can be modified in order to achieve such in situ detection.
Immunoassays for wild type, mutant, or expanded fingerprint gene peptides typically comprise incubating a biological sample, such as a biological fluid, a tissue extract, freshly harvested cells, or cells which have been incubated in tissue culture, in the presence of a detectably labeled antibody capable of identifying fingerprint gene peptides, and detecting the bound antibody by any of a number of techniques well known in the art.
The biological sample may be brought in contact with and immobilized onto a solid ~ phase support or caa-ier such as nitrocellulose, or other solid support which is capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by treatment with the detectably labeled gene-specific antibody.
The solid phase support may then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on solid support may then be detected by conventional means.
By "solid phase support or carrier" is intended any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc.
Preferred supports include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.
The binding activity of a given lot of anti-wild type or -mutant fingerprint gene l0 peptide antibody may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.
One of the ways in which the gene peptide-specific antibody can be detectably labeled is by linking the same to an enzyme and using it in an enzyme immunoassay (EIA) (Volley, Ric Clin Lczb, 8:289-98 (1978) ["The Enzyme Linked Immunosorbent Assay (ELISA)", Diagnostic Horizons 2:1-7, 1978, Microbiological Associates Quarterly Publication, Walkersville, Md.]; Volley, et ccl., J. Clin. Pathol., 31:507-20 (1978);
Butler, Meth. Enzymol., 73:482-523 (1981); Maggio (ed.), Enzyme Immunoassay, CRC Press, Boca Raton, Fla.
(1980); Ishikawa, et ~cl., (eds.) Enzyme Immunoassay, Igaku-Shoin, Tokyo (1981)). The enzyme which is bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorimetric or by visual means.
Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate, dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, crease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. The detection can be accomplished by colorimetric methods which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.
Detection may also be accomplished using any of a variety of other immunoassays.
For example, by radioactively labeling the antibodies or antibody fragments, it is possible to detect fingerprint gene wild type, mutant, or expanded peptides through the use of a radioimmunoassay (RIA) (see, e.g., Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986). The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.
It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
The antibody can also be detectably labeled using fluorescence emitting metals such as 152Eu, or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentacetic acid (DTPA) or ethylenediamine-tetraacetic acid (EDTA).
The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction.
Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.
Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in, which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes bf labeling are luciferin, luciferase and aequorin.
Throughout this application, various publications, patents and published patent applications are referred to by an identifying citation. The disclosures of these publications, patents and published patent specifications referenced in this application are hereby incorporated by reference into the present disclosure to more fully describe the state of the art to which this invention pertains.
The following examples are intended only to illustrate the present invention and should in no way be construed as limiting the subject invention.
Examples Example 1: Direct Construct Construction from a Plasmid Library Genomic libraries using the lambda ZAPTM system were prepared as follows.
Embryonic stem cells were grown in 100 mm tissue culture plates. High molecular weight genomic DNA was isolated from these ES cells by adding 5 ml of lysis buffer (10 mM Tris-HCL pH7.5, 10 mM EDTA pH 8.0, 10 mM NaCI, 0.5°lo SDS, and 1 mg/ml Proteinase K) to a confluent 100 mm plate of embryonic stem cells. The cells were then incubated at 60°C for several hours or until fully lysed. Genomic DNA was purified from the lysed cells by several rounds of gentle phenol:chloroform extractions followed by ethanol precipitation.
The genomic DNA was partially digested with the restriction enzyme Sau 3A I to generate fragments of approximately 5-20 kb. The ends of these fragments were partially filled in by addition of dATP and dGTP in the present of Klenow DNA
polymerise, creating incompatible ends on the genomic fragments. Size fragments of between 5 and 10 kb were then purified by agarose gel electrophoresis (lx TAE, 0.8% gel). The DNA was then isolated from the excised agarose pieces using a QIAquick gel extraction kit (Qiagen, Inc., Valencia, CA).
The genomic fragments were ligated into the Lambda ZapTM II vector (Stratagene, Inc., La Jolla, CA) that had been cut with Xho I and partially filled in using dTTP, dCTP, and Klenow DNA polymerise. After ligation, the DNA was packaged using a lambda packaging mix (Gigapack III gold, Stratagene, Inc., La Jolla, CA) and the titer was determined.
Circular phagemid DNA was derived from the lambda library by growing the lambda clones on the appropriate bacterial strain (XL-1 Blue MRF~, Stratagene, Inc.) in the presence of the M13 helper phage, ExAssist (Stratagene, Inc.). Specifically, approximately 100,000 lambda clones were incubated with a 10-100 fold excess of both bacteria and helper phage for 20 minutes at 37°C. One ml of LB media + 10 mM MgS04 was added to each excision reaction and it was incubated overnight at 37°C with shaking. Typically 24-96 of these reactions were set up at a time in a 96 well deep-well block. The following morning, the block was heated to 65°C for 15 minutes to kill both the bacteria and the lambda phage.
Bacterial debris was removed by centrifugation at approximately 3000g for 15 minutes. The supernatant containing the circular phagemid DNA, was retained and used directly in plasmid PCR .
The pools of phagemid DNA described above were screened for specific genes of interest using long-range PCR and "outward pointing" oligos, chosen as described above based on the known sequence (depicted in Figure 1). The PCR reactions contains 2 p,1 of a pool phagemid DNA sample, 3 ~tl of lOx PCR Buffer 3 (Boehringer Mannheim), 1.1 ~I 10 mM dNTPs, 50 nM primers, 0.3 ~1 of EXPAND Long Template PCR Enzyme Mix (Boehringer-Mannheim) and 30 ~1 of HBO. Cycling conditions were 94°C
for 2 minutes (1 cycle); 94°C for 10 seconds, 65°C for 30 seconds, 68°C
for 15 seconds (15 cycles); 94°C for seconds, 60°C for 30 seconds, 68°C for 15 seconds plus 20 seconds increase per each additional cycle (25 cycles); 68°C for 7 minutes (1 cycle) and holding at 4°C.
The products of the PCR reactions were separated by electrophoresis through agarose gels containing 1X TAE buffer and visualized with ethidium bromide and UV
light. Any large fragments indicative of successful long-range PCR were excised from the gel and 10 purified using QIAquick PCR purification kit (Qiagen).
In order to eliminate the need to restriction map the PCR fragments, the following ligation-independent cloning strategy was employed. The long-range PCR
fragment of interest was "purified" using a QIAquick PCR purification kit (Qiagen, Inc., Santa Clarita, California). Single-stranded ends of the PCR fragments were generated by mixing: 0.1-2 p,g ~5 of the fragment; 2 ~I of NEB (New England BioLabs) Buffer 4; 1 ~,l of 2 mM
dTTP, 6 units of T4 DNA polymerise (NEB), H20 to total volume of 20 ~l and incubating at 25°C for 30 minutes. The polymerise was inactivated by heating at 75°C for 20 minutes. Single-stranded ends were also created on the Neo' selectable marker fragment by digesting the plasmid vector pDG2 at the unique restriction sites, with Sac I and Sac II (pDG2 depicted in Figure 2A) and treating each reaction with T4 DNA polymerise as above. The vector shown in Figure 1 was prepared with single-stranded ends complementary to those on the long-range PCR fragment.
The vector and frabments were then assembled into constructs using either a two-step cloning strategy or a tour-way, single-step protocol. Briefly, a reaction containing 10 ng of T4-treated Neo' cassette, 1 ~l of T4-treated PCR fragment, 0.2 ~tl of 0.5 M
EDTA, 0.3 ~I of 0.5 M NaCI and H20 up to 4 ~,1 was heated to 65°C and allowed to cool to room temperature over approximately 45 minutes. The mixture was then transformed into subcloning efficiency DH5-a competent cells.
3o Example 2: Generation of Constructs from Phage Libraries A mouse embryonic stem cell library was prepared in lambda phage as follows.
Genomic libraries were constructed from genomic DNA by partial cleavage of DNA
at Sau 3AI sites to yield genomic fragments of approximately 20 kb in length. The terminal sequences of these DNA fragments were partially filled in using Klenow enzyme in the presence of dGTP and dATP and the fragments were'ligated using T4 DNA ligase into Xho I
sites of an appropriate lambda cloning vector, e.g., lambda Fix II
(Stratagene, Inc., La Jolla, California), which had been partially filled in using Klenow in the presence of dTTP and dCTP. Alternatively, the partially digested genomic DNA was size selected using a sucrose gradient and sequences of approximately 20 kb selected for. The enriched fraction was cloned into a Bam HI cut lambda vector, e.g., lambda Datsh II (Stratagene, Inc., La Jolla, California). .
The library was plated onto 1,152 plates, each plate containing approximately 1,000 clones. Thus, a total of 1.1 million clones (the equivalent of 8 genomes) was plated.
The phage were eluted from each plate by adding 4 ml of lambda elution buffer (10 mM MgCl2, 10 mM Tris-pH 8.0) to each plate and incubating for 3 to 5 hours at room temperature. After incubation, 2 ml of buffer was collected from each plate and placed into one well of a 96 deep well plate (Costar, In.). Twelve 96-well plates were filled and referred to as the "sub-pool library."
Using the sub-pool library, "pool libraries" were made by placing 100 p1 of 12 different sub-pool wells into one well of a new 96 well plate. The 12 sub-pool plates were combined to form 1 plate of pool libraries.
Using a pair of oligonucleotides that were known to PCR-amplify the gene of interest, supernatant from the 96 pools of the "large-pool library" were amplified. PCR
was performed in the presence of 0.5 units of Amplitaq GoIdTM (Perkin Elmer), 1 p,M of each oligonucleotide, 200 ~,M dNTPs, 2 ~1 of a 1 to 5 dilution of the pool (or subpool) supernatant, 50 mM KC1, 100 mM Tris-HC1 (pH 8.3), and either 1.5 mM or 1.25 mM MgCI,.
Cycling conditions were 95°C for 8 minutes (1 cycle); 95°C for 30 seconds, 60°C for 30 seconds, 72°C for 45 seconds (55 cycles); 72°C for 7 minutes (1 cycle) and holding at 4°C.
Depending on the gene, between about 3 and 12 pool yielded positive signals as identified on agarose gels as described in Example 1. In cases where further purification was necessary (i.e. where a clear signal was not present after amplification), the 12 sub-pools making up the pool were subjected to amplification using the same primers and a single sub-pool (1000 clones) was identified.
Ce~aenation of flavking fi-cignaents. As described above, knock-out constructs contain two blocks of DNA sequence homologous to the target gene, flanking a positive selection marker. Long-range PCR was performed from the pools of lambda clones positively identified as described above in Example 2. Each fragment was generated using a pair of oligonucleotides with predetermined sequences lacking one type of base and complementary to predetermined sequences on the vector. The fragments obtained were between 1 and 5 kb.
A third fragment, longer than 5 kb, is also generated using appropriate oligonucleotides. This third fragment was then used to obtain DNA sequences near the gene to be knocked out but outside of the vector.
Example 3: 'Two-Step Cloning- General Procedure The pDG2 plasmid vector (Figure 2A) contains unique restriction sites Sac II
and Sac l0 I. Appropriate single-stranded annealing sites were generated by digesting the pDG2 vector with either restriction enzyme Sac II or Sac I and treating each reaction with polymerise and dTTP as described above. Four reactions were set up in microtitre plates for each vector, the reaction containing 1 ~tl of either (1) T4 DNA polymerise-treated fragments;
(2) a 1:10 dilution of the T4-treated fragments reaction; (3) a 1:100 dilution of the T4-treated fragments or (4) H20 (no insert control). The microtitre plates were sealed, placed in-between two temperature blocks heated to 65°C, and allowed to cool slowly at room temperature for 30 to 45 minutes.
The microtitre plate was then placed on ice and 20-25 ~1 of subcloning efficiency competent cells added to each well. The plate was incubated on ice for 20-30 minutes. The microtitre plate was then placed between two temperature blocks heated to 42°C for 2 minutes, followed by 2 minutes on ice. 100 p1 of LB was added to each well, the plate covered with parafilm and incubated 30-60 minutes at 37°C. The entire contents of each well were plated on one LB-Amp plate and incubated at 37°C overnight.
Between about 12-24 colonies were picked from plates which had at least 2-4 times more colonies than the no insert control. The colonies were grown in deep well plates overnight at 37°C and then the plasmid DNA extracted using a Qiagen mini-prep kit.
The plasmid DNA was digested with Not I and Sal I enzymes. As shown in Figure 2A, a Not I/Sal I digestion will generate a large fragment containing cloning sites 3 and 4 and a smaller fragment containing cloning sites 1 and 2 and the Neo' gene. After digestion, the reactions were run on a 0.8°70 agarose gel containing 0.2 p,g/ml ethidium bromide. For no inserts, two bands were present, one of 1975 base pairs and one of 2793 base pairs. When an insert fragment was present, at least one of these bands would be larger because it would also contain a fragment (insert 1 or 2) either at the annealing site 1/2 or the site 3/4. The insert bands were excised and treated with a QIAquick gel extraction kit. A second ligation reaction was performed containing 1 ~tl of lOX ligase buffer (50 mM Tris-HCI
pH 7.5, 10 mM MgCl~, 10 mM dithiothreitol, 1 mM ATP, 25 ~tg/ml bovine serum albumin), 1 p,1 T4 DNA ligase, 1-2 p1 fragment (site 3/4 band), 5 p1 of site 1/2 band and H20 up to 10 p1.
Controls were also set up replacing either the site 3/4 fragment or the site 1/2 fragment with water. The reactions were incubated 1 to 2 hours at room temperature and transformed with 25 p1 of competent cells.
"Flanking DNA" in the context of these examples refers to the genomic sequences flanking the region in the target gene that is to be deleted or mutated.
"Flanking DNA" is t0 also described above as the blocks of DNA sequence homologous to the target gene. R1 genomic library refers to a genomic library prepared from the R1 ES cell line.
Such libraries can be prepared such as described in Example 1.
Example 4: Generation and Analysis of Mice Comprising Retina-Specific ~5 Nuclear Receptor Gene Disruptions To investigate the role of retina-specific nuclear receptors, disruptions in retina-specific nuclear receptor genes were produced by homologous recombination.
Specifically, transgenic mice comprising disruptions in retina-specific nuclear receptor genes were created.
20 More particularly, a retina-specific targeting construct having the ability to disrupt or modify retina-specific nuclear receptor genes, specifically comprising SEQ ID N0:19 was created using the oligonucleotide sequences identified herein as SEQ >D N0:20 or SEQ
>D N0:21.
The targeting construct was introduced into ES cells derived from the 129/Sv-+P+Mgf-SLJ/J
mouse substrain to generate chimeric mice. F1 mice were generated by breeding with 25 C57BL/6 females. F2 homozygous mutant mice were produced by intererossing heterozygous males and females. The transgenic animals comprising disruptions in retina-specific nuclear receptor genes were analyzed for phenotypic changes and expression patterns. The phenotypes associated with a disruption in a retina-specific nuclear receptor gene were determined as follows:
30 Hontozygous Mice:
The homozygous mice analyzed demonstrated at least one of the following phenotypes:
Eyes. Eye abnormalities, including severe retinal dysplasia characterized by extensive rosette formation and retinal folding; segmental thinning of the outer nuclear layer 35 of the retina with rods and cones filling the foci; and complete unilateral absence of the retina. Moreover, the space normally occupied by the retina was filled with fibrous connective tissue, spicules of osteoid and some mineral. In areas, connective tissue was adherent to the posterior lens capsule. Posterior synechia with a thickened iris adherent to the anterior aspect of the lens was detected. The pigmented epithelial layer of the retina was thickened and its cells were increased in size and number. The internal structure of the lens was disorganized and comprised swollen and degenerated fibers. In instances where the retina was absent unilaterally, small focal remnants were present.
Ga.strointestival tract. Abnormalities in the gastrointestinal tract included multifocal infiltrates of neutrophils in the deep mucosa and submucosa in the stomach.
l0 'Skirv. Abnormalities in the skin included focal lymphocytic inflammation within the dermi s.
TesteslEpidiclymicles. Abnormalities in the testes and epididymides included reduced spermatogenesis. Specifically, seminiferous tubules had scattered degenerate or necrotic spermatogenetic epithelial cells and multinucleated giant cells. The epididymides had reduced number of spermatids, and degenerated cells were present in tubules. The epithelial cells of some epididymal tubules were vacuolated.
Clinical Chem.i.strylBlood Analysis. Abnormalities included low alanine aminotransferase (ALT) values, aspartate aminotransferase (AST), and creatinine kinase (CK) values as compared to wild-type control values. Alkaline phosphatase (ALP) activity, however, was elevated. Hematological evaluation showed lower total white blood cell count.
Heterozygous Mice:
Skin. Abnormalities included local fibrosis and lymphocytic dermatitis.
Liver. Abnormalities included pericholangitis with bile duct hyperplasia and fibrosis.
Example 5: Generation and Analysis of Mice Comprising Lymphoid-Specific G-Protein-Coupled Receptor Gene Disruptions To investigate the role of lymphoid-specific G-protein coupled receptors, disruptions in lymphoid-specific G-protein coupled receptor genes were produced by homologous recombination. Specifically, transgenic mice comprising disruptions in lymphoid-specific G-protein coupled receptor genes were created. More particularly, a lymphoid-specific GPCR
targeting construct having the ability to disrupt or modify lymphoid-specific G-protein coupled receptor genes, specifically comprising SEQ 1D N0:22 was created using the oligonucleotide sequences identified herein as SEQ 1D N0:23 and SEQ ID N0:24.
The targeting construct was inserted into ES cells derived from the I29/OlaHsd mouse substrain to generate chimeric mice. F1 mice were generated by breeding with C57BL/6 females. F2 homozygous mutant mice were produced by intercrossing F1 heterozygous males and females. The transgenic animals comprising disruptions in lymphoid-specific G-protein coupled receptor genes were analyzed for phenotypic changes and expression patterns. The phenotypes associated with a disruption in a lymphoid-specific GPCR were determined as follows:
Nonzozygous Mice:
The homozygous mice demonstrated at least one of the following phenotypes:
Lzcng. Abnormalities in the lung included cellular infiltrates around bronchioles.
l0 Pulmonary changes, exhibiting varying degrees of patchy peribronchial lymphocytic cellular infiltrates were detected. The infiltrates were primarily composed of small lymphocytes.
Peribronchial lymphocytic cuffing included focal subpleural collections of lymphocytes;
fibrinoid necrosis in vessel walls; and hyperplasia of bronchial epithelium.
Pancreas. Abnormalities in the pancreas included pancreatic cellular infiltrates near 15 ducts and islets. Specifically, periductular cellular infiltrates or peri-islet cellular infiltrates were present, and were primarily composed of small lymphocytes.
Ston2ach. Abnormalities in the stomach included gastric mixed cellular infiltrates composed of small lymphocytes, granulocytes, and plasma cells. The infiltrates involved the deep mucosa, submucosa and/ or the muscularis of the stomach.
20 Liver. Abnormalities in the liver included cellular infiltrates, predominately lymphocytes that involved the portal triad.
Expression Analysis:
LacZ (beta-galactosidase) expression was detected in the spleen and lymph nodes.
Specifically, in the lymph nodes, several cells showed strong X-Gal staining.
In the spleen, 25 strong staining was detected in some cells in the red pulp.
Example 6: Generation and Analysis of Mice Comprising Melanocyte Stimulating Hormone Receptor Gene Disruptions 30 To investigate the role of GPCR melanocyte stimulating hormones, disruptions in GPCR melanocyte stimulating hormone genes were produced by homologous recombination.
Specifically, transgenic mice comprising disruptions in GPCR melanocyte stimulating hormone genes were created. More particularly, a melanocyte stimulating hormone targeting construct having the ability to disrupt or modify genes encoding melanoyte stimulating 35 hormone receptors, specifically comprising SEQ B7 N0:25 was created using the oligonucleotide sequences identified herein as SEQ 1D N0:26 and SEQ 1D N0:27.
The targeting construct was inserted into ES cells derived from the 129/OlaHsd mouse substrain to generate chimeric mice. F1 mice were generated by breeding with C57BL/6 females. F2 homozygous mutant mice were produced by intercrossing F1 heterozygous males and females.
The transgenic animals comprising disruptions in melanocyte stimulating hormone receptor genes were analyzed for phenotypic changes and expression patterns.
The phenotypes associated with a disruption in a melanocyte stimulating hormone receptor gene were determined as follows:
Behavioral Ar2alysis. The homozygous mice were significantly different from wild-type mice in the total distance traveled in the open field test. The homozygous mice were hypoactive, in that they moved about and explored the open field significantly than their wild-type counterparts. The open field test has been used to demonstrate the changes in activity level and anxiety. Thus, the open field data demonstrates that the homozygous mice were hypoactive than the wild-type control mice.
LucZ Expression Anulysis. LacZ (beta-galactosidase) expression was detected in the esophagus, skin, and in the male reproductive system.
2o Example 7: Generation and Analysis of Mice Comprising Magnesium-Dependent Protein Phosphatase Gene Disruptions To investigate the role of magnesium-dependent protein phosphatase genes, disruptions in magnesium-dependent protein phosphatase genes were produced by homologous recombination. Specifically, transgenic mice comprising disruptions in magnesium-dependent protein phosphatase genes were created. More particularly, a magnesium-dependent protein phosphatase gene targeting construct having the ability to disrupt and mutate magnesium-dependent protein phosphatase genes, specifically genes comprising SEQ 1D N0:28, was created using the oligonucleotide sequences identified herein as SEQ >D N0:29 and SEQ >D N0:30. The targeting construct was inserted into ES
cells derived from the 129/OIaEIsd mouse substrain to generate chimeric mice. F1 mice were generated by breeding with C57BL/6 females. F2 homozygous mutant mice were produced by intercrossing F1 heterozygous males and females.
The transgenic animals comprising disruptions in magnesium-dependent protein phosphatase genes were analyzed for phenotypic changes and expression patterns. The phenotypes associated with a disruption in magnesium-dependent protein genes were determined as follows:
Homozygous Mice:
The homozygous mice demonstrated at least one of the following phenotypes:
Lung. Abnormalities in the lung included pulmonary lesions suggestive of foreign body aspiration pneumonia. Patchy, peribronchial, acute inflammation with associated granulomata (probably foreign body), foamy alveolar macrophages, and eosinophilic crystals within alveolar macrophages were found in the lungs. Patchy yellow-red discoloration of the lungs was also detected.
l0 Hematology. Abnormalities in the blood included elevated white blood cell (WBC) count.
Necropsy Examination. Patchy, red-yellow lung discoloration. Muscles and bones were softer than wild-type controls.
Expression Analysis:
l5 Strong IacZ expression was detectable in all tissue or organs examined, including the brain, spinal cord, sciatic nerve, eyes, harderian glands, thymus, spleen, lymph nodes, bone marrow, aorta, heart, lung, liver, gallbladder, pancreas, kidney, urinary bladder, trachea, larynx, esophagus, thyroid gland, pituitary gland, adrenal gland, salivary gland, tongue, skeletal muscle, skin, and female and male reproductive systems.
Example 8: Generation and Analysis of Mice Comprising a Chemokine Receptor 1-Like Protein Gene Disruptions To investigate the role of chemokine receptor 1-like protein genes, disruptions in chemokine receptor 1-like genes were produced by homologous recombination.
Specifically, transgenic mice comprising disruptions in chemokine receptor 1-like genes were created.
More particularly, a chemokine receptor 1-like gene targeting construct having the ability to disrupt and mutate chemokine receptor 1-like genes, specifically comprising SEQ ID N0:31 , was created using the oligonucleotide sequences identified herein as SEQ ID
N0:32 and SEQ
ID N0:33. The targeting construct was inserted into ES cells derived from the 129/OlaHsd mouse substrain to generate chimeric mice. F1 mice were generated by breeding with C57BL/6 females. F2 homozygous mutant mice were produced by intercrossing F1 heterozygous males and females.
Example 9: Generation and Analysis of Mice Comprising cGMP
Phosphodiesterase Gene Disruption To investigate the role of cGMP phosphodiesterase genes, disruptions in cGMP
phosphodiesterase genes were produced by homologous recombination.
Specifically, transgenic mice comprising disruptions in cGMP phosphodiesterase genes were created.
More particularly, a cGMP phosphodiesterase gene targeting construct having the ability to disrupt and mutate cGMP phosphodiesterase genes, specifically comprising SEQ
)D N0:34, was created using the oligonucleotide sequences identified herein as SEQ >D
N0:35 and SEQ
>D N0:36. The targeting construct was inserted into ES cells derived from the 129/OlaHsd mouse substrain to generate chimeric mice. F1 mice were generated by breeding with C57BL/G females. F2 homozygous mutant mice were produced by intercrossing F1 heterozygous males and females.
The transgenic animals comprising disruptions in cGMP phosphodiesterase genes were analyzed for phenotypic changes and expression patterns. The phenotypes associated with a disruption in cGMP phosphodiesterase genes were determined as follows:
Homozygous Mice:
The homozygous mice demonstrated at least one of the following phenotypes:
Eyes. Homozygous mice demonstrated eye abnormalities, particularly involving the retina and more specifically, retinal degeneration (RD), including severe bilateral retinal degeneration or retinal dysplasia, accompanied with complete absence of photoreceptor layers (i.e., rods and cones, outer nuclear layer, outer plexiform layer). The rods and cones are the dendrites of the photoreceptor cells, the outer nuclear layer represents the nuclei of the photoreceptor cells, and the outer plexiform layer represents the axon fibers of the photoreceptor cells. Such eye abnormalities may be accompanied by vision problems or blindness. Other changes in the eyes of these mice included: thinning and vacuolation of the inner nuclear layer; thinning of the inner plexiform layer; loss of ganglion cell nuclei, especially large ganglion cells; gliosis of the nerve fiber layer; and, attenuation of retinal vasculature. The RD observed in mice is analogous to retinitis pigmentosa (RP) in humans.
Aorta. Abnormality in the aorta included adventitia or inflammation of the aorta.
Kidney. The kidney abnormalities included tubular dilation or pyelitis.
Liver. The liver abnormalities detected included extramedullary hematopoiesis.
Lymph Nodes. Abnormalities in the lymph nodes included lymphoid hyperplasia, lymphoid atrophy, or hemorrhage.
Skin. Skin abnormalities included dermatitis.
Body Weight. Abnormalities included increased body weights and length.
Specifically, body weight was increased by about 11%-37% in males, and body length was increased by about 13% over control mice. Body weight to body length ratio was increased about 23~Io.
Orgcen Weight. Increased organ weights were found in the spleen and thymus gland, kidney and liver. Specifically, spleen weight increases ranged from about 13%
to 28%, and thymus gland weight increases ranged from about 17% to 30%. Kidney weight was increased by about 16% and liver weight was increased by about 38%.
Cliniccel Chemistry. Elevated levels of ALT (alanine aminotransferase), phosphorus, potassium, or bilirubin were detected.
Behavioral Ancclysis. Homozygous mice exhibited significantly increased activity, traveling a much greater total distance and exploring the open field more in the open field test. This observation indicated hyperactivity in the homozygous mice.
Heterozygous Mice:
Eyes. Eye abnormalities included discoloration including pink eyes.
LaeZ Expression Analysis:
LacZ (beta-galactosidase) expression was detected in the thyroid glands, salivary glands proper, salivary glands of the larynx, peritracheal and submucosal glands of the trachea and the mucous glands of the tongue.
Example 10: Generation and Analysis of Mice Comprising Sulfotransferase Genc Disruptions To investigate the role of sulfotransferases, disruptions in sulfotransferase genes were produced by homologous recombination. Specifically, transgenic mice comprising disruptions in sulfotransferase genes were created. More particularly, a sulfotransferase gene targeting construct having the ability to disrupt or modify sulfotransferase genes, specifically genes comprising SEQ ID N0:37, was created using the oligonucleotide sequences identified herein as SEQ ID N0:38 and SEQ ID N0:39. The targeting construct was introduced into ES cells derived from the 129/OIaHsd mouse substrain to generate chimeric mice. F1 mice were generated by breeding with C57BL/6 females. F2 homozygous mutant mice were produced by intercrossing Fl heterozygous males and females. The animals were evaluated for phenotypic changes. The phenotypes associated with a disruption in a sulfotransferase gene were determined as follows:
Homozygous Mice:
Liver. The homozygous mice demonstrated abnormalities in the liver as compared to wild-type mice. The homozygous mice demonstrated at least one of the following: patchy pallor of acinar zone 3 hepatocytes; eosinophilic globules of varying size with intranuclear invaginations within the cytoplasm of hepatocytes; or anisocytosis, anisonucleosis and increased mitotic cellular activity as compared to wild-type mice.
Saldvary Glands. Homozygous mice demonstrated abnormalities in the Harderian glands and salivary glands. Specifically, there was focal pigment deposition in the glands and atrophy and fibrosis in the submandibular gland.
I0 Behavioral Analy.si.s. The homozygous mice demonstrated aggressive, hyperactive and less anxious behavior as compared to wild-type mice. Specifically, beginning at two weeks of age, the homozygote mutant male mice exhibited increased aggression compare to wild-type littermates. During home cage observations, these animals attacked their cage-mates more than normal male mice, and had to be housed separately to prevent such attacks.
In addition, the homozygote mutant mice were significantly different from the wild-type mice in the open field test. Mutants were hyperactive moving about, and exploring the open field more readily than wild-type mice, exhibiting increased activity and decreased anxiety compared to the wild-type mice.
The homozygote mice were significantly different from wild-types in the Open field (°Io of time spent in central). The homozygous mice were less anxious spending a higher percentage of time in the central portion of the open field than the wild-type mice.
As is apparent to one of skill in the art, various modifications of the above embodiments can be made without departing from the spirit and scope of this invention.
These modifications and variations are within the scope of this invention.
The passive avoidance or shuttle box test generally involves exposure to two or more environments, one of which is noxious, providing a choice to be learned by the animal.
Behavioral measures include, for example, response latency, number of correct responses, and consistency of response. (See, e.g., R. Ader, et al., Psychon. Sci. 26:125-128 (1972); R.
R. Holson, Phys. Behcav. 37:221-230 (1986)). Alternatively, a zero-maze can be used. In a zero-maze, the animals can, for example, be placed in a closed quadrant of an elevated IS annular platform having, e.g., 2 open and 2 closed quadrants, and are allowed to explore for approximately 5 minutes. This paradigm exploits an approach-avoidance conflict between normal exploratory activity and an aversion to open spaces in rodents. This test measures anxiety levels and can be used to evaluate the effectiveness of anti-anxiolytic drugs. The time spent in open quadrants versus closed quadrants may be recorded automatically, with, for example, the placement of photobeams at each transition site.
The food avoidance test involves exposure to novel food and objectively measuring, for example, food intake and intake latency. The behaviors measured are statistically analyzed using standard statistical tests. (See, e.g., B. A. Campbell, et al., J. Comp. Physiol.
Psychol. 67:15-22 (1969)).
The elevated plus-maze test comprises exposure to a maze, without sides, on a platform, the animal's behavior is objectively measured by counting the number of maze entries and maze learning. The behavior is statistically analyzed using standard statistical tests. (See, e.g., H. A. Baldwin, et al., Brain Res. Bull, 20:603-606 (1988)).
The stimulant-induced hyperactivity test involves injection of stimulant drugs (e.g., amphetamines, cocaine, PCP, and the like), and objectively measuring, for example, motor activity, social interactions, cognitive behavior. The animal's behaviors are statistically analyzed using standard statistical tests. (See, e.g., P. B. S. Clarke, et al., Psychopharrrcacology 96:51 L-520 (1988); P. Kuczenski, et al., J. Neuroscience 11:2703-2712 (1991)).
The self-stimulation test generally comprises providing the mouse with the opportunity to regulate electrical and/or chemical stimuli to its own brain.
Behavior is measured by frequency and pattern of self-stimulation. Such behaviors are statistically analyzed using standard statistical tests. (See, e.g., S. Nassif, et al., Brain Re.s., 332:247-257 (1985); W. L. Isaac, et al., Behav. Neurosci. 103:345-355 (1989)).
The reward test involves shaping a variety of behaviors, e.g., motor, cognitive, and social, measuring, for example, rapidity and reliability of behavioral change, and statistically analyzing the behaviors measured. (See, e.g., L. E. Jarrard, et al., Exp.
Brain Res. 61:519-530 (1986)).
The DRL (differential reinforcement to low rates of responding) performance test involves exposure to intermittent reward paradigms and measuring the number of proper responses, e.g., lever pressing. Such behavior is statistically analyzed using standard statistical tests. (See, e.g., J. D. Sinden, et al., Behav. Neurosci. 100:320-329 (1986); V.
Nalwa, et al., Behav Brain Res. 17:73-76 (1985); and A. J. Nonneman, et al., J. Comp.
Physiol. Psych. 95:588-602 (1981)).
The spatial learning test involves exposure to a complex novel environment, measuring the rapidity and extent of spatial learning, and statistically analyzing the behaviors measured. (See, e.g., N. Pitsikas, et al., Pharm. Bioch. Behav. 38:931-934 (1991); B. poucet, et al., Brain Res. 37:269-280 (1990); D. Christie, et al., Brain Res. 37:263-268 (1990); and F.
Van Haaren, et al., Behav. Neurosci. 102:481-488 (1988)). Alternatively, an open-field (of) test may be used, in which the greater distance traveled for a given amount of time is a measure of the activity level and anxiety of the animal. When the open field is a novel environment, it is believed that an approach-avoidance situation is created, in which the animal is "torn" between the drive to explore and the drive to protect itself.
Because the chamber is lighted and has no places to hide other than the corners, it is expected that a "normal" mouse will spend more time in the corners and around the periphery than it will in the center where there is no place to hide. "Normal" mice will, however, venture into the central regions as they explore more and more of the chamber. It can then be extrapolated that especially anxious mice will spend most of their time in the corners, with relatively little or no exploration of the central region, whereas bold (i.e., less anxious) mice will travel a greater distance, showing little preference for the periphery versus the central region.
The visual, somatosensory and auditory neglect tests generally comprise exposure to a sensory stimulus, objectively measuring, for example, orientating responses, and statistically analyzing the behaviors measured. (See, e.g., J. M. Vargo, et al., Exp.
Neurol. 102:199-209 (1988)).
The consummatory behavior test generally comprises feeding and drinking, and objectively measuring quantity of consumption. The behavior measured is statistically analyzed using standard statistical tests. (See, e.g., P. J. Fletcher, et al., Psychopharmacol.
102:301-308 (1990); M. G. Corda, et al." Proc. Nato Acad. Sci. USA 80:2072-2076 (1983)).
A visual discrimination test can also be used to evaluate the visual processing of an animal. One or two similar objects are placed in an open field and the animal is allowed to explore for about 5-10 minutes. The time spent exploring each object (proximity to, i.e., l0 movement within, e.g., about 3-5 cm of the object is considered exploration of an object) is recorded. The animal is then removed from the open field, and the objects are replaced by a similar object and a novel object. The animal is returned to the open field and the percent time spent exploring the novel object over the old object is measured (again, over about a 5-minute span). "Normal" animals will typically spend a higher percentage of time exploring the novel object rather than the old object. If a delay is imposed between sampling and testing, the memory task becomes more hippocampal-dependent. If no delay is imposed, the task is more based on simple visual discrimination. This test can also be used for olfactory discrimination, in which the objects (preferably, simple blocks) can be sprayed or otherwise treated to hold an odor. This test can also be used to determine if the animal can make gustatory discriminations; animals that return to the previously eaten food instead of novel food exhibit gustatory neophobia.
A hot plate analgesia test can be used to evaluate an animal's sensitivity to heat or painful stimuli. For example, a mouse can be placed on an approximately 55°C hot plate and the mouse's response latency (e.g., time to pick up and lick a hind paw) can be recorded.
These responses are not reflexes, but rather "higher" responses requiring cortical involvement. This test may be used to evaluate a nociceptive disorder.
An accelerating rotarod test may be used to measure coordination and balance in mice. Animals can be, for example, placed on a rod that acts like a rotating treadmill (or rolling log). The rotarod can be made to rotate slowly at first and then progressively faster until it reaches a speed of, e.g., approximately 60 rpm. The mice must continually reposition themselves in order to avoid falling off. The animals are preferably tested in at least three trials, a minimum of 20 minutes apart. Those mice that are able to stay on the rod the longest are believed to have better coordination and balance.
A metrazol administration test can be used to screen animals for varying susceptibilities to seizures or similar events. For example, a 5mg/ml solution of metrazol can be infused through the tail vein of a mouse at a rate of, e.g., approximately 0.375 ml/min.
The infusion will cause all mice to experience seizures, followed by death.
Those mice that enter the seizure stage the soonest are believed to be more prone to seizures.
Four distinct physiological stages can be recorded: soon after the start of infusion, the mice will exhibit a noticeable "twitch", followed by a series of seizures, ending in a final tensing of the body known as "tonic extension", which is followed by death.
Target Gene Products The present invention further contemplates use of the target gene sequence to produce target gene products. Target gene products may include proteins that represent functionally equivalent gene products. Such an equivalent gene product may contain deletions, additions or substitutions of amino acid residues within the amino acid sequence encoded by the gene sequences described herein, but which result in a silent change, thus producing a functionally t5 equivalent target gene product. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.
For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine;
positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
"Functionally equivalent", as utilized herein, refers to a protein capable of exhibiting a substantially similar in vivo activity as the endogenous gene products encoded by the target gene sequences.
Alternatively, when utilized as part of an assay, "functionally equivalent"
may refer to peptides capable of interacting with other cellular or extracellular molecules in a manner substantially similar to the way in which the corresponding portion of the endogenous gene product would.
Other protein products useful according to the methods of the invention are peptides derived from or based on the target gene produced by recombinant or synthetic means (derived peptides).
Target gene products may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing the gene polypeptides and peptides of the invention by expressing nucleic acid encoding gene sequences are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing gene protein coding sequences and appropriate transcriptional/translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination (see, e.g., Sambrook, et al., 1989, supra, and Ausubel, et al., 1989, supra).
Alternatively, RNA capable of encoding gene protein sequences may be chemically synthesized using, for example, automated synthesizers (see, e.g.
Oligonucleotide Synthesis:
A Practical Approach, Gait, M. J. ed., IRL Press, Oxford (1984)).
A variety of host-expression vector systems may be utilized to express the gene t0 coding sequences of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, exhibit the gene protein of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing gene protein coding sequences; yeast (e.g. Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing the gene protein coding sequences;
insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the gene protein coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing gene protein coding sequences; or mammalian cell systems (e.g. COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5 K promoter).
In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the gene protein being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of antibodies or to screen peptide libraries, for example, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the E. coli expression vector pUR278 (Ruther et al., EMBO J., 2:1791-94 (1983)), in which the gene protein coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN
vectors (Inouye & Inouye, Nucleic Acids Res., 13:3101-09 (1985); Van Heeke et al., J. Biol.
Chem., 264:5503-9 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene protein can be released from the GST moiety.
In a prefen-ed embodiment, full length cDNA sequences are appended with in-frame Bam HI sites at the amino terminus and Eco RI sites at the carboxyl terminus using standard PCR methodologies (Innis, et al. (eds) PCR Protocols: A Guide to Methods and Applications, l0 Academic Press, San Diego (1990)) and ligated into the pGEX-2TK vector (Pharmacia, Uppsala, Sweden). The resulting cDNA construct contains a kinase recognition site at the amino terminus for radioactive labeling and glutathione S-transferase sequences at the carboxyl terminus for affinity purification (Nilsson, et al., EMBO J., 4: 1075-80 (1985);
Zabeau et al., EMBO J., 1: 1217-24 (1982)).
IS In an insect system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in Spodoptera frugiperda cells.
The gene coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV
promoter (for example the polyhedrin promoter). Successful insertion of gene coding sequence will 20 result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect Spodoptera frugiperda cells in which the inserted gene is expressed (see, e.g., Smith, et al., J. Virol. 46: 584-93 (1983); U.S.
Pat. No.
4,745,051 ).
25 In mammalian host cells, a number of viral-based expression systems may be utilized.
In cases where an adenovirus is used as an expression vector, the gene coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of 30 the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing gene protein in infected hosts. (e.g., see Logan et al., Proc. Natl. Acad.
Sci. USA, 81:3655-59 (1984)). Specific initiation signals may also be required for efficient translation of inserted gene coding sequences. These signals include the ATG
initiation codon and adjacent sequences. In cases where an entire gene, including its own initiation 35 codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of the gene coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bitter, et al., Methods in Enzymol., 153:516-44 (1987)).
l0 In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification 15 of proteins. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, 20 WI38, etc.
For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the gene protein may be engineered.
Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., 25 promoter, enhances, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells which stably integrate the plasmid into their chromosomes and grow, to form 30 foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the gene protein.
Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the gene protein.
In a preferred embodiment, control of timing and/or quantity of expression of the 35 recombinant protein can be controlled using an inducible expression construct. Inducible constructs and systems for inducible expression of recombinant proteins will be well known to those skilled in the art. Examples of such inducible promoters or other gene regulatory elements include, but are not limited to, tetracycline, metallothionine, ecdysone, and other steroid-responsive promoters, rapamycin responsive promoters, and the like (No, et al., Proc.
Natl. Acad. Sci. USA, 93:3346-51 (1996); Furth, et al., Proc. Natl. Acad. Sci.
USA, 91:9302-6 (1994)). Additional control elements that can be used include promoters requiring specific transcription factors such as viral, particularly HN, promoters. In one in embodiment, a Tet inducible gene expression system is utilized. (Gossen et al., Proc. Natl.
Acad. Sci. USA, l0 89:5547-51 (1992); Gossen, et al., Science, 268:1766-69 (1995)). Tet Expression Systems are based on two regulatory elements derived from the tetracycline-resistance operon of the E. coli TnlO transposon-the tetracycline repressor protein (TetR) and the tetracycline operator sequence (tet0) to which TetR binds. Using such a system, expression of the recombinant protein is placed under the control of the tet0 operator sequence and transfected or transformed into a host cell. In the presence of TetR, which is co-transfected into the host cell, expression of the recombinant protein is repressed due to binding of the TetR protein to the tet0 regulatory element. High-level, regulated gene expression can then be induced in response to varying concentrations of tetracycline (Tc) or Tc derivatives such as doxycycline (Dox), which compete with tet0 elements for binding to TetR. Constructs and materials for tet inducible gene expression are available commercially from CLONTECH
Laboratories, Inc.,~Palo Alto, CA.
When used as a component in an assay system, the gene protein may be labeled, either directly or indirectly, to facilitate detection of a complex formed between the gene protein and a test substance. Any of a variety of suitable labeling systems may be used including but not limited to radioisotopes such as 125I; enzyme labeling systems that generate a detectable calorimetric signal or light when exposed to substrate;
and fluorescent labels. Where recombinant DNA technology is used to produce the gene protein for such assay systems, it may be advantageous to engineer fusion proteins that can facilitate labeling, immobilization and/or detection.
Indirect labeling involves the use of a protein, such as a labeled antibody, which specifically binds to the gene product. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments and fragments produced by a Fab expression library.
Production of Antibodies Described herein are methods for the production of antibodies capable of specifically recognizing one or more epitopes. Such antibodies may include, but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab~2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Such antibodies may be used, for example, in the detection of a target gene in a biological sample, or, alternatively, as a method for the inhibition of abnormal target gene activity. Thus, such antibodies may be utilized as part of disease treatment methods, and/or l0 may be used as part of diagnostic techniques whereby patients may be tested for abnormal levels of target gene proteins, or for the presence of abnormal forms of the such proteins.
For the production of antibodies, various host animals may be immunized by injection with the target gene, its expression product or a portion thereof. Such host animals may include but are not limited to rabbits, mice, and rats, to name but a few.
Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium loarvacm.
Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen, such as target gene product, or an antigenic functional derivative thereof. For the production of polyclonal antibodies, host animals such as those described above, may be-immunized by injection with gene product supplemented with adjuvants as also described above.
Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to the hybridoma technique of Kohler and Milstein, Nature, 256:495-7 (1975); and U.S. Pat.
No. 4,376,110), the human B-cell hybridoma technique (Kosbor, et al., Immunology Today, 4:72 (1983); Cote, et al., Proc. Natl. Acad. Sci. USA, 80:2026-30 (1983)), and the EBV-hybridoma technique (Cole, et al., in Monoclonal Antibodies And Cancer Therapy, Alan R.
Liss, Inc., New York, pp. 77-96 (1985)). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the presently preferred method of production.
In addition, techniques developed for the production of "chimeric antibodies"
(Morrison, et al., Proc. Natl. Acad. Sci., 81:6851-6855 (1984); Takeda, et al., Nature, 314:452-54 (1985)) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.
Alternatively, techniques described for the production of single chain antibodies (U.S.
Pat. No. 4,946,778; Bird, Science 242:423-26 (1988); Huston, et al., Proc.
Natl. Acad. Sci.
USA, 85:5879-83 (1988); and Ward, et al., Nature, 334:544-46 (1989)) can be adapted to produce gene-single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.
Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include but are not limited to: the F(ab~2 fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab~2 fragments.
Alternatively, Fab expression libraries may be constructed (Huse, et al., Science, 246:1275-81 (1989)) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.
Screening for Therapeutic Agents Cells that contain and express target gene sequences may be used to screen for therapeutic agents. Such cells may include non-recombinant monocyte cell lines, such as U937 (ATCC# CRL-1593), THP-1 (ATCC# TIB-202), and P388D1 (ATCC# TIB-63);
endothelial cells such as HUVEC's and bovine aortic endothelial cells (BAEC's); as well as generic mammalian cell lines such as HeLa cells and COS cells, e.g., COS-7 (ATCC# CRL-1651). Further, such cells may include recombinant, transgenic cell lines. For example, the knockout mice of the invention may be used to generate cell lines, containing one or more cell types involved in a disease, that can be used as cell culture models for that disorder.
While cells, tissues, and primary cultures derived from the disease transgenic animals of the invention may be utilized, the generation of continuous cell lines is preferred. For examples of techniques which may be used to derive a continuous cell line from the transgenic animals, see Small, et al., Mol. Cell Biol., 5:642-48 (1985).
Target gene sequences may be introduced into, and overexpressed in, the genome of the cell of interest. In order to overexpress a target gene sequence, the coding portion of the target gene sequence may be ligated to a regulatory sequence which is capable of driving gene expression in the cell type of interest. Such regulatory regions will be well known to those of skill in the art, and may be utilized in the absence of undue experimentation. Target gene sequences may also be disrupted or underexpressed. Cells having target gene disruptions or underexpressed target gene sequences may be used, for example, to screen for agents capable of affecting alternative pathways which compensate for any loss of function attributable to the disruption or underexpression.
In vitro systems may be designed to identify compounds capable of binding the target gene products. Such compounds may include, but are not limited to, peptides made of D-and/or L-configuration amino acids (in, for example, the form of random peptide libraries;
see e.g., Lam, et al., Natc~re, 354:82-4 (1991)), phosphopeptides (in, for example, the form of random or partially degenerate, directed phosphopeptide libraries; see, e.g., Songyang, et al., Cell, 72:767-78 (1993)), antibodies, and small organic or inorganic molecules.
Compounds identified may be useful, for example, in modulating the activity of target gene proteins, preferably mutant target gene proteins; elaborating the biological function of the target gene protein; or screening for compounds that disrupt normal target gene interactions or themselves disrupt such interactions.
The principle of the assays used to identify compounds that bind to the target gene protein involves preparing a reaction mixture of the target gene protein and the test compound under conditions and for a time sufficient to allow the two components to interact and bind, thus forming a complex which can be removed and/or detected in the reaction mixture. These assays can be conducted in a variety of ways. For example, one method to conduct such an assay would involve anchoring the target gene protein or the test substance onto a solid phase and detecting target protein/test substance complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method, the target gene protein may be anchored onto a solid surface, and the test compound, which is not anchored, may be labeled, either directly or indirectly.
In practice, microtitre plates are conveniently utilized. The anchored component may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished simply by coating the solid surface with a solution of the protein and drying.
Alternatively, an immobilized antibody, preferably a monoclonal antibody, specific for the protein may be used to anchor the protein to the solid surface. The surfaces may be prepared in advance and stored.
In order to conduct the assay, the nonimmobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the previously l0 nonimmobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously nonimmobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface;
e.g., using a labeled antibody specific for the previously nonimmobilized component (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody).
Alternatively, a reaction can be conducted in a liquid phase, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for target gene product or the test compound to anchor any complexes formed in solution, and a labeled antibody specific for the other component of the possible complex to detect anchored complexes.
Compounds that are shown to bind to a particular target gene product through one of the methods described above can be further tested for their ability to elicit a biochemical response from the target gene protein. Agonists, antagonists and/or inhibitors of the expression product can be identified utilizing assays well known in the art.
Antisense, Ribozymes, and Antibodies Other agents which may be used as therapeutics include the target gene, its expression products) and functional fragments thereof. Additionally, agents which reduce or inhibit mutant target gene activity may be used to ameliorate disease symptoms. Such agents include antisense, ribozyme, and triple helix molecules. Techniques for the production and use of such molecules are well known to those of skill in the art.
Anti-sense RNA and DNA molecules act to directly block the translation of mRNA
by hybridizing to targeted mRNA and preventing protein translation. With respect to antisense DNA, oligodeoxyribonucleotides derived from the translation initiation site, e.g., between the -10 and +10 regions of the target gene nucleotide sequence of interest, are preferred.
Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage.
The composition of ribozyme molecules must include one or more sequences complementary to the target gene mRNA, and must include the well known catalytic sequence responsible for mRNA cleavage. For this sequence, see U.S. Pat. No. 5,093,246, which is incorporated by reference herein in its entirety. As such within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of RNA sequences encoding target gene proteins.
Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the molecule of interest for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features, such as secondary structure, that may render the oligonucleotide sequence unsuitable. The suitability of candidate sequences may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.
Nucleic acid molecules to be used in triple helix formation for the inhibition of transcription should be single stranded and composed of deoxyribonucleotides.
The base composition of these oligonucleotides must be designed to promote triple helix formation via Hoogsteen base pairing rules, which generally require sizeable stretches of either purines or pyrimidines to be present on one strand of a duplex. Nucleotide sequences may be pyrimidine-based, which will result in TAT and CGC triplets across the three associated strands of the resulting triple helix. The pyrimidine-rich molecules provide base complementarity to a purine-rich region of a single strand of the duplex in a parallel orientation to that strand. In addition, nucleic acid molecules may be chosen that are purine-rich, for example, containing a stretch of G residues. These molecules will form a triple helix with a DNA duplex that is rich in GC pairs, in which the majority of the purine residues are located on a single strand of the targeted duplex, resulting in GGC triplets across the three strands in the triplex.
Alternatively, the potential sequences that can be targeted for triple helix formation may be increased by creating a so called "switchback" nucleic acid molecule.
Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.
It is possible that the antisense, ribozyme, and/or triple helix molecules described herein may reduce or inhibit the transcription (triple helix) andlor translation (antisense, ribozyme) of mRNA produced by both normal and mutant target gene alleles. In order to ensure that substantially normal levels of target gene activity are maintained, nucleic acid molecules that encode and express target gene polypeptides exhibiting normal activity may l0 be introduced into cells that do not contain sequences susceptible to whatever antisense, ribozyme, or triple helix treatments are being utilized. Alternatively, it may be preferable to coadminister normal target gene protein into the cell or tissue in order to maintain the requisite level of cellular or tissue target gene activity.
Anti-sense RNA and DNA, ribozyme, and triple helix molecules of the invention may be prepared by any method known in the art for the synthesis of DNA and RNA
molecules.
These include techniques for chemically synthesizing oligodeoxyribonucleotides and oligoribonucleotides well known in the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molecule. Such DNA
sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerise promoters such as the T7 or SP6 polymerise promoters.
Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.
Various well-known modifications to the DNA molecules may be introduced as a means of increasing intracellular stability and half-life. Possible modifications include but are not limited to the addition of flanking sequences of ribonucleotides or deoxyribonucleotides to the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the oligodeoxyribonucleotide backbone.
Antibodies that are both specific for target gene protein, and in particular, mutant gene protein, and interfere with its activity may be used to inhibit mutant target gene function. Such antibodies may be generated against the proteins themselves or against peptides corresponding to portions of the proteins using standard techniques known in the art and as also described herein. Such antibodies include but are not limited to polyclonal, monoclonal, Fab fragments, single chain antibodies, chimeric antibodies, etc.
In instances where the target gene protein is intracellular and whole antibodies are used, internalizing antibodies may be preferred. However, lipofectin liposomes may be used to deliver the antibody or a fragment of the Fab region which binds to the target gene epitope into cells. Where fragments of the antibody are used, the smallest inhibitory fragment which binds to the target or expanded target protein's binding domain is preferred.
For example, peptides having an amino acid sequence corresponding to the domain of the variable region of the antibody that binds to the target gene protein may be used. Such peptides may be synthesized chemically or produced via recombinant DNA technology using methods well known in the art (see, e.g., Creighton, Proteins: Structures and Molecular Principles (1984) W.1-I. Freeman, New York 1983, sccpra; and Sambrook, et al., 1989, supra).
Alternatively, single chain neutralizing antibodies which bind to intracellular target gene epitopes may also be administered. Such single chain antibodies may be administered, for example, by expressing nucleotide sequences encoding single-chain antibodies within the target cell population by utilizing, for example, techniques such as those described in Marasco, et al., Proc. Natl. Acad. Sci. USA, 90:7889-93 (1993).
RNA sequences encoding target gene protein may be directly administered to a patient exhibiting disease symptoms, at a concentration sufficient to produce a level of target gene protein such that disease symptoms are ameliorated. Patients may be treated by gene replacement therapy. One or more copies of a normal target gene, or a portion of the gene that directs the production of a normal target gene protein with target gene function, may be inserted into cells using vectors which include, but are not limited to adenovirus, adeno-associated virus, and retrovirus vectors, in addition to other particles that introduce DNA into cells, such as liposomes. Additionally, techniques such as those described above may be utilized for the introduction of normal target gene sequences into human cells.
Cells, preferably, autologous cells, containing normal target gene expressing gene sequences may then be introduced or reintroduced into the patient at positions which allow for the amelioration of disease symptoms.
Pharmaceutical Compositions, Effective Dosages, and Routes of Administration The identified compounds that inhibit target mutant gene expression, synthesis and/or activity can be administered to a patient at therapeutically effective doses to treat or ameliorate the disease. A therapeutically effective dose refers to that amount of the compound sufficient to result in amelioration of symptoms of the disease.
Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LDso (the dose lethal to 50°Io of the population) and the EDSO (the dose therapeutically effective in 50°70 of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LDSOBDSO. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the EDSO
with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the 15 invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the ICSO (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
Such information can be used to more accurately determine useful doses in humans.
Levels in 20 plasma may be measured, for example, by high performance liquid chromatography.
Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients. Thus, the compounds and their physiologically acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the 25 nose) or oral, buccal, parenteral, topical, subcutaneous, intraperitoneal, intraveneous, intrapleural, intraoccular, intraarterial, or rectal administration. It is also contemplated that pharmaceutical compositions may be administered with other products that potentiate the activity of the compound and optionally, may include other therapeutic ingredients.
For oral administration, the pharmaceutical compositions may take the form of, for 30 example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyn-olidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or 35 wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats);
emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, l0 flavoring, coloring and sweetening agents as appropriate.
Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.
For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. Oral ingestion is possibly the easiest method of taking any medication.
Such a route of administration, is generally simple and straightforward and is frequently the least inconvenient or unpleasant route of administration from the patient's point of view.
However. this involves passing the material through the stomach, which is a hostile environment for many materials, including proteins and other biologically active compositions. As the acidic, hydrolytic and proteolytic environment of the stomach has evolved efficiently to digest proteinaceous materials into amino acids and oligopeptides for subsequent anabolism, it is hardly surprising that very little or any of a wide variety of biologically active proteinaceous material, if simply taken orally, would survive its passage through the stomach to be taken up by the body in the small intestine. The result, is that many proteinaceous medicaments must be taken in through another method, such as parenterally, often by subcutaneous, intramuscular or intravenous injection.
l0 Pharmaceutical compositions may also include various buffers (e.g., Tris, acetate, phosphate), solubilizers (e.g., Tween, Polysorbate), carriers such as human serum albumin, preservatives (thimerosol, benzyl alcohol) and anti-oxidants such as ascorbic acid in order to stabilize pharmaceutical activity. The stabilizing agent may be a detergent, such as tween-20, tween-80, NP-40 or Triton X-100. EBP may also be incorporated into particulate preparations of polymeric compounds for controlled delivery to a patient over an extended period of time. A more extensive survey of components in pharmaceutical compositions is found in Remington's Pharmaceutical Sciences, 18th ed., A. R. Gennaro, ed., Mack Publishing, Easton, Pa. (1990).
In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil). or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.
Dia ng ostics A variety of methods may be employed to diagnose disease conditions associated with the target gene. Specifically, reagents may be used, for example, for the detection of the .
presence of target gene mutations, or the detection of either over or under expression of target gene mRNA.
According to the diagnostic and prognostic method of the present invention, alteration of the wild-type target gene locus is detected. In addition, the method can be performed by detecting the wild-type target gene locus and confirming the lack of a predisposition or neoplasia. "Alteration of a wild-type gene" encompasses all forms of mutations including deletions, insertions and point mutations in the coding and noncoding regions.
Deletions may be of the entire gene or only a portion of the gene. Point mutations may result in stop codons, frameshift mutations or amino acid substitutions. Somatic mutations are those which occur only in certain tissues, e.g., in the tumor tissue, and are not inherited in the germline.
Germline mutations can be found in any of a body's tissues and are inherited.
If only a single allele is somatically mutated, an early neoplastic state is indicated.
However, if both alleles are mutated, then a late neoplastic state may be indicated. The finding of gene mutations thus provides both diagnostic and prognostic information. A target gene allele which is not deleted (e.g., that found on the sister chromosome to a chromosome carrying a target gene deletion) can be screened for other mutations, such as insertions, small deletions, and point mutations. Mutations found in tumor tissues may be linked to decreased expression of the target gene product. However, mutations leading to non-functional gene products may also be linked to a cancerous state. Point mutational events may occur in regulatory regions, such as in the promoter of the gene, leading to loss or diminution of expression of the mRNA.
Point mutations may also abolish proper RNA processing, leading to loss of expression of the target gene product, or a decrease in mRNA stability or translation efficiency.
One test available for detecting mutations in a candidate locus is to directly compare genomic target sequences from cancer patients with those from a control population.
Alternatively, one could sequence messenger RNA after amplification, e.g., by PCR, thereby eliminating the necessity of determining the exon structure of the candidate gene. Mutations from cancer patients falling outside the coding region of the target gene can be detected by examining the non-coding regions, such as introns and regulatory sequences near or within the target gene. An early indication that mutations in noncoding regions are important may come from Northern blot experiments that reveal messenger RNA molecules of abnormal size or abundance in cancer patients as compared to control individuals.
The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one specific gene nucleic acid or anti-gene antibody reagent described herein, which may be conveniently used, e.g., in clinical settings, to diagnose patients exhibiting disease symptoms or at risk for developing disease.
Any cell type or tissue, preferably monocytes, endothelial cells, or smooth muscle cells, in which the gene is expressed may be utilized in the diagnostics described below.
DNA or RNA from the cell type or tissue to be analyzed may easily be isolated using procedures which are well known to those in the art. Diagnostic procedures may also be performed in situ directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections, such that no nucleic acid purification is necessary. Nucleic acid reagents may be used as probes and/or primers for such in situ procedures (see, for example, Nuovo, PCR In Situ Hybridization: Protocols and Applications, Raven Press, N.Y. (1992)).
Gene nucleotide sequences, either RNA or DNA, may, for example, be used in hybridization or amplification assays of biological samples to detect disease-related gene structures and expression. Such assays may include, but are not limited to, Southern or Northern analyses, restriction fragment length polymorphism assays, single stranded conformational polymorphism analyses, in situ hybridization assays, and polymerase chain reaction analyses. Such analyses may reveal both quantitative aspects of the expression pattern of the gene, and qualitative aspects of the gene expression and/or gene composition.
That is, such aspects may include, for example, point mutations, insertions, deletions, chromosomal rearrangements, and/or activation or inactivation of gene expression.
Preferred diagnostic methods for the detection of gene-specific nucleic acid molecules may involve for example, contacting and incubating nucleic acids, derived from the cell type or tissue being analyzed, with one or more labeled nucleic acid reagents under conditions favorable for the specific annealing of these reagents to their complementary sequences within the nucleic acid molecule of interest. Preferably, the lengths of these nucleic acid reagents are at least 9 to 30 nucleotides. After incubation, all non-annealed nucleic acids are removed from the nucleic acid:fingeiprint molecule hybrid. The presence of nucleic acids from the fingerprint tissue which have hybridized, if any such molecules exist, is then detected. Using such a detection scheme, the nucleic acid from the tissue or cell type of interest may be immobilized, for example, to a solid support such as a membrane, or a plastic surface such as that on a microtitre plate or polystyrene beads. In this case, after incubation, non-annealed, labeled nucleic acid reagents are easily removed. Detection of the remaining, annealed, labeled nucleic acid reagents is accomplished using standard techniques well-known to those in the art.
Alternative diagnostic methods for the detection of gene-specific nucleic acid molecules may involve their amplification, e.g., by PCR (the experimental embodiment set forth in Mullis U.S. Pat. No. 4,683,202 (1987)), ligase chain reaction (Barany, Proc. Natl.
Aced. Sci. USA, 88:189-93 (1991 )), self sustained sequence replication (Guatelli, et al., Proc.
Natl. Acad. Sci. USA, 87:1874-78 (1990)), transcriptional amplification system (Kwoh, etal., Proc. Natl. Accc~l. Sci. USA, 86:1173-77 ( 1989)), Q-Beta Replicase (Lizardi et cal., BiolTechnology, 6:1197 (1988)), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.
In one embodiment of such a detection scheme, a cDNA molecule is obtained from an RNA molecule of interest (e.g., by reverse transcription of the RNA molecule into cDNA).
Cell types or tissues from which such RNA may be isolated include any tissue in which wild type fingerprint gene is known to be expressed, including, but not limited, to monocytes, endothelium, and/or smooth muscle. A sequence within the cDNA is then used as the template for a nucleic acid amplification reaction, such as a PCR
amplification reaction, or the like. The nucleic acid reagents used as synthesis initiation reagents (e.g., primers) in the reverse transcription and nucleic acid amplification steps of this method may be chosen from among the gene nucleic acid reagents described herein. The preferred lengths of such nucleic acid reagents are at least 15-30 nucleotides. For detection of the amplified product, the nucleic acid amplification may be performed using radioactively or non-radioactively labeled nucleotides. Alternatively, enough amplified product may be made such that the product may be visualized by standard ethidium bromide staining or by utilizing any other suitable nucleic acid staining method.
Antibodies directed against wild type or mutant gene peptides may also be used as disease diagnostics and prognostics. Such diagnostic methods, may be used to detect abnormalities in the level of gene protein expression, or abnormalities in the structure and/or tissue, cellular, or subcellular location of fingerprint gene protein.
Structural differences may include, for example, differences in the size, electronegativity, or antigenicity of the mutant fingerprint gene protein relative to the normal fingerprint gene protein.
Protein from the tissue or cell type to be analyzed may easily be detected or isolated using techniques which are well known to those of skill in the art, including but not limited to western blot analysis. For a detailed explanation of methods for carrying out western blot analysis, see Sambrook, et al. (1989) supra, at Chapter 18. The protein detection and isolation methods employed herein may also be such as those described in Harlow and Lane, for example, (Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1988)).
Preferred diagnostic methods for the detection of wild type or mutant gene peptide molecules may involve, for example, immunoassays wherein fingerprint gene peptides are detected by their interaction with an anti-fingerprint gene-specific peptide antibody.
For example, antibodies, or fragments of antibodies useful in the present invention may be used to quantitatively or qualitatively detect the presence of wild type or mutant gene peptides. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody (see below) coupled with light microscopic, flow cytometric, or fluorimetric detection. Such techniques are especially preferred if the fingerprint gene peptides are expressed on the cell surface.
The antibodies (or fragments thereof) useful in the present invention may, l0 additionally, be employed histologically, as in immunofluorescence or immunoelectron microscopy, for i~z situ detection of fingerprint gene peptides. In situ detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labeled antibody of the present invention. The antibody (or fragment) is preferably applied by overlaying the labeled antibody (or fragment) onto a biological sample.
Through the use of such a procedure, it is possible to determine not only the presence of the fingerprint gene peptides, but also their distribution in the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of a wide variety of histological methods (such as staining procedures) can be modified in order to achieve such in situ detection.
Immunoassays for wild type, mutant, or expanded fingerprint gene peptides typically comprise incubating a biological sample, such as a biological fluid, a tissue extract, freshly harvested cells, or cells which have been incubated in tissue culture, in the presence of a detectably labeled antibody capable of identifying fingerprint gene peptides, and detecting the bound antibody by any of a number of techniques well known in the art.
The biological sample may be brought in contact with and immobilized onto a solid ~ phase support or caa-ier such as nitrocellulose, or other solid support which is capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by treatment with the detectably labeled gene-specific antibody.
The solid phase support may then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on solid support may then be detected by conventional means.
By "solid phase support or carrier" is intended any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc.
Preferred supports include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.
The binding activity of a given lot of anti-wild type or -mutant fingerprint gene l0 peptide antibody may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.
One of the ways in which the gene peptide-specific antibody can be detectably labeled is by linking the same to an enzyme and using it in an enzyme immunoassay (EIA) (Volley, Ric Clin Lczb, 8:289-98 (1978) ["The Enzyme Linked Immunosorbent Assay (ELISA)", Diagnostic Horizons 2:1-7, 1978, Microbiological Associates Quarterly Publication, Walkersville, Md.]; Volley, et ccl., J. Clin. Pathol., 31:507-20 (1978);
Butler, Meth. Enzymol., 73:482-523 (1981); Maggio (ed.), Enzyme Immunoassay, CRC Press, Boca Raton, Fla.
(1980); Ishikawa, et ~cl., (eds.) Enzyme Immunoassay, Igaku-Shoin, Tokyo (1981)). The enzyme which is bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorimetric or by visual means.
Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate, dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, crease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. The detection can be accomplished by colorimetric methods which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.
Detection may also be accomplished using any of a variety of other immunoassays.
For example, by radioactively labeling the antibodies or antibody fragments, it is possible to detect fingerprint gene wild type, mutant, or expanded peptides through the use of a radioimmunoassay (RIA) (see, e.g., Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986). The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.
It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
The antibody can also be detectably labeled using fluorescence emitting metals such as 152Eu, or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentacetic acid (DTPA) or ethylenediamine-tetraacetic acid (EDTA).
The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction.
Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.
Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in, which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes bf labeling are luciferin, luciferase and aequorin.
Throughout this application, various publications, patents and published patent applications are referred to by an identifying citation. The disclosures of these publications, patents and published patent specifications referenced in this application are hereby incorporated by reference into the present disclosure to more fully describe the state of the art to which this invention pertains.
The following examples are intended only to illustrate the present invention and should in no way be construed as limiting the subject invention.
Examples Example 1: Direct Construct Construction from a Plasmid Library Genomic libraries using the lambda ZAPTM system were prepared as follows.
Embryonic stem cells were grown in 100 mm tissue culture plates. High molecular weight genomic DNA was isolated from these ES cells by adding 5 ml of lysis buffer (10 mM Tris-HCL pH7.5, 10 mM EDTA pH 8.0, 10 mM NaCI, 0.5°lo SDS, and 1 mg/ml Proteinase K) to a confluent 100 mm plate of embryonic stem cells. The cells were then incubated at 60°C for several hours or until fully lysed. Genomic DNA was purified from the lysed cells by several rounds of gentle phenol:chloroform extractions followed by ethanol precipitation.
The genomic DNA was partially digested with the restriction enzyme Sau 3A I to generate fragments of approximately 5-20 kb. The ends of these fragments were partially filled in by addition of dATP and dGTP in the present of Klenow DNA
polymerise, creating incompatible ends on the genomic fragments. Size fragments of between 5 and 10 kb were then purified by agarose gel electrophoresis (lx TAE, 0.8% gel). The DNA was then isolated from the excised agarose pieces using a QIAquick gel extraction kit (Qiagen, Inc., Valencia, CA).
The genomic fragments were ligated into the Lambda ZapTM II vector (Stratagene, Inc., La Jolla, CA) that had been cut with Xho I and partially filled in using dTTP, dCTP, and Klenow DNA polymerise. After ligation, the DNA was packaged using a lambda packaging mix (Gigapack III gold, Stratagene, Inc., La Jolla, CA) and the titer was determined.
Circular phagemid DNA was derived from the lambda library by growing the lambda clones on the appropriate bacterial strain (XL-1 Blue MRF~, Stratagene, Inc.) in the presence of the M13 helper phage, ExAssist (Stratagene, Inc.). Specifically, approximately 100,000 lambda clones were incubated with a 10-100 fold excess of both bacteria and helper phage for 20 minutes at 37°C. One ml of LB media + 10 mM MgS04 was added to each excision reaction and it was incubated overnight at 37°C with shaking. Typically 24-96 of these reactions were set up at a time in a 96 well deep-well block. The following morning, the block was heated to 65°C for 15 minutes to kill both the bacteria and the lambda phage.
Bacterial debris was removed by centrifugation at approximately 3000g for 15 minutes. The supernatant containing the circular phagemid DNA, was retained and used directly in plasmid PCR .
The pools of phagemid DNA described above were screened for specific genes of interest using long-range PCR and "outward pointing" oligos, chosen as described above based on the known sequence (depicted in Figure 1). The PCR reactions contains 2 p,1 of a pool phagemid DNA sample, 3 ~tl of lOx PCR Buffer 3 (Boehringer Mannheim), 1.1 ~I 10 mM dNTPs, 50 nM primers, 0.3 ~1 of EXPAND Long Template PCR Enzyme Mix (Boehringer-Mannheim) and 30 ~1 of HBO. Cycling conditions were 94°C
for 2 minutes (1 cycle); 94°C for 10 seconds, 65°C for 30 seconds, 68°C
for 15 seconds (15 cycles); 94°C for seconds, 60°C for 30 seconds, 68°C for 15 seconds plus 20 seconds increase per each additional cycle (25 cycles); 68°C for 7 minutes (1 cycle) and holding at 4°C.
The products of the PCR reactions were separated by electrophoresis through agarose gels containing 1X TAE buffer and visualized with ethidium bromide and UV
light. Any large fragments indicative of successful long-range PCR were excised from the gel and 10 purified using QIAquick PCR purification kit (Qiagen).
In order to eliminate the need to restriction map the PCR fragments, the following ligation-independent cloning strategy was employed. The long-range PCR
fragment of interest was "purified" using a QIAquick PCR purification kit (Qiagen, Inc., Santa Clarita, California). Single-stranded ends of the PCR fragments were generated by mixing: 0.1-2 p,g ~5 of the fragment; 2 ~I of NEB (New England BioLabs) Buffer 4; 1 ~,l of 2 mM
dTTP, 6 units of T4 DNA polymerise (NEB), H20 to total volume of 20 ~l and incubating at 25°C for 30 minutes. The polymerise was inactivated by heating at 75°C for 20 minutes. Single-stranded ends were also created on the Neo' selectable marker fragment by digesting the plasmid vector pDG2 at the unique restriction sites, with Sac I and Sac II (pDG2 depicted in Figure 2A) and treating each reaction with T4 DNA polymerise as above. The vector shown in Figure 1 was prepared with single-stranded ends complementary to those on the long-range PCR fragment.
The vector and frabments were then assembled into constructs using either a two-step cloning strategy or a tour-way, single-step protocol. Briefly, a reaction containing 10 ng of T4-treated Neo' cassette, 1 ~l of T4-treated PCR fragment, 0.2 ~tl of 0.5 M
EDTA, 0.3 ~I of 0.5 M NaCI and H20 up to 4 ~,1 was heated to 65°C and allowed to cool to room temperature over approximately 45 minutes. The mixture was then transformed into subcloning efficiency DH5-a competent cells.
3o Example 2: Generation of Constructs from Phage Libraries A mouse embryonic stem cell library was prepared in lambda phage as follows.
Genomic libraries were constructed from genomic DNA by partial cleavage of DNA
at Sau 3AI sites to yield genomic fragments of approximately 20 kb in length. The terminal sequences of these DNA fragments were partially filled in using Klenow enzyme in the presence of dGTP and dATP and the fragments were'ligated using T4 DNA ligase into Xho I
sites of an appropriate lambda cloning vector, e.g., lambda Fix II
(Stratagene, Inc., La Jolla, California), which had been partially filled in using Klenow in the presence of dTTP and dCTP. Alternatively, the partially digested genomic DNA was size selected using a sucrose gradient and sequences of approximately 20 kb selected for. The enriched fraction was cloned into a Bam HI cut lambda vector, e.g., lambda Datsh II (Stratagene, Inc., La Jolla, California). .
The library was plated onto 1,152 plates, each plate containing approximately 1,000 clones. Thus, a total of 1.1 million clones (the equivalent of 8 genomes) was plated.
The phage were eluted from each plate by adding 4 ml of lambda elution buffer (10 mM MgCl2, 10 mM Tris-pH 8.0) to each plate and incubating for 3 to 5 hours at room temperature. After incubation, 2 ml of buffer was collected from each plate and placed into one well of a 96 deep well plate (Costar, In.). Twelve 96-well plates were filled and referred to as the "sub-pool library."
Using the sub-pool library, "pool libraries" were made by placing 100 p1 of 12 different sub-pool wells into one well of a new 96 well plate. The 12 sub-pool plates were combined to form 1 plate of pool libraries.
Using a pair of oligonucleotides that were known to PCR-amplify the gene of interest, supernatant from the 96 pools of the "large-pool library" were amplified. PCR
was performed in the presence of 0.5 units of Amplitaq GoIdTM (Perkin Elmer), 1 p,M of each oligonucleotide, 200 ~,M dNTPs, 2 ~1 of a 1 to 5 dilution of the pool (or subpool) supernatant, 50 mM KC1, 100 mM Tris-HC1 (pH 8.3), and either 1.5 mM or 1.25 mM MgCI,.
Cycling conditions were 95°C for 8 minutes (1 cycle); 95°C for 30 seconds, 60°C for 30 seconds, 72°C for 45 seconds (55 cycles); 72°C for 7 minutes (1 cycle) and holding at 4°C.
Depending on the gene, between about 3 and 12 pool yielded positive signals as identified on agarose gels as described in Example 1. In cases where further purification was necessary (i.e. where a clear signal was not present after amplification), the 12 sub-pools making up the pool were subjected to amplification using the same primers and a single sub-pool (1000 clones) was identified.
Ce~aenation of flavking fi-cignaents. As described above, knock-out constructs contain two blocks of DNA sequence homologous to the target gene, flanking a positive selection marker. Long-range PCR was performed from the pools of lambda clones positively identified as described above in Example 2. Each fragment was generated using a pair of oligonucleotides with predetermined sequences lacking one type of base and complementary to predetermined sequences on the vector. The fragments obtained were between 1 and 5 kb.
A third fragment, longer than 5 kb, is also generated using appropriate oligonucleotides. This third fragment was then used to obtain DNA sequences near the gene to be knocked out but outside of the vector.
Example 3: 'Two-Step Cloning- General Procedure The pDG2 plasmid vector (Figure 2A) contains unique restriction sites Sac II
and Sac l0 I. Appropriate single-stranded annealing sites were generated by digesting the pDG2 vector with either restriction enzyme Sac II or Sac I and treating each reaction with polymerise and dTTP as described above. Four reactions were set up in microtitre plates for each vector, the reaction containing 1 ~tl of either (1) T4 DNA polymerise-treated fragments;
(2) a 1:10 dilution of the T4-treated fragments reaction; (3) a 1:100 dilution of the T4-treated fragments or (4) H20 (no insert control). The microtitre plates were sealed, placed in-between two temperature blocks heated to 65°C, and allowed to cool slowly at room temperature for 30 to 45 minutes.
The microtitre plate was then placed on ice and 20-25 ~1 of subcloning efficiency competent cells added to each well. The plate was incubated on ice for 20-30 minutes. The microtitre plate was then placed between two temperature blocks heated to 42°C for 2 minutes, followed by 2 minutes on ice. 100 p1 of LB was added to each well, the plate covered with parafilm and incubated 30-60 minutes at 37°C. The entire contents of each well were plated on one LB-Amp plate and incubated at 37°C overnight.
Between about 12-24 colonies were picked from plates which had at least 2-4 times more colonies than the no insert control. The colonies were grown in deep well plates overnight at 37°C and then the plasmid DNA extracted using a Qiagen mini-prep kit.
The plasmid DNA was digested with Not I and Sal I enzymes. As shown in Figure 2A, a Not I/Sal I digestion will generate a large fragment containing cloning sites 3 and 4 and a smaller fragment containing cloning sites 1 and 2 and the Neo' gene. After digestion, the reactions were run on a 0.8°70 agarose gel containing 0.2 p,g/ml ethidium bromide. For no inserts, two bands were present, one of 1975 base pairs and one of 2793 base pairs. When an insert fragment was present, at least one of these bands would be larger because it would also contain a fragment (insert 1 or 2) either at the annealing site 1/2 or the site 3/4. The insert bands were excised and treated with a QIAquick gel extraction kit. A second ligation reaction was performed containing 1 ~tl of lOX ligase buffer (50 mM Tris-HCI
pH 7.5, 10 mM MgCl~, 10 mM dithiothreitol, 1 mM ATP, 25 ~tg/ml bovine serum albumin), 1 p,1 T4 DNA ligase, 1-2 p1 fragment (site 3/4 band), 5 p1 of site 1/2 band and H20 up to 10 p1.
Controls were also set up replacing either the site 3/4 fragment or the site 1/2 fragment with water. The reactions were incubated 1 to 2 hours at room temperature and transformed with 25 p1 of competent cells.
"Flanking DNA" in the context of these examples refers to the genomic sequences flanking the region in the target gene that is to be deleted or mutated.
"Flanking DNA" is t0 also described above as the blocks of DNA sequence homologous to the target gene. R1 genomic library refers to a genomic library prepared from the R1 ES cell line.
Such libraries can be prepared such as described in Example 1.
Example 4: Generation and Analysis of Mice Comprising Retina-Specific ~5 Nuclear Receptor Gene Disruptions To investigate the role of retina-specific nuclear receptors, disruptions in retina-specific nuclear receptor genes were produced by homologous recombination.
Specifically, transgenic mice comprising disruptions in retina-specific nuclear receptor genes were created.
20 More particularly, a retina-specific targeting construct having the ability to disrupt or modify retina-specific nuclear receptor genes, specifically comprising SEQ ID N0:19 was created using the oligonucleotide sequences identified herein as SEQ >D N0:20 or SEQ
>D N0:21.
The targeting construct was introduced into ES cells derived from the 129/Sv-+P+Mgf-SLJ/J
mouse substrain to generate chimeric mice. F1 mice were generated by breeding with 25 C57BL/6 females. F2 homozygous mutant mice were produced by intererossing heterozygous males and females. The transgenic animals comprising disruptions in retina-specific nuclear receptor genes were analyzed for phenotypic changes and expression patterns. The phenotypes associated with a disruption in a retina-specific nuclear receptor gene were determined as follows:
30 Hontozygous Mice:
The homozygous mice analyzed demonstrated at least one of the following phenotypes:
Eyes. Eye abnormalities, including severe retinal dysplasia characterized by extensive rosette formation and retinal folding; segmental thinning of the outer nuclear layer 35 of the retina with rods and cones filling the foci; and complete unilateral absence of the retina. Moreover, the space normally occupied by the retina was filled with fibrous connective tissue, spicules of osteoid and some mineral. In areas, connective tissue was adherent to the posterior lens capsule. Posterior synechia with a thickened iris adherent to the anterior aspect of the lens was detected. The pigmented epithelial layer of the retina was thickened and its cells were increased in size and number. The internal structure of the lens was disorganized and comprised swollen and degenerated fibers. In instances where the retina was absent unilaterally, small focal remnants were present.
Ga.strointestival tract. Abnormalities in the gastrointestinal tract included multifocal infiltrates of neutrophils in the deep mucosa and submucosa in the stomach.
l0 'Skirv. Abnormalities in the skin included focal lymphocytic inflammation within the dermi s.
TesteslEpidiclymicles. Abnormalities in the testes and epididymides included reduced spermatogenesis. Specifically, seminiferous tubules had scattered degenerate or necrotic spermatogenetic epithelial cells and multinucleated giant cells. The epididymides had reduced number of spermatids, and degenerated cells were present in tubules. The epithelial cells of some epididymal tubules were vacuolated.
Clinical Chem.i.strylBlood Analysis. Abnormalities included low alanine aminotransferase (ALT) values, aspartate aminotransferase (AST), and creatinine kinase (CK) values as compared to wild-type control values. Alkaline phosphatase (ALP) activity, however, was elevated. Hematological evaluation showed lower total white blood cell count.
Heterozygous Mice:
Skin. Abnormalities included local fibrosis and lymphocytic dermatitis.
Liver. Abnormalities included pericholangitis with bile duct hyperplasia and fibrosis.
Example 5: Generation and Analysis of Mice Comprising Lymphoid-Specific G-Protein-Coupled Receptor Gene Disruptions To investigate the role of lymphoid-specific G-protein coupled receptors, disruptions in lymphoid-specific G-protein coupled receptor genes were produced by homologous recombination. Specifically, transgenic mice comprising disruptions in lymphoid-specific G-protein coupled receptor genes were created. More particularly, a lymphoid-specific GPCR
targeting construct having the ability to disrupt or modify lymphoid-specific G-protein coupled receptor genes, specifically comprising SEQ 1D N0:22 was created using the oligonucleotide sequences identified herein as SEQ 1D N0:23 and SEQ ID N0:24.
The targeting construct was inserted into ES cells derived from the I29/OlaHsd mouse substrain to generate chimeric mice. F1 mice were generated by breeding with C57BL/6 females. F2 homozygous mutant mice were produced by intercrossing F1 heterozygous males and females. The transgenic animals comprising disruptions in lymphoid-specific G-protein coupled receptor genes were analyzed for phenotypic changes and expression patterns. The phenotypes associated with a disruption in a lymphoid-specific GPCR were determined as follows:
Nonzozygous Mice:
The homozygous mice demonstrated at least one of the following phenotypes:
Lzcng. Abnormalities in the lung included cellular infiltrates around bronchioles.
l0 Pulmonary changes, exhibiting varying degrees of patchy peribronchial lymphocytic cellular infiltrates were detected. The infiltrates were primarily composed of small lymphocytes.
Peribronchial lymphocytic cuffing included focal subpleural collections of lymphocytes;
fibrinoid necrosis in vessel walls; and hyperplasia of bronchial epithelium.
Pancreas. Abnormalities in the pancreas included pancreatic cellular infiltrates near 15 ducts and islets. Specifically, periductular cellular infiltrates or peri-islet cellular infiltrates were present, and were primarily composed of small lymphocytes.
Ston2ach. Abnormalities in the stomach included gastric mixed cellular infiltrates composed of small lymphocytes, granulocytes, and plasma cells. The infiltrates involved the deep mucosa, submucosa and/ or the muscularis of the stomach.
20 Liver. Abnormalities in the liver included cellular infiltrates, predominately lymphocytes that involved the portal triad.
Expression Analysis:
LacZ (beta-galactosidase) expression was detected in the spleen and lymph nodes.
Specifically, in the lymph nodes, several cells showed strong X-Gal staining.
In the spleen, 25 strong staining was detected in some cells in the red pulp.
Example 6: Generation and Analysis of Mice Comprising Melanocyte Stimulating Hormone Receptor Gene Disruptions 30 To investigate the role of GPCR melanocyte stimulating hormones, disruptions in GPCR melanocyte stimulating hormone genes were produced by homologous recombination.
Specifically, transgenic mice comprising disruptions in GPCR melanocyte stimulating hormone genes were created. More particularly, a melanocyte stimulating hormone targeting construct having the ability to disrupt or modify genes encoding melanoyte stimulating 35 hormone receptors, specifically comprising SEQ B7 N0:25 was created using the oligonucleotide sequences identified herein as SEQ 1D N0:26 and SEQ 1D N0:27.
The targeting construct was inserted into ES cells derived from the 129/OlaHsd mouse substrain to generate chimeric mice. F1 mice were generated by breeding with C57BL/6 females. F2 homozygous mutant mice were produced by intercrossing F1 heterozygous males and females.
The transgenic animals comprising disruptions in melanocyte stimulating hormone receptor genes were analyzed for phenotypic changes and expression patterns.
The phenotypes associated with a disruption in a melanocyte stimulating hormone receptor gene were determined as follows:
Behavioral Ar2alysis. The homozygous mice were significantly different from wild-type mice in the total distance traveled in the open field test. The homozygous mice were hypoactive, in that they moved about and explored the open field significantly than their wild-type counterparts. The open field test has been used to demonstrate the changes in activity level and anxiety. Thus, the open field data demonstrates that the homozygous mice were hypoactive than the wild-type control mice.
LucZ Expression Anulysis. LacZ (beta-galactosidase) expression was detected in the esophagus, skin, and in the male reproductive system.
2o Example 7: Generation and Analysis of Mice Comprising Magnesium-Dependent Protein Phosphatase Gene Disruptions To investigate the role of magnesium-dependent protein phosphatase genes, disruptions in magnesium-dependent protein phosphatase genes were produced by homologous recombination. Specifically, transgenic mice comprising disruptions in magnesium-dependent protein phosphatase genes were created. More particularly, a magnesium-dependent protein phosphatase gene targeting construct having the ability to disrupt and mutate magnesium-dependent protein phosphatase genes, specifically genes comprising SEQ 1D N0:28, was created using the oligonucleotide sequences identified herein as SEQ >D N0:29 and SEQ >D N0:30. The targeting construct was inserted into ES
cells derived from the 129/OIaEIsd mouse substrain to generate chimeric mice. F1 mice were generated by breeding with C57BL/6 females. F2 homozygous mutant mice were produced by intercrossing F1 heterozygous males and females.
The transgenic animals comprising disruptions in magnesium-dependent protein phosphatase genes were analyzed for phenotypic changes and expression patterns. The phenotypes associated with a disruption in magnesium-dependent protein genes were determined as follows:
Homozygous Mice:
The homozygous mice demonstrated at least one of the following phenotypes:
Lung. Abnormalities in the lung included pulmonary lesions suggestive of foreign body aspiration pneumonia. Patchy, peribronchial, acute inflammation with associated granulomata (probably foreign body), foamy alveolar macrophages, and eosinophilic crystals within alveolar macrophages were found in the lungs. Patchy yellow-red discoloration of the lungs was also detected.
l0 Hematology. Abnormalities in the blood included elevated white blood cell (WBC) count.
Necropsy Examination. Patchy, red-yellow lung discoloration. Muscles and bones were softer than wild-type controls.
Expression Analysis:
l5 Strong IacZ expression was detectable in all tissue or organs examined, including the brain, spinal cord, sciatic nerve, eyes, harderian glands, thymus, spleen, lymph nodes, bone marrow, aorta, heart, lung, liver, gallbladder, pancreas, kidney, urinary bladder, trachea, larynx, esophagus, thyroid gland, pituitary gland, adrenal gland, salivary gland, tongue, skeletal muscle, skin, and female and male reproductive systems.
Example 8: Generation and Analysis of Mice Comprising a Chemokine Receptor 1-Like Protein Gene Disruptions To investigate the role of chemokine receptor 1-like protein genes, disruptions in chemokine receptor 1-like genes were produced by homologous recombination.
Specifically, transgenic mice comprising disruptions in chemokine receptor 1-like genes were created.
More particularly, a chemokine receptor 1-like gene targeting construct having the ability to disrupt and mutate chemokine receptor 1-like genes, specifically comprising SEQ ID N0:31 , was created using the oligonucleotide sequences identified herein as SEQ ID
N0:32 and SEQ
ID N0:33. The targeting construct was inserted into ES cells derived from the 129/OlaHsd mouse substrain to generate chimeric mice. F1 mice were generated by breeding with C57BL/6 females. F2 homozygous mutant mice were produced by intercrossing F1 heterozygous males and females.
Example 9: Generation and Analysis of Mice Comprising cGMP
Phosphodiesterase Gene Disruption To investigate the role of cGMP phosphodiesterase genes, disruptions in cGMP
phosphodiesterase genes were produced by homologous recombination.
Specifically, transgenic mice comprising disruptions in cGMP phosphodiesterase genes were created.
More particularly, a cGMP phosphodiesterase gene targeting construct having the ability to disrupt and mutate cGMP phosphodiesterase genes, specifically comprising SEQ
)D N0:34, was created using the oligonucleotide sequences identified herein as SEQ >D
N0:35 and SEQ
>D N0:36. The targeting construct was inserted into ES cells derived from the 129/OlaHsd mouse substrain to generate chimeric mice. F1 mice were generated by breeding with C57BL/G females. F2 homozygous mutant mice were produced by intercrossing F1 heterozygous males and females.
The transgenic animals comprising disruptions in cGMP phosphodiesterase genes were analyzed for phenotypic changes and expression patterns. The phenotypes associated with a disruption in cGMP phosphodiesterase genes were determined as follows:
Homozygous Mice:
The homozygous mice demonstrated at least one of the following phenotypes:
Eyes. Homozygous mice demonstrated eye abnormalities, particularly involving the retina and more specifically, retinal degeneration (RD), including severe bilateral retinal degeneration or retinal dysplasia, accompanied with complete absence of photoreceptor layers (i.e., rods and cones, outer nuclear layer, outer plexiform layer). The rods and cones are the dendrites of the photoreceptor cells, the outer nuclear layer represents the nuclei of the photoreceptor cells, and the outer plexiform layer represents the axon fibers of the photoreceptor cells. Such eye abnormalities may be accompanied by vision problems or blindness. Other changes in the eyes of these mice included: thinning and vacuolation of the inner nuclear layer; thinning of the inner plexiform layer; loss of ganglion cell nuclei, especially large ganglion cells; gliosis of the nerve fiber layer; and, attenuation of retinal vasculature. The RD observed in mice is analogous to retinitis pigmentosa (RP) in humans.
Aorta. Abnormality in the aorta included adventitia or inflammation of the aorta.
Kidney. The kidney abnormalities included tubular dilation or pyelitis.
Liver. The liver abnormalities detected included extramedullary hematopoiesis.
Lymph Nodes. Abnormalities in the lymph nodes included lymphoid hyperplasia, lymphoid atrophy, or hemorrhage.
Skin. Skin abnormalities included dermatitis.
Body Weight. Abnormalities included increased body weights and length.
Specifically, body weight was increased by about 11%-37% in males, and body length was increased by about 13% over control mice. Body weight to body length ratio was increased about 23~Io.
Orgcen Weight. Increased organ weights were found in the spleen and thymus gland, kidney and liver. Specifically, spleen weight increases ranged from about 13%
to 28%, and thymus gland weight increases ranged from about 17% to 30%. Kidney weight was increased by about 16% and liver weight was increased by about 38%.
Cliniccel Chemistry. Elevated levels of ALT (alanine aminotransferase), phosphorus, potassium, or bilirubin were detected.
Behavioral Ancclysis. Homozygous mice exhibited significantly increased activity, traveling a much greater total distance and exploring the open field more in the open field test. This observation indicated hyperactivity in the homozygous mice.
Heterozygous Mice:
Eyes. Eye abnormalities included discoloration including pink eyes.
LaeZ Expression Analysis:
LacZ (beta-galactosidase) expression was detected in the thyroid glands, salivary glands proper, salivary glands of the larynx, peritracheal and submucosal glands of the trachea and the mucous glands of the tongue.
Example 10: Generation and Analysis of Mice Comprising Sulfotransferase Genc Disruptions To investigate the role of sulfotransferases, disruptions in sulfotransferase genes were produced by homologous recombination. Specifically, transgenic mice comprising disruptions in sulfotransferase genes were created. More particularly, a sulfotransferase gene targeting construct having the ability to disrupt or modify sulfotransferase genes, specifically genes comprising SEQ ID N0:37, was created using the oligonucleotide sequences identified herein as SEQ ID N0:38 and SEQ ID N0:39. The targeting construct was introduced into ES cells derived from the 129/OIaHsd mouse substrain to generate chimeric mice. F1 mice were generated by breeding with C57BL/6 females. F2 homozygous mutant mice were produced by intercrossing Fl heterozygous males and females. The animals were evaluated for phenotypic changes. The phenotypes associated with a disruption in a sulfotransferase gene were determined as follows:
Homozygous Mice:
Liver. The homozygous mice demonstrated abnormalities in the liver as compared to wild-type mice. The homozygous mice demonstrated at least one of the following: patchy pallor of acinar zone 3 hepatocytes; eosinophilic globules of varying size with intranuclear invaginations within the cytoplasm of hepatocytes; or anisocytosis, anisonucleosis and increased mitotic cellular activity as compared to wild-type mice.
Saldvary Glands. Homozygous mice demonstrated abnormalities in the Harderian glands and salivary glands. Specifically, there was focal pigment deposition in the glands and atrophy and fibrosis in the submandibular gland.
I0 Behavioral Analy.si.s. The homozygous mice demonstrated aggressive, hyperactive and less anxious behavior as compared to wild-type mice. Specifically, beginning at two weeks of age, the homozygote mutant male mice exhibited increased aggression compare to wild-type littermates. During home cage observations, these animals attacked their cage-mates more than normal male mice, and had to be housed separately to prevent such attacks.
In addition, the homozygote mutant mice were significantly different from the wild-type mice in the open field test. Mutants were hyperactive moving about, and exploring the open field more readily than wild-type mice, exhibiting increased activity and decreased anxiety compared to the wild-type mice.
The homozygote mice were significantly different from wild-types in the Open field (°Io of time spent in central). The homozygous mice were less anxious spending a higher percentage of time in the central portion of the open field than the wild-type mice.
As is apparent to one of skill in the art, various modifications of the above embodiments can be made without departing from the spirit and scope of this invention.
These modifications and variations are within the scope of this invention.
Claims (155)
1. A targeting construct comprising:
(a) a first polynucleotide sequence homologous to a target gene, wherein the target gene is selected from the group consisting of a retina-specific nuclear receptor gene, a lymphoid-specific GPCR gene, a melanocyte stimulating hormone receptor gene, a magnesium-dependent protein phosphatase gene, chemokine receptor 1-like protein gene, a cGMP phosphodiesterase gene or a sulfotransferase gene;
(b) a second polynucleotide sequence homologous to the target gene; and (c) a selectable marker.
(a) a first polynucleotide sequence homologous to a target gene, wherein the target gene is selected from the group consisting of a retina-specific nuclear receptor gene, a lymphoid-specific GPCR gene, a melanocyte stimulating hormone receptor gene, a magnesium-dependent protein phosphatase gene, chemokine receptor 1-like protein gene, a cGMP phosphodiesterase gene or a sulfotransferase gene;
(b) a second polynucleotide sequence homologous to the target gene; and (c) a selectable marker.
2. The targeting construct of claim 1, wherein the targeting construct further comprises a screening marker.
3. A method of producing a targeting construct for a target gene, wherein the target gene is selected from the group consisting of a retina-specific nuclear receptor gene, a lymphoid-specific GPCR gene, a melanocyte stimulating hormone receptor gene, a magnesium-dependent protein phosphatase gene, chemokine receptor 1-like protein gene, a cGMP
phosphodiesterase gene or a sulfotransferase gene, the method comprising:
(a) obtaining a first polynucleotide sequence homologous to a target gene;
(b) obtaining a second polynucleotide sequence homologous to the target gene;
(c) providing a vector comprising a selectable marker; and (d) inserting the first and second sequences into the vector, to produce the targeting construct.
phosphodiesterase gene or a sulfotransferase gene, the method comprising:
(a) obtaining a first polynucleotide sequence homologous to a target gene;
(b) obtaining a second polynucleotide sequence homologous to the target gene;
(c) providing a vector comprising a selectable marker; and (d) inserting the first and second sequences into the vector, to produce the targeting construct.
4. A method of producing a targeting construct for a target gene, wherein the target gene is selected from the group consisting of a retina-specific nuclear receptor gene, a lymphoid-specific GPCR gene, a melanocyte stimulating hormone receptor gene, a magnesium-dependent protein phosphatase gene, chemokine receptor 1-like protein gene, a cGMP
phosphodiesterase gene or a sulfotransferase gene, the method comprising:
(a) providing a polynucleotide sequence homologous to the target gene;
(b) generating two different fragments of the polynucleotide sequence;
(c) providing a vector having a gene encoding a selectable marker; and (d) inserting the two different fragments into the vector to form the targeting construct.
phosphodiesterase gene or a sulfotransferase gene, the method comprising:
(a) providing a polynucleotide sequence homologous to the target gene;
(b) generating two different fragments of the polynucleotide sequence;
(c) providing a vector having a gene encoding a selectable marker; and (d) inserting the two different fragments into the vector to form the targeting construct.
5. A cell comprising a disruption in a target gene, wherein the target gene is selected from the group consisting of a retina-specific nuclear receptor gene, a lymphoid-specific GPCR
gene, a melanocyte stimulating hormone receptor gene, a magnesium-dependent protein phosphatase gene, chemokine receptor 1-like protein gene, a cGMP
phosphodiesterase gene or a sulfotransferase gene.
gene, a melanocyte stimulating hormone receptor gene, a magnesium-dependent protein phosphatase gene, chemokine receptor 1-like protein gene, a cGMP
phosphodiesterase gene or a sulfotransferase gene.
6. The cell of claim 5, wherein the cell is a murine cell.
7. The cell of claim 6, wherein the murine cell is an embryonic stem cell.
8. A non-human transgenic animal comprising a disruption in a target gene, wherein said target gene is selected from the group consisting of a retina-specific nuclear receptor gene, a lymphoid-specific GPCR gene, a melanocyte stimulating hormone receptor gene, a magnesium-dependent protein phosphatase gene, chemokine receptor 1-like protein gene, a cGMP phosphodiesterase gene or a sulfotransferase gene.
9. A cell derived from the non-human transgenic animal of claim 8.
10. A method of producing a transgenic mouse comprising a disruption in a target gene, the method comprising:
(a) introducing the targeting construct of claim 1 into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse.
(a) introducing the targeting construct of claim 1 into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse.
11. A method of identifying an agent that modulates the expression of a target gene, wherein the target gene is selected from the group consisting of a retina-specific nuclear receptor gene, a lymphoid-specific GPCR gene, a melanocyte stimulating hormone receptor gene, a magnesium-dependent protein phosphatase gene, chemokine receptor 1-like protein gene, a cGMP phosphodiesterase gene or a sulfotransferase gene, the method comprising:
(a) providing a non-human transgenic animal comprising a disruption in the target gene;
(b) administering an agent to the non-human transgenic animal; and (c) determining whether the expression of the disrupted target gene in the non-human transgenic animal is modulated.
(a) providing a non-human transgenic animal comprising a disruption in the target gene;
(b) administering an agent to the non-human transgenic animal; and (c) determining whether the expression of the disrupted target gene in the non-human transgenic animal is modulated.
12. A method of identifying an agent that modulates the function of a target gene, wherein the target gene is selected from the group consisting of a retina-specific nuclear receptor gene, a lymphoid-specific GPCR gene, a melanocyte stimulating hormone receptor gene, a magnesium-dependent protein phosphatase gene, chemokine receptor 1-like protein gene, a cGMP phosphodiesterase gene or a sulfotransferase gene, the method comprising:
(a) providing a non-human transgenic animal comprising a disruption in the target gene;
(b) administering an agent to the non-human transgenic animal; and (c) determining whether the function of the disrupted target gene in the non-human transgenic animal is modulated.
(a) providing a non-human transgenic animal comprising a disruption in the target gene;
(b) administering an agent to the non-human transgenic animal; and (c) determining whether the function of the disrupted target gene in the non-human transgenic animal is modulated.
13. A method of identifying an agent that modulates the expression of a target gene, wherein the target gene is selected from the group consisting of a retina-specific nuclear receptor gene, a lymphoid-specific GPCR gene, a melanocyte stimulating hormone receptor gene, a magnesium-dependent protein phosphatase gene, chemokine receptor 1-like protein gene, a cGMP phosphodiesterase gene or a sulfotransferase gene, the method comprising:
(a) providing a cell comprising a disruption in a target gene;
(b) contacting the cell with an agent; and (c) determining whether expression of the target gene is modulated.
(a) providing a cell comprising a disruption in a target gene;
(b) contacting the cell with an agent; and (c) determining whether expression of the target gene is modulated.
14. A method of identifying an agent that modulates the function of a target gene, wherein the target gene is selected from the group consisting of a retina-specific nuclear receptor gene, a lymphoid-specific GPCR gene, a melanocyte stimulating hormone receptor gene, a magnesium-dependent protein phosphatase gene, chemokine receptor 1-like protein gene, a cGMP phosphodiesterase gene or a sulfotransferase gene, the method comprising:
(a) providing a cell comprising a disruption in a target gene;
(b) contacting the cell with an agent; and (c) determining whether the function of the target gene is modulated.
(a) providing a cell comprising a disruption in a target gene;
(b) contacting the cell with an agent; and (c) determining whether the function of the target gene is modulated.
15. The method of claim 13 or claim 14, wherein the cell is derived from the non-human transgenic animal of claim 8.
16. An agent identified by the method of claim 11, claim 12, claim 13, or claim 14.
17. A transgenic mouse comprising a disruption in a retina-specific nuclear receptor gene, wherein the transgenic mouse exhibits an eye abnormality.
18. The transgenic mouse of claim 17, wherein the eye abnormality is a retinal abnormality.
19. The transgenic mouse of claim 18, wherein the retinal abnormality is characterized by retinal dysplasia.
20. The transgenic mouse of claim 19, wherein the transgenic mouse exhibits at least one of the following characteristics: rosette formation in the retina, retinal folding, segmental thinning or absence of the outer nuclear layer of the retina, or absence of the retina.
21. The transgenic mouse of claim 17, wherein the transgenic mouse is heterozygous for a disruption in a retina-specific nuclear receptor gene.
22. The transgenic mouse of claim 17, wherein the transgenic mouse is homozygous for a disruption in a retina-specific nuclear receptor gene.
23. A method of producing a transgenic mouse comprising a disruption in a retina-specific nuclear receptor gene, wherein the transgenic mouse exhibits an eye abnormality, the method comprising:
(a) introducing a retina-specific nuclear receptor gene targeting construct into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in a retina-specific nuclear receptor gene.
(a) introducing a retina-specific nuclear receptor gene targeting construct into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in a retina-specific nuclear receptor gene.
24. A transgenic mouse comprising a disruption in a retina-specific nuclear receptor gene, wherein the transgenic animal exhibits at least one of the following phenotypes: an abnormality of the gastrointestinal tract; an abnormality of the skin; an abnormality of the testes or epididymides; or an abnormality in the blood.
25. A cell derived from the transgenic mouse of claim 17, claim 23 or claim 24, wherein the cell comprises a disruption in a retina-specific nuclear receptor gene.
26. A method of identifying an agent that ameliorates an eye abnormality, the method comprising:
(a) administering an agent to a transgenic mouse comprising a disruption in a retina-specific nuclear receptor gene; and (b) determining whether the agent ameliorates the eye abnormality of the transgenic mouse.
(a) administering an agent to a transgenic mouse comprising a disruption in a retina-specific nuclear receptor gene; and (b) determining whether the agent ameliorates the eye abnormality of the transgenic mouse.
27. The method of claim 26, wherein the eye abnormality is a retinal abnormality.
28. The method of claim 27, wherein the retinal abnormality is characterized by retinal dysplasia.
29. The method of claim 28, wherein the transgenic mouse exhibits at least one of the following characteristics: rosette formation in the retina, retinal folding, segmental thinning or absence of the outer nuclear layer of the retina, or absence of the retina.
30. A method of identifying an agent which modulates retina-specific nuclear receptor gene expression, the method comprising:
(a) administering an agent to the transgenic mouse comprising a disruption in a retina-specific nuclear receptor gene; and (b) determining whether the agent modulates retina-specific nuclear receptor gene expression in the transgenic mouse, wherein the agent modulates a phenotype associated with a disruption in a retina-specific nuclear receptor gene.
(a) administering an agent to the transgenic mouse comprising a disruption in a retina-specific nuclear receptor gene; and (b) determining whether the agent modulates retina-specific nuclear receptor gene expression in the transgenic mouse, wherein the agent modulates a phenotype associated with a disruption in a retina-specific nuclear receptor gene.
31. The method of claim 30, wherein the phenotype comprises any one of the following: an eye abnormality; an abnormality of the gastrointestinal tract; an abnormality of the skin; an abnormality of the testes or epididymides; or an abnormality in the blood.
32. A method of identifying an agent which modulates a phenotype associated with a disruption in a retina-specific nuclear receptor gene, the method comprising:
(a) administering an agent to a transgenic mouse comprising a disruption in a retina-specific nuclear receptor gene; and (b) determining whether the agent modulates the phenotype.
(a) administering an agent to a transgenic mouse comprising a disruption in a retina-specific nuclear receptor gene; and (b) determining whether the agent modulates the phenotype.
33. The method of claim 32, wherein the phenotype comprises any one of the following: an eye abnormality; an abnormality of the gastrointestinal tract; an abnormality of the skin; an abnormality of the testes or epididymides; or an abnormality in the blood.
34. A method of identifying an agent which modulates retina-specific nuclear receptor gene expression, the method comprising:
(a) providing a cell comprising a disruption in a retina-specific nuclear receptor gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates retina-specific nuclear receptor gene expression, wherein the agent modulates a phenotype associated with a disruption in a retina-specific nuclear receptor gene.
(a) providing a cell comprising a disruption in a retina-specific nuclear receptor gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates retina-specific nuclear receptor gene expression, wherein the agent modulates a phenotype associated with a disruption in a retina-specific nuclear receptor gene.
35. The method of claim 34, wherein the phenotype comprises any one of the following: an eye abnormality; an abnormality of the gastrointestinal tract; an abnormality of the skin; an abnormality of the testes or epididymides; or an abnormality in the blood.
36. A method of identifying an agent which modulates retina-specific nuclear receptor gene function, the method comprising:
(a) providing a cell comprising a disruption in a retina-specific nuclear receptor gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates retina-specific nuclear receptor gene function, wherein the agent modulates a phenotype associated with a disruption in a retina-specific nuclear receptor gene.
(a) providing a cell comprising a disruption in a retina-specific nuclear receptor gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates retina-specific nuclear receptor gene function, wherein the agent modulates a phenotype associated with a disruption in a retina-specific nuclear receptor gene.
37. The method of claim 36, wherein the phenotype comprises any one of the following: an eye abnormality; an abnormality of the gastrointestinal tract; an abnormality of the skin; an abnormality of the testes or epididymides; or an abnormality in the blood.
38. An agent identified by the method of claim 26, claim 30, claim 32, claim 34 or claim 36.
39. A transgenic mouse comprising a disruption in a lymphoid-specific GPCR
gene, wherein the transgenic mouse exhibits cellular infiltration.
gene, wherein the transgenic mouse exhibits cellular infiltration.
40. The transgenic mouse of claim 39, wherein the cellular infiltration is comprised of lymphocytes.
41. The transgenic mouse of claim 40, wherein the cellular infiltration occurs in any one of the following organs: lung, pancreas, stomach or liver.
42. The transgenic mouse of claim 39, wherein the transgenic mouse is heterozygous for a disruption in a lymphoid-specific GPCR gene.
43. The transgenic mouse of claim 39, wherein the transgenic mouse is homozygous for a disruption in a lymphoid-specific GPCR gene.
44. A method of producing a transgenic mouse comprising a disruption in a lymphoid-specific GPCR gene, wherein the transgenic mouse exhibits cellular infiltration, the method comprising:
(a) introducing a lymphoid-specific GPCR targeting construct into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in a lymphoid-specific GPCR gene.
(a) introducing a lymphoid-specific GPCR targeting construct into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in a lymphoid-specific GPCR gene.
45. A transgenic mouse comprising a disruption in a lymphoid-specific GPCR
gene, wherein the transgenic mouse exhibits at least one of the following phenotypes:
peribronchiolar cellular infiltrates in the lungs; periductular cellular infiltrates in the pancreas; cellular infiltrates in the deep mucosa, submucosa, or muscularis of the stomach; or cellular infiltrates in the portal triads of the liver.
gene, wherein the transgenic mouse exhibits at least one of the following phenotypes:
peribronchiolar cellular infiltrates in the lungs; periductular cellular infiltrates in the pancreas; cellular infiltrates in the deep mucosa, submucosa, or muscularis of the stomach; or cellular infiltrates in the portal triads of the liver.
46. A cell derived from the transgenic mouse of claim 39, claim 44 or claim 45, wherein the cell comprises a disruption in a lymphoid-specific GPCR gene.
47. A method of identifying an agent that ameliorates cellular infiltration, the method comprising:
(a) administering the agent to the transgenic mouse comprising a disruption in a lymphoid-specific GPCR gene; and (b) determining whether the agent ameliorates cellular infiltration in the transgenic mouse.
(a) administering the agent to the transgenic mouse comprising a disruption in a lymphoid-specific GPCR gene; and (b) determining whether the agent ameliorates cellular infiltration in the transgenic mouse.
48. The method of claim 47, wherein the cellular infiltration is comprised of lymphocytes.
49. The method of claim 48, wherein the cellular infiltration occurs in any one of the following organs: lung, pancreas, stomach or liver.
50. A method of identifying an agent which modulates lymphoid-specific GPCR
gene expression, the method comprising:
(a) administering an agent to the transgenic mouse comprising a disruption in a lymphoid-specific GPCR gene; and (b) determining whether the agent modulates lymphoid-specific GPCR expression in the transgenic mouse, wherein the agent modulates a phenotype associated with a disruption in a lymphoid-specific GPCR gene.
gene expression, the method comprising:
(a) administering an agent to the transgenic mouse comprising a disruption in a lymphoid-specific GPCR gene; and (b) determining whether the agent modulates lymphoid-specific GPCR expression in the transgenic mouse, wherein the agent modulates a phenotype associated with a disruption in a lymphoid-specific GPCR gene.
51. The method of claim 50, wherein the phenotype comprises cellular infiltration in any one of the following organs: lung, pancreas, stomach or liver.
52. The method of claim 51, wherein the cellular infiltration is comprised of lymphocytes.
53. A method of identifying an agent which modulates lymphoid-specific GPCR
gene expression, the method comprising:
(a) providing a cell comprising a disruption in a lymphoid-specific GPCR gene;
(b) contacting the cell with the agent; and (c) determining whether the agent modulates lymphoid-specific GPCR gene expression, wherein the agent modulates a phenotype associated with a disruption in a lymphoid-specific GPCR gene.
gene expression, the method comprising:
(a) providing a cell comprising a disruption in a lymphoid-specific GPCR gene;
(b) contacting the cell with the agent; and (c) determining whether the agent modulates lymphoid-specific GPCR gene expression, wherein the agent modulates a phenotype associated with a disruption in a lymphoid-specific GPCR gene.
54. The method of claim 53, wherein the phenotype comprises cellular infiltration in any one of the following organs: lung, pancreas, stomach or liver.
55. The method of claim 54, wherein the cellular infiltration is comprised of lymphocytes.
56. A method of identifying an agent which modulates lymphoid-specific GPCR
gene function, the method comprising:
(a) providing a cell comprising disruption in a lymphoid-specific GPCR gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates lymphoid-specific GPCR gene function, wherein the agent modulates a phenotype associated with a disruption in a lymphoid-specific GPCR gene.
gene function, the method comprising:
(a) providing a cell comprising disruption in a lymphoid-specific GPCR gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates lymphoid-specific GPCR gene function, wherein the agent modulates a phenotype associated with a disruption in a lymphoid-specific GPCR gene.
57. The method of claim 56, wherein the phenotype comprises cellular infiltration in any one of the following organs: lung, pancreas, stomach or liver.
58. A method of identifying an agent which modulates a phenotype associated with a disruption in a lymphoid-specific GPCR gene, the method comprising:
(a) administering an agent to a transgenic mouse comprising a disruption in a lymphoid-specific GPCR gene; and (b) determining whether the agent modulates the phenotype.
(a) administering an agent to a transgenic mouse comprising a disruption in a lymphoid-specific GPCR gene; and (b) determining whether the agent modulates the phenotype.
59. The method of claim 58, wherein the phenotype comprises cellular infiltration in any one of the following organs: lung, pancreas, stomach or liver.
60. An agent identified by the method of claim 47, claim 50, claim 53, claim 56 or claim 58.
61. A transgenic mouse comprising a disruption in a melanocyte stimulating hormone receptor gene, wherein the transgenic mouse exhibits hypoactive behavior.
62. The transgenic mouse of claim 61, wherein the transgenic mouse is heterozygous for a disruption in a melanocyte stimulating hormone receptor gene.
63. The transgenic mouse of claim 61, wherein the transgenic mouse is homozygous for a disruption in a melanocyte stimulating hormone receptor gene.
64. A method of producing a transgenic mouse comprising a disruption in a melanocyte stimulating hormone receptor gene, wherein the transgenic mouse exhibits hypoactive behavior, the method comprising:
(a) introducing melanocyte stimulating hormone receptor gene targeting construct into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in a retina-specific nuclear receptor gene.
(a) introducing melanocyte stimulating hormone receptor gene targeting construct into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in a retina-specific nuclear receptor gene.
65. A cell derived from the transgenic mouse of claim 61 or claim 64, wherein the cell comprises a disruption in a melanocyte stimulating hormone receptor gene.
66. A method of identifying an agent that ameliorates hypoactive behavior, the method comprising:
(a) administering an agent to a transgenic mouse comprising a disruption in a melanocyte stimulating hormone receptor gene; and (b) determining whether the agent ameliorates hypoactive behavior of the transgenic mouse.
(a) administering an agent to a transgenic mouse comprising a disruption in a melanocyte stimulating hormone receptor gene; and (b) determining whether the agent ameliorates hypoactive behavior of the transgenic mouse.
67. A method of identifying an agent which modulates melanocyte stimulating hormone receptor gene expression, the method comprising:
(a) administering an agent to the transgenic mouse comprising a disruption in a melanocyte stimulating hormone receptor gene; and (b) determining whether the agent modulates melanocyte stimulating hormone receptor gene expression in the transgenic mouse, wherein the agent has an effect on hypoactive behavior of the transgenic mouse.
(a) administering an agent to the transgenic mouse comprising a disruption in a melanocyte stimulating hormone receptor gene; and (b) determining whether the agent modulates melanocyte stimulating hormone receptor gene expression in the transgenic mouse, wherein the agent has an effect on hypoactive behavior of the transgenic mouse.
68. A method of identifying an agent which modulates hypoactive associated with a disruption in a melanocyte stimulating hormone receptor gene, the method comprising:
(a) administering an agent to a transgenic mouse comprising a disruption in a melanocyte stimulating hormone receptor gene; and (b) determining whether the agent modulates hypoactive behavior of the transgenic mouse.
(a) administering an agent to a transgenic mouse comprising a disruption in a melanocyte stimulating hormone receptor gene; and (b) determining whether the agent modulates hypoactive behavior of the transgenic mouse.
69. An agent identified by the method of claim 66, claim 67 or claim 68.
70. A transgenic mouse comprising a disruption in a magnesium-dependent protein phosphatase gene, wherein the transgenic mouse exhibits a lung abnormality or an elevated white blood cell count.
71. The transgenic mouse of claim 70, wherein the lung abnormality comprises pulmonary lesions.
72. The transgenic mouse of claim 71, wherein the pulmonary lesions are consistent with pneumonia.
73. The transgenic mouse of claim 70, wherein the transgenic mouse is heterozygous for a disruption in a magnesium-dependent protein phosphatase gene.
74. The transgenic mouse of claim 70, wherein the transgenic mouse is homozygous for a disruption in a magnesium-dependent protein phosphatase gene.
75. A method of producing a transgenic mouse comprising a disruption in a magnesium-dependent protein phosphatase gene, wherein the transgenic mouse exhibits a lung abnormality or an elevated white blood cell count, the method comprising:
(a) introducing a magnesium-dependent protein phosphatase gene targeting construct into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in a magnesium-dependent protein phosphatase gene.
(a) introducing a magnesium-dependent protein phosphatase gene targeting construct into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in a magnesium-dependent protein phosphatase gene.
76. A cell derived from the transgenic mouse of claim 70 or claim 75, wherein the cell comprises a disruption in a magnesium-dependent protein phosphatase gene.
77. A method of identifying an agent that ameliorates a lung abnormality, the method comprising:
(a) administering an agent to a transgenic mouse comprising a disruption in a magnesium-dependent protein phosphatase gene; and (b) determining whether the agent ameliorates the lung abnormality of the transgenic mouse.
(a) administering an agent to a transgenic mouse comprising a disruption in a magnesium-dependent protein phosphatase gene; and (b) determining whether the agent ameliorates the lung abnormality of the transgenic mouse.
78. The method of claim 77, wherein the lung abnormality comprises pulmonary lesions.
79. The method of claim 78, wherein the pulmonary lesions are consistent with pneumonia.
80. A method of identifying an agent that reduces white blood cell count, the method comprising:
(a) administering an agent to a transgenic mouse comprising a disruption in a magnesium-dependent protein phosphatase gene; and (b) determining whether the agent reduces white blood cell count in the transgenic mouse.
(a) administering an agent to a transgenic mouse comprising a disruption in a magnesium-dependent protein phosphatase gene; and (b) determining whether the agent reduces white blood cell count in the transgenic mouse.
81. A method of identifying an agent which modulates magnesium-dependent protein phosphatase gene expression, the method comprising:
(a) administering an agent to the transgenic mouse comprising a disruption in a magnesium-dependent protein phosphatase gene; and (b) determining whether the agent modulates magnesium-dependent protein phosphatase gene expression in the transgenic mouse, wherein the agent modulates a phenotype associated with a disruption in a magnesium-dependent protein phosphatase gene.
(a) administering an agent to the transgenic mouse comprising a disruption in a magnesium-dependent protein phosphatase gene; and (b) determining whether the agent modulates magnesium-dependent protein phosphatase gene expression in the transgenic mouse, wherein the agent modulates a phenotype associated with a disruption in a magnesium-dependent protein phosphatase gene.
82. The method of claim 81, wherein the phenotype comprises a lung abnormality or an elevated white blood cell count.
83. The method of claim 82, wherein the lung abnormality comprises pulmonary lesions.
84. The method of claim 83, wherein the pulmonary lesions are consistent with pneumonia.
85. A method of identifying an agent which modulates a phenotype associated with a disruption in a magnesium-dependent protein phosphatase gene, the method comprising:
(a) administering an agent to a transgenic mouse comprising a disruption in a magnesium-dependent protein phosphatase gene; and (b) determining whether the agent modulates the phenotype.
(a) administering an agent to a transgenic mouse comprising a disruption in a magnesium-dependent protein phosphatase gene; and (b) determining whether the agent modulates the phenotype.
86. The method of claim 85, wherein the phenotype comprises a lung abnormality or an elevated white blood cell count.
87. The method of claim 86, wherein the lung abnormality comprises pulmonary lesions.
88. The method of claim 87, wherein the pulmonary lesions are consistent with pneumonia.
89. A method of identifying an agent which modulates magnesium-dependent protein phosphatase gene expression, the method comprising:
(a) providing a cell comprising a disruption in a magnesium-dependent protein phosphatase gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates magnesium-dependent protein phosphatase gene expression, wherein the agent modulates a phenotype associated with a disruption in a magnesium-dependent protein phosphatase gene.
(a) providing a cell comprising a disruption in a magnesium-dependent protein phosphatase gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates magnesium-dependent protein phosphatase gene expression, wherein the agent modulates a phenotype associated with a disruption in a magnesium-dependent protein phosphatase gene.
90. The method of claim 89, wherein the phenotype comprises a lung abnormality or an elevated white blood cell count.
91. The method of claim 90, wherein the lung abnormality comprises pulmonary lesions.
92. The method of claim 91, wherein the pulmonary lesions are consistent with pneumonia.
93. A method of identifying an agent which modulates magnesium-dependent protein phosphatase gene function, the method comprising:
(a) providing a cell comprising a disruption in a magnesium-dependent protein phosphatase gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates magnesium-dependent protein phosphatase gene function, wherein the agent modulates a phenotype associated with a disruption in a magnesium-dependent protein phosphatase gene.
(a) providing a cell comprising a disruption in a magnesium-dependent protein phosphatase gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates magnesium-dependent protein phosphatase gene function, wherein the agent modulates a phenotype associated with a disruption in a magnesium-dependent protein phosphatase gene.
94. The method of claim 93, wherein the phenotype comprises a lung abnormality or an elevated white blood cell count.
95. The method of claim 94, wherein the lung abnormality comprises pulmonary lesions.
96. The method of claim 95, wherein the pulmonary lesions are consistent with pneumonia.
97. An agent identified by the method of claim 77, claim 80, claim 81, claim 85, claim 89, or claim 93.
98. A transgenic mouse comprising a disruption in an cGMP phosphodiesterase gene, wherein the transgenic mouse exhibits an eye abnormality.
99. The transgenic mouse of claim 98, wherein the eye abnormality is a retinal abnormality.
100. The transgenic mouse of claim 99, wherein the retinal abnormality is characterized by retinal degeneration or retinal dysplasia.
101. The transgenic mouse of claim 100, wherein the transgenic mouse exhibits an absence of photoreceptor layers.
102. The transgenic mouse of claim 98, wherein the eye abnormality is consistent with vision problems or blindness.
103. The transgenic mouse of claim 99, wherein the retinal abnormality is consistent with retinitis pigmentosa.
104. The transgenic mouse of claim 98, wherein the eye abnormality comprises at least one of the following: thinning or vacuolation of the inner nuclear layer of the eye; thinning of the inner plexiform layer of the eye; loss of ganglion cell nuclei; gliosis of the nerve fiber layer;
or attenuation of retinal vasculature.
or attenuation of retinal vasculature.
105. The transgenic mouse. of claim 98, wherein the transgenic mouse is heterozygous for a disruption in an cGMP phosphodiesterase gene.
106. The transgenic mouse of claim 98, wherein the transgenic mouse is homozygous for a disruption in an cGMP phosphodiesterase gene.
107. A method of producing a transgenic mouse comprising a disruption in an cGMP
phosphodiesterase gene, wherein the transgenic mouse exhibits an eye abnormality, the method comprising:
(a) introducing an cGMP phosphodiesterase gene targeting construct into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in an cGMP phosphodiesterase gene.
phosphodiesterase gene, wherein the transgenic mouse exhibits an eye abnormality, the method comprising:
(a) introducing an cGMP phosphodiesterase gene targeting construct into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in an cGMP phosphodiesterase gene.
108. A transgenic mouse comprising a disruption in an cGMP phosphodiesterase gene, wherein the transgenic mouse exhibits at least one of the following phenotypes: an abnormality in the aorta; an abnormality of the kidney; an abnormality in the liver; an abnormality in the lymph nodes; an abnormality in the skin; increased body and organ weight; or elevated levels of ALT, phosphorus, potassium, or bilirubin.
109. A cell derived from the transgenic mouse of claim 98, claim 104, claim 107 or claim 108, wherein the cell comprises a disruption in an cGMP phosphodiesterase gene.
110. A method of identifying an agent that ameliorates an eye abnormality, the method comprising:
(a) administering an agent to a transgenic mouse comprising a disruption in an cGMP
phosphodiesterase gene; and (b) determining whether the agent ameliorates the eye abnormality of the transgenic mouse.
(a) administering an agent to a transgenic mouse comprising a disruption in an cGMP
phosphodiesterase gene; and (b) determining whether the agent ameliorates the eye abnormality of the transgenic mouse.
111. The method of claim 110, wherein the eye abnormality is a retinal abnormality.
112. The method of claim 111, wherein the retinal abnormality is characterized by retinal degeneration or retinal dysplasia.
113. The method of claim 110, wherein the transgenic mouse exhibits an absence of photoreceptor layers.
114. The method of claim 110, wherein the eye abnormality comprises at least one of the following: thinning or vacuolation of the inner nuclear layer of the eye;
thinning of the inner plexiform layer of the eye; loss of ganglion cell nuclei in the eye; gliosis of the nerve fiber layer of the eye; or attenuation of retinal vasculature in the eye.
thinning of the inner plexiform layer of the eye; loss of ganglion cell nuclei in the eye; gliosis of the nerve fiber layer of the eye; or attenuation of retinal vasculature in the eye.
115. A method of identifying an agent which modulates cGMP phosphodiesterase gene expression, the method comprising:
(a) administering an agent to the transgenic mouse comprising a disruption in an cGMP phosphodiesterase gene; and (b) determining whether the agent modulates cGMP phosphodiesterase gene expression in the transgenic mouse, wherein the agent modulates a phenotype associated with a disruption in an cGMP phosphodiesterase gene.
(a) administering an agent to the transgenic mouse comprising a disruption in an cGMP phosphodiesterase gene; and (b) determining whether the agent modulates cGMP phosphodiesterase gene expression in the transgenic mouse, wherein the agent modulates a phenotype associated with a disruption in an cGMP phosphodiesterase gene.
117. The method of claim 115, wherein the phenotype comprises any one of the following:
an eye abnormality; abnormality of the aorta; an abnormality of the kidney; an abnormality of the liver; an abnormality of the lymph nodes; an abnormality of the skin;
increased body weight or organ weight; or elevated levels of ALT, phosphorus, potassium, or bilirubin.
an eye abnormality; abnormality of the aorta; an abnormality of the kidney; an abnormality of the liver; an abnormality of the lymph nodes; an abnormality of the skin;
increased body weight or organ weight; or elevated levels of ALT, phosphorus, potassium, or bilirubin.
117. A method of identifying an agent which modulates a phenotype associated with a disruption in an cGMP phosphodiesterase gene, the method comprising:
(a) administering an agent to a transgenic mouse comprising a disruption in an cGMP
phosphodiesterase gene; and (b) determining whether the agent modulates the phenotype.
(a) administering an agent to a transgenic mouse comprising a disruption in an cGMP
phosphodiesterase gene; and (b) determining whether the agent modulates the phenotype.
118. The method of claim 117, wherein the phenotype comprises any one of the following:
an eye abnormality; an abnormality of the aorta; an abnormality of the kidney;
an abnormality of the liver; an abnormality of the lymph nodes; an abnormality of the skin;
increased body weight or organ weight; or elevated levels of ALT, phosphorus, potassium, or bilirubin.
an eye abnormality; an abnormality of the aorta; an abnormality of the kidney;
an abnormality of the liver; an abnormality of the lymph nodes; an abnormality of the skin;
increased body weight or organ weight; or elevated levels of ALT, phosphorus, potassium, or bilirubin.
119. A method of identifying an agent which modulates cGMP phosphodiesterase gene expression, the method comprising:
(a) providing a cell comprising a disruption in cGMP phosphodiesterase gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates cGMP phosphodiesterase gene expression, wherein the agent modulates a phenotype associated with a disruption in a cGMP phosphodiesterase gene.
(a) providing a cell comprising a disruption in cGMP phosphodiesterase gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates cGMP phosphodiesterase gene expression, wherein the agent modulates a phenotype associated with a disruption in a cGMP phosphodiesterase gene.
120. The method of claim 119, wherein the phenotype comprises any one of the following:
an eye abnormality; abnormality of the aorta; an abnormality of the kidney; an abnormality of the liver; an abnormality of the lymph nodes; an abnormality of the skin;
increased body weight or organ weight; or elevated levels of ALT, phosphorus, potassium, or bilirubin.
an eye abnormality; abnormality of the aorta; an abnormality of the kidney; an abnormality of the liver; an abnormality of the lymph nodes; an abnormality of the skin;
increased body weight or organ weight; or elevated levels of ALT, phosphorus, potassium, or bilirubin.
121. A method of identifying an agent which modulates cGMP phosphodiesterase gene function, the method comprising:
(a) providing a cell comprising a disruption in a cGMP phosphodiesterase gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates cGMP phosphodiesterase gene function, wherein the agent modulates a phenotype associated with a disruption in a cGMP
phosphodiesterase gene.
(a) providing a cell comprising a disruption in a cGMP phosphodiesterase gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates cGMP phosphodiesterase gene function, wherein the agent modulates a phenotype associated with a disruption in a cGMP
phosphodiesterase gene.
122. The method of claim 121, wherein the phenotype comprises any one of the following:
an eye abnormality; abnormality of the aorta; an abnormality of the kidney; an abnormality of the liver; an abnormality of the lymph nodes; an abnormality of the skin;
increased body weight or organ weight; or elevated levels of ALT, phosphorus, potassium, or bilirubin. .
an eye abnormality; abnormality of the aorta; an abnormality of the kidney; an abnormality of the liver; an abnormality of the lymph nodes; an abnormality of the skin;
increased body weight or organ weight; or elevated levels of ALT, phosphorus, potassium, or bilirubin. .
123. An agent identified by the method of claim 110, claim 115, claim 117, claim 119 or claim 121.
124. A transgenic mouse comprising a disruption in a cGMP phosphodiesterase gene, wherein the transgenic mouse exhibits decreased anxiety behavior.
125. The transgenic mouse of claim 124, wherein the transgenic mouse is heterozygous for a disruption in an cGMP phosphodiesterase gene.
126. The transgenic mouse of claim 125, wherein the transgenic mouse is homozygous for a disruption in an cGMP phosphodiesterase gene.
127. A method of identifying an agent that ameliorates hyperactive behavior, the method comprising:
(a) administering an agent to a transgenic mouse comprising a disruption in an cGMP
phosphodiesterase gene; and (b) determining whether the agent ameliorates hyperactive behavior of the transgenic mouse.
(a) administering an agent to a transgenic mouse comprising a disruption in an cGMP
phosphodiesterase gene; and (b) determining whether the agent ameliorates hyperactive behavior of the transgenic mouse.
128. A method of identifying an agent which modulates an cGMP
phosphodiesterase gene expression, the method comprising:
(a) administering an agent to the transgenic mouse comprising a disruption in an cGMP phosphodiesterase gene; and (b) determining whether the agent modulates cGMP phosphodiesterase gene expression in the transgenic mouse, wherein the agent has an effect on hyperactive behavior of the transgenic mouse.
phosphodiesterase gene expression, the method comprising:
(a) administering an agent to the transgenic mouse comprising a disruption in an cGMP phosphodiesterase gene; and (b) determining whether the agent modulates cGMP phosphodiesterase gene expression in the transgenic mouse, wherein the agent has an effect on hyperactive behavior of the transgenic mouse.
129. A method of identifying an agent which modulates a phenotype associated with a disruption in a cGMP phosphodiesterase gene, the method comprising:
(a) administering an agent to a transgenic mouse comprising a disruption in a cGMP
phosphodiesterase gene; and (b) determining whether the agent modulates hyperactive behavior of the transgenic mouse.
(a) administering an agent to a transgenic mouse comprising a disruption in a cGMP
phosphodiesterase gene; and (b) determining whether the agent modulates hyperactive behavior of the transgenic mouse.
130. An agent identified by the method of claim 127, claim 128 or claim 129.
131. A transgenic mouse comprising a disruption in a sulfotransferase gene, wherein the transgenic mouse exhibits at least one of the following: aggressive, hyperactive, increased activity or decreased anxiety behavior.
132. The transgenic mouse of claim 131, wherein the transgenic mouse is heterozygous for a disruption in a sulfotransferase gene.
133. The transgenic mouse of claim 131, wherein the transgenic mouse is homozygous for a disruption in a sulfotransferase gene.
134. A method of producing a transgenic mouse comprising a disruption in a sulfotransferase gene, wherein the transgenic mouse exhibits at least one of the following:
aggressive, hyperactive, increased activity or decreased anxiety behavior, the method comprising:
(a) introducing a sulfotransferase gene targeting construct into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in a sulfotransferase gene.
aggressive, hyperactive, increased activity or decreased anxiety behavior, the method comprising:
(a) introducing a sulfotransferase gene targeting construct into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in a sulfotransferase gene.
135. A cell derived from the transgenic mouse of claim 131 or claim 134, wherein the cell comprises a disruption in a sulfotransferase gene.
136. A method of identifying an agent that ameliorates a behavior associated with a disruption in a sulfotransferase gene, the method comprising:
(a) administering an agent to a transgenic mouse comprising a disruption in a sulfotransferase gene; and (b) determining whether the agent ameliorates aggressive, hyperactive, increased activity or decreased anxiety behavior of the transgenic mouse.
(a) administering an agent to a transgenic mouse comprising a disruption in a sulfotransferase gene; and (b) determining whether the agent ameliorates aggressive, hyperactive, increased activity or decreased anxiety behavior of the transgenic mouse.
137. A method of identifying an agent which modulates sulfotransferase gene expression, the method comprising:
(a) administering an agent to the transgenic mouse comprising a disruption in a sulfotransferase gene; and (b) determining whether the agent modulates sulfotransferase gene expression in the transgenic mouse, wherein the agent has an effect on aggressive, hyperactive, increased activity or decreased anxiety behavior of the transgenic mouse.
(a) administering an agent to the transgenic mouse comprising a disruption in a sulfotransferase gene; and (b) determining whether the agent modulates sulfotransferase gene expression in the transgenic mouse, wherein the agent has an effect on aggressive, hyperactive, increased activity or decreased anxiety behavior of the transgenic mouse.
138. A method of identifying an agent which modulates a behavior associated with a disruption in a sulfotransferase gene, the method comprising:
(a) administering an agent to a transgenic mouse comprising a disruption in a sulfotransferase gene; and (b) determining whether the agent modulates aggressive, hyperactive, increased activity or decreased anxiety behavior of the transgenic mouse.
(a) administering an agent to a transgenic mouse comprising a disruption in a sulfotransferase gene; and (b) determining whether the agent modulates aggressive, hyperactive, increased activity or decreased anxiety behavior of the transgenic mouse.
139. An agent identified by the method of claim 136, claim 137 or claim 138.
140. A transgenic mouse comprising a disruption in a sulfotransferase gene, wherein the transgenic mouse exhibits at least one of the following: an abnormality in the liver or an abnormality in the salivary gland.
141. The transgenic mouse of claim 140, wherein the abnormality in the liver is characterized by at least one of the following: hepatocyte abnormalities, anisocytosis, anisonucleosis, and increased mitotic cellular activity in the liver.
142. A transgenic mouse comprising a disruption in a sulfotransferase gene, wherein the abnormality in the salivary gland is characterized by at least one of the following: focal pigment deposition, atrophy or fibrosis in the salivary gland.
143. A method of identifying an agent which modulates sulfotransferase gene expression, the method comprising:
(a) administering an agent to the transgenic mouse comprising a disruption in a sulfotransferase gene; and (b) determining whether the agent modulates sulfotransferase gene expression in the transgenic mouse, wherein the agent modulates a phenotype associated with a disruption in sulfotransferase gene.
(a) administering an agent to the transgenic mouse comprising a disruption in a sulfotransferase gene; and (b) determining whether the agent modulates sulfotransferase gene expression in the transgenic mouse, wherein the agent modulates a phenotype associated with a disruption in sulfotransferase gene.
144. The method of claim 143, wherein the phenotype comprises any one of the following:
an abnormality in the liver or an abnormality in the salivary gland.
an abnormality in the liver or an abnormality in the salivary gland.
145. A method of identifying an agent which modulates a phenotype associated with a disruption in a sulfotransferase gene, the method comprising:
(a) administering an agent to a transgenic mouse comprising a disruption in a sulfotransferase gene; and (b) determining whether the agent modulates the phenotype.
(a) administering an agent to a transgenic mouse comprising a disruption in a sulfotransferase gene; and (b) determining whether the agent modulates the phenotype.
146. The method of claim 145, wherein the phenotype comprises any one of the following:
an abnormality in the liver or an abnormality in the salivary gland.
an abnormality in the liver or an abnormality in the salivary gland.
147. A method of identifying an agent which modulates sulfotransferase gene expression, the method comprising:
(a) providing a cell comprising a disruption in a sulfotransferase gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates sulfotransferase gene expression, wherein the agent modulates a phenotype associated with a disruption in a sulfotransferase gene.
(a) providing a cell comprising a disruption in a sulfotransferase gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates sulfotransferase gene expression, wherein the agent modulates a phenotype associated with a disruption in a sulfotransferase gene.
148. The method of claim 147, wherein the phenotype comprises any one of the following:
an abnormality in the liver or an abnormality in the salivary gland.
an abnormality in the liver or an abnormality in the salivary gland.
149. A method of identifying an agent which modulates sulfotransferase function, the method comprising:
(a) providing a cell comprising a disruption in a sulfotransferase gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates sulfotransferase gene function, wherein the agent modulates a phenotype associated with a disruption in a sulfotransferase gene.
(a) providing a cell comprising a disruption in a sulfotransferase gene;
(b) contacting the cell with an agent; and (c) determining whether the agent modulates sulfotransferase gene function, wherein the agent modulates a phenotype associated with a disruption in a sulfotransferase gene.
150. The method of claim 149, wherein the phenotype comprises any one of the following:
an abnormality in the liver or an abnormality in the salivary gland.
an abnormality in the liver or an abnormality in the salivary gland.
151. A method of identifying an agent which modulates sulfotransferase gene expression, the method comprising:
(a) administering an agent to the transgenic mouse comprising a disruption in a sulfotransferase gene; and (b) determining whether the agent modulates sulfotransferase gene expression in the transgenic mouse, wherein the agent modulates a phenotype associated with a disruption in a phosphatase gene.
(a) administering an agent to the transgenic mouse comprising a disruption in a sulfotransferase gene; and (b) determining whether the agent modulates sulfotransferase gene expression in the transgenic mouse, wherein the agent modulates a phenotype associated with a disruption in a phosphatase gene.
152. The method of claim 151, wherein the phenotype comprises any one of the following:
an abnormality in the liver or an abnormality in the salivary gland.
an abnormality in the liver or an abnormality in the salivary gland.
153. An agent identified by the method of claim 143, claim 145, claim 147, claim 149 or claim 151.
154. A method of producing a transgenic mouse comprising a disruption in a sulfotransferase gene, wherein the transgenic mouse exhibits at least one of the following: an abnormality in the liver or an abnormality in the salivary glands, the method comprising:
(a) introducing a sulfotransferase gene targeting construct into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in a sulfotransferase gene.
(a) introducing a sulfotransferase gene targeting construct into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in a sulfotransferase gene.
155. A cell derived from the transgenic mouse of claim 140 or claim 154.
Applications Claiming Priority (37)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19034800P | 2000-03-16 | 2000-03-16 | |
US60/190,348 | 2000-03-16 | ||
US19112800P | 2000-03-22 | 2000-03-22 | |
US19114200P | 2000-03-22 | 2000-03-22 | |
US19112900P | 2000-03-22 | 2000-03-22 | |
US19123500P | 2000-03-22 | 2000-03-22 | |
US19123600P | 2000-03-22 | 2000-03-22 | |
US19124000P | 2000-03-22 | 2000-03-22 | |
US60/191,129 | 2000-03-22 | ||
US60/191,235 | 2000-03-22 | ||
US60/191,240 | 2000-03-22 | ||
US60/191,236 | 2000-03-22 | ||
US60/191,128 | 2000-03-22 | ||
US60/191,142 | 2000-03-22 | ||
US20422700P | 2000-05-15 | 2000-05-15 | |
US20423000P | 2000-05-15 | 2000-05-15 | |
US60/204,227 | 2000-05-15 | ||
US60/204,230 | 2000-05-15 | ||
US21521400P | 2000-06-29 | 2000-06-29 | |
US60/215,214ETAL. | 2000-06-29 | ||
US21624900P | 2000-07-06 | 2000-07-06 | |
US21626400P | 2000-07-06 | 2000-07-06 | |
US21676500P | 2000-07-06 | 2000-07-06 | |
US60/216,264 | 2000-07-06 | ||
US60/216,249 | 2000-07-06 | ||
US60/216,765 | 2000-07-06 | ||
US21807500P | 2000-07-12 | 2000-07-12 | |
US60/218,075 | 2000-07-12 | ||
US21918200P | 2000-07-19 | 2000-07-19 | |
US21916700P | 2000-07-19 | 2000-07-19 | |
US60/219,182 | 2000-07-19 | ||
US60/219,167 | 2000-07-19 | ||
US22148500P | 2000-07-27 | 2000-07-27 | |
US60/221,485 | 2000-07-27 | ||
US22317300P | 2000-08-07 | 2000-08-07 | |
US60/223,173 | 2000-08-07 | ||
PCT/US2001/008664 WO2001067855A2 (en) | 2000-03-16 | 2001-03-16 | Transgenic mice containing targeted gene disruptions |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2402912A1 true CA2402912A1 (en) | 2001-09-20 |
Family
ID=27586188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002402912A Abandoned CA2402912A1 (en) | 2000-03-16 | 2001-03-16 | Transgenic mice containing targeted gene disruptions |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1304920A2 (en) |
JP (1) | JP2004500102A (en) |
AU (1) | AU2001245843A1 (en) |
CA (1) | CA2402912A1 (en) |
IL (1) | IL151759A0 (en) |
WO (1) | WO2001067855A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002004621A2 (en) * | 2000-07-11 | 2002-01-17 | Deltagen, Inc. | Methods of creating constructs useful for introducing sequences into embryonic stem cells |
US20020116729A1 (en) * | 2000-12-06 | 2002-08-22 | Allen Keith D. | Transgenic mice containing NTTP1 phosphatase gene disruptions |
US8010189B2 (en) | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
US9675796B2 (en) | 2013-11-10 | 2017-06-13 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
EP3093043B1 (en) | 2015-05-13 | 2018-11-14 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6030794A (en) * | 1993-05-18 | 2000-02-29 | Institut National De La Sante Et De La Recherche Medicale | Genetically engineered mice and cell lines containing alterations in the genes encoding retinoic acid receptor and retinoid X receptor proteins |
CA2314434A1 (en) * | 1997-12-12 | 1999-06-17 | Merck & Co., Inc. | Dna molecules encoding human nuclear receptor protein, nnr5 |
AU5550099A (en) * | 1998-08-07 | 2000-02-28 | Tularik Inc. | A novel retinal nuclear hormone receptor |
-
2001
- 2001-03-16 WO PCT/US2001/008664 patent/WO2001067855A2/en active Search and Examination
- 2001-03-16 EP EP01918805A patent/EP1304920A2/en not_active Withdrawn
- 2001-03-16 CA CA002402912A patent/CA2402912A1/en not_active Abandoned
- 2001-03-16 AU AU2001245843A patent/AU2001245843A1/en not_active Abandoned
- 2001-03-16 JP JP2001566337A patent/JP2004500102A/en not_active Withdrawn
- 2001-03-16 IL IL15175901A patent/IL151759A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2001245843A1 (en) | 2001-09-24 |
IL151759A0 (en) | 2003-04-10 |
WO2001067855A3 (en) | 2003-02-13 |
EP1304920A2 (en) | 2003-05-02 |
JP2004500102A (en) | 2004-01-08 |
WO2001067855A2 (en) | 2001-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060160211A1 (en) | Transgenic mice containing, cGMP phosphodiesterase gene disruptions | |
US20030106083A1 (en) | Transgenic mice containing RPTPB tyrosine phosphatase gene disruptions | |
CA2402912A1 (en) | Transgenic mice containing targeted gene disruptions | |
WO2002048345A2 (en) | Transgenic mice containing glutamate receptor (grik5) gene disruptions | |
WO2002045498A2 (en) | Transgenic mice containing channel protein target gene disruptions | |
WO2002006445A9 (en) | Transgenic mice containing targeted gene disruptions | |
US20030079243A1 (en) | Transgenic mice containing TRP6 calcium ion channel gene disruptions | |
US20020116730A1 (en) | Transgenic mice containing PERK protein kinase gene disruptions | |
US20020108138A1 (en) | Transgenic mice containing RORgamma gene disruptions | |
US20060253915A1 (en) | Transgenic Mice Containing Kir3.3 Potassium Channel Gene Disruptions | |
US20060150265A1 (en) | Transgenic mice containing sulfotransferase gene disruptions | |
US20040040046A1 (en) | Transgenic mice containing retina-specific nuclear receptor gene disruptions | |
WO2002003793A2 (en) | Transgenic mice containing targeted gene disruptions | |
US20060172413A1 (en) | Transgenic mice containing melanocyte stimulating hormone receptor gene disruptions | |
US6717032B2 (en) | Transgenic mice containing DEZ orphan receptor gene disruptions | |
US20030023998A1 (en) | Transgenic mice containing 5-HT-2B gene disruptions | |
US20020133839A1 (en) | Transgenic mice containing Kir2.3 potassium channel gene disruptions | |
US20030167493A1 (en) | Transgenic mice containing GPRC5B-like gene disruptions | |
WO2002047478A2 (en) | Transgenic mice containing proliferator-activated receptor gene disruptions | |
WO2002079378A2 (en) | Transgenic mice containing gpcr-like transmembrane protein disruptions | |
US20020133840A1 (en) | Transgenic mice containing disruptions in genes encoding A2D2 calcium ion channel subunit proteins | |
US20020023275A1 (en) | Transgenic mice containing matrix metalloprotease gene disruptions | |
US20060212955A1 (en) | Transgenic mice containing lymphoid-specific GPCR gene disruptions | |
US20020177134A1 (en) | Transgenic mice containing PAFR gene disruptions | |
US20020068324A1 (en) | Transgenic mice containing melanocortin-3 receptor gene disruptions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |